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Ephrin-B1 Regulation of Cell Positioning in Craniofacial  
Development and Congenital Disease 
Terren Kathryn Niethamer 
 
Congenital craniofacial anomalies represent one-third of all structural birth defects, but 
although the genetic causes of many syndromes are known, the molecular and cellular 
mechanisms often remain poorly understood. This is the case for craniofrontonasal syndrome 
(CFNS), an X-linked syndrome caused by mutations in EFNB1 and characterized by 
craniofacial, skeletal, and neurological anomalies. EFNB1 encodes ephrin-B1, a member of the 
Eph/ephrin family of signaling molecules that regulate cell positioning and tissue morphology 
during embryonic development. Unlike most X-linked diseases, CFNS manifests very mildly in 
hemizygous males with no functional ephrin-B1, whereas females heterozygous for ephrin-B1 
mutations are severely affected. The increased severity that occurs in the presence of 
mosaicism of ephrin-B1 expressing and non-expressing cells after random X chromosome 
inactivation has been named “cellular interference.” In Efnb1+/- mice, ephrin-B1 expressing and 
non-expressing cells aberrantly segregate from one another in the neural plate neuroepithelium, 
providing a general potential mechanism for cellular interference; however, whether and how 
ephrin-B1-mediated cell segregation contributes to craniofacial phenotypes in human patients 
was not known. Using mouse models and the first human induced pluripotent stem cell model of 
a human craniofacial disease, we established that ephrin-B1 mosaicism drives pathogenic cell 
segregation in human cell types relevant to CFNS and that ephrin-B1 is a potent regulator of 
segregation not only in the early neuroepithelium, but also in the craniofacial mesenchyme, 
correlating with dysmorphology of facial structures. Ephrin-B1 also regulates EphB receptor 
levels when these molecules are coexpressed, and aberrant EphB receptor accumulation in 
ephrin-B1 mosaic cell populations may influence segregation or phenotypic outcome and 
disease severity. These discoveries contribute to a greater understanding of the role of ephrin-
 xii 
B1 in regulating cell positioning during development, as well as how disruption of its function 
can result in congenital craniofacial disease. 
 
 
 xiii 
TABLE OF CONTENTS 
CHAPTER 1. Introduction to craniofacial development and congenital disease.................. 1 
CHAPTER 2. Introduction to Eph/ephrin signaling in cell positioning during embryonic 
development ............................................................................................................................ 15 
CHAPTER 3. EPHRIN-B1 mosaicism drives cell segregation in craniofrontonasal 
syndrome hiPSC-derived neuroepithelial cells ..................................................................... 60 
Summary .............................................................................................................................. 61 
Introduction ........................................................................................................................... 61 
Results .................................................................................................................................. 63 
Discussion ............................................................................................................................ 67 
Materials and Methods .......................................................................................................... 70 
CHAPTER 4. Aberrant cell segregation in craniofacial primordia and the emergence of 
facial dysmorphology in craniofrontonasal syndrome ........................................................ 85 
Summary .............................................................................................................................. 86 
Introduction ........................................................................................................................... 86 
Results .................................................................................................................................. 91 
Discussion .......................................................................................................................... 101 
Materials and Methods ........................................................................................................ 104 
CHAPTER 5. Mechanisms of ephrin-B1 cis regulation of EphB receptor signaling ......... 122 
Summary ............................................................................................................................ 123 
Introduction ......................................................................................................................... 123 
Results ................................................................................................................................ 127 
Discussion .......................................................................................................................... 136 
Materials and Methods ........................................................................................................ 143 
CHAPTER 6. Conclusions and future work ......................................................................... 158 
References ............................................................................................................................ 166 
 xiv 
LIST OF TABLES 
Table 1. Eph/ephrin relationships and roles in cell positioning in the developing embryo .......... 52 
Table 2. HUMARA demonstrates clonal inactivation of maternal (wild type) X chromosome in 
each CFNShet hiPSC line ......................................................................................................... 75 
Table 3. Significant influences on facial shape at E11.5 ......................................................... 109 
Table 4. Significant influences on facial shape from E12.5-E14.5 ........................................... 110 
Table 5. Age-specific comparisons of the Procrustes distances between the mean shape of 
affected and control genotypes, after accounting for allometry ................................................ 111 
Table 6. Antibody information for immunofluorescence (IF) and immunoblotting (IB) .............. 163 
Table 7. Primer sequence information .................................................................................... 164 
Table 8. Genetic crosses and sample sizes for mouse embryo experiments .......................... 165 
 xv 
LIST OF FIGURES 
Figure 1. An overview of the development of the midface ........................................................ 12 
Figure 2. Essential questions in the study of CFNS .................................................................. 13 
Figure 3. Eph/ephrin signaling modes ...................................................................................... 54 
Figure 4. Differentiating Eph/ephrin forward and reverse signaling in the development of two  
axon tracts, the corpus callosum and the anterior commissure ................................................. 55 
Figure 5. Eph/ephrin signaling provides support and guidance for migrating cells during 
development ............................................................................................................ 57 
Figure 6. Eph/ephrin signaling mechanisms in developmental tissue separation ...................... 58 
Figure 7. Reprogramming of wild-type, CFNShet, and CFNShemi HDFs to hiPSCs ................ 76 
Figure 8. Differentiation and characterization of hNE cells from hiPSCs ................................... 77 
Figure 9. Robust cell segregation in neuroepithelial cells mosaic for EPHRIN-B1 expression .. 78 
Figure 10. Ephrin-B1 has a significant effect on embryonic facial shape from E11.5 to E14.5 
that mirrors CFNS .................................................................................................. 112 
Figure 11. Ephrin-B1 mosaicism in neural progenitors produces cell segregation in the brain, 
whereas neural crest-specific mosaicism does not ................................................ 114 
Figure 12. Ephrin-B1-mediated cell segregation in the brain does not affect development of 
craniofacial structures ............................................................................................ 115 
Figure 13. Craniofacial cell segregation first occurs in the post-migratory neural crest-derived 
mesenchyme, correlating with the onset of upregulation of ephrin-B1 ................... 117  
Figure 14. Neural crest cells mosaic for ephrin-B1 expression undergo cell segregation in 
craniofacial primordia............................................................................................. 118 
Figure 15. Palate-specific ephrin-B1 mosaicism results in cell segregation in the anterior palate 
mesenchyme after E11.5 ....................................................................................... 119 
Figure 16. Post-migratory neural crest cell segregation correlates with local dysmorphology in 
the secondary palate ............................................................................................. 120  
 xvi 
Figure 17. Post-migratory neural crest cell segregation correlates with dysmorphology in the 
nasal conchae of the frontonasal prominence ........................................................ 121 
Figure 18. Individual and combinatorial mutations to the G-H loop of ephrin-B1 dramatically 
reduce EphB receptor binding ............................................................................... 148 
Figure 19. Single G-H loop mutants of ephrin-B1 retain the ability to activate EphB2, while a 
triple G-H loop mutant does not ............................................................................. 149 
Figure 20. Coexpression of EphB2 and trans-competent ephrin-B1 blinds cells to receipt of 
further signals from ephrin-B1 in trans ................................................................... 150 
Figure 21. Cis-expression of ephrin-B1 desensitizes EphB2-expressing cells through reduction 
of EphB2 protein levels .......................................................................................... 152 
Figure 22. Ephrin-B1 misexpression mouse construct design, testing, and targeting ............. 154  
Figure 23. Differences in cis expression effects of ephrin-As and ephrin-Bs ........................... 156 
 
 
 xvii 
LIST OF SUPPLEMENTAL FIGURES 
Figure S1. Genetic characterization of CFNS patient-derived hiPSCs ...................................... 79 
Figure S2. CFNS patient-derived hiPSCs possess differentiation potential to all three          
germ layers .............................................................................................................. 80 
Figure S3. CFNS patient-derived hiPSCs express pluripotency markers .................................. 81 
Figure S4. Expression of additional EphB/ephrin-B signaling family members in hiPSCs        
and hNE .................................................................................................................. 82 
Figure S5. Time lapse imaging of hNE cell mixing experiments ............................................... 84  
Figure S6. Preliminary characterization of ROSA26Efnb1-3xTD mouse ESCs .............................. 157
 1 
 
 
 
 
 
 
 
 
CHAPTER 1. Introduction to craniofacial development and congenital disease 
 
 2 
Summary  
Development of the face during early embryogenesis is a complex series of events 
requiring not only cell proliferation, apoptosis, and differentiation, but also changes to cell 
positioning. These events contribute to morphogenesis, the process by which these tissues 
begin to develop their shape. Many transcription factor networks and signaling pathways 
contribute to the morphogenesis of the face, and disruption to any of these networks and 
pathways results in congenital disease. This work concentrates on one such signaling pathway, 
the Eph family of receptor tyrosine kinases and their membrane-bound signaling partners, the 
ephrins. Eph/ephrin signaling directs cell positioning during morphogenesis in many different 
embryonic contexts (for a full review of this topic, please see Chapter 2), including the 
development of craniofacial structures. Mutations in Eph/ephrin signaling family members result 
in a number of different developmental phenotypes in mice. In humans, the congenital 
craniofacial disease craniofrontonasal syndrome (CFNS) is caused by mutations to ephrin-B1, 
which is the focus of this work. To understand the developmental etiology of CFNS, the 
contributions of ephrin-B1 to different morphogenetic processes in the development of the face, 
and the possibility of developing novel molecular therapeutics for this disorder, it is first 
necessary to appreciate the events that take place during development of the craniofacial 
complex as well as what remains unknown about these processes.  
 
Development and morphogenesis of the midface 
The face forms from neural crest cells, a multipotent stem cell population 
Neural crest cells (NCCs) are a specialized, highly migratory population of multipotent 
stem cells that arise at the neural plate border, delaminate, and travel in discrete streams 
through the developing embryo to contribute to skeletal, connective, vascular, and nervous 
system tissues, including the craniofacial primordia (LaBonne and Bronner-Fraser, 1998; Le 
Douarin and Dupin, 2003). The face begins to form with the induction of NCCs at the border 
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between the neural and non-neural ectoderm of the neural plate prior to neural tube closure 
(LaBonne and Bronner-Fraser, 1998). This occurs early in embryonic development, from week 3 
in humans (40 week total gestation period) and from embryonic day (E) 8 in mouse (21 day total 
gestation period) (Moore et al., 2007). NCCs then delaminate from this position and migrate 
ventrolaterally in defined paths, differentiating to form neurons and glia of the peripheral nervous 
system, melanocytes, smooth muscle, and craniofacial mesenchyme from which bone and 
cartilage of the face and some structures of the skull will be derived (Le Douarin and Dupin, 
2003). Many transcription factor networks and signaling pathways coordinate to regulate NCCs 
during these early developmental events (Betancur et al., 2010), and the cellular and molecular 
processes they direct must function and coordinate properly to correctly form the face. Defects 
in any stage of NCC development from induction to migration to differentiation result in 
disorders known as neurocristopathies (Etchevers et al., 2006). Because neurocristopathies 
affect NCCs and their derivatives, they have a wide variety of symptoms ranging from 
craniofacial dysmorphology to peripheral nervous system deficiencies to pigmentation defects, 
among others. Other precursor cells at the neural plate, the neuroepithelial cells, have also 
been proposed to contribute to neurocristopathies when damage to these cells occurs prior to 
neural crest induction (Jones et al., 2008; Sakai et al., 2016). The broad scope of craniofacial 
and other phenotypes evident in neurocristopathy patients demonstrates the incredible range 
and importance of NCCs to proper development of many tissues in the forming embryo, 
including the craniofacial complex.  
The face forms from five initial prominences composed of NCC-derived mesenchyme, 
which is enclosed by a thin layer of epithelial cells. At E9.5 in mouse (22 days in humans), the 
frontonasal prominence (FNP), two maxillary prominences (MXP), and two mandibular 
prominences (MDP) frame the primitive mouth, the stomodeum; by E10.5 (28 days in humans), 
the two mandibular prominences have fused at the midline (Figure 1A). As development of 
these structures progresses, additional complexity is introduced as the lateral portion of the FNP 
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divides into lateral and medial nasal prominences (LNP and MNP) surrounding the forming 
nasal pits by E11.5 in mouse (33 days in humans) (Figure 1B). The LNP, MNP, and MXP will 
fuse surrounding the nasal pit on each side of the face at the lambdoid (l) junction to form the 
upper lip by E12.0 (35 days in humans) (Figure 1C) (Depew and Compagnucci; Jiang et al., 
2006). The secondary palatal shelves extend from the maxillary prominences at E12.0-12.5 (35-
40 days in humans) and will later elevate above the tongue, grow out towards the midline, and 
fuse to form the secondary palate (Bush and Jiang, 2012; Kim et al., 2015). Following the 
formation and fusion of these structures, craniofacial cartilage and bone will differentiate from 
NCC-derived mesenchyme as more mature facial structures develop; these are evident by 
E17.0 in mouse (10 weeks in humans) (Figure 1D). Formation of normal facial structures is an 
intricate process that involves both proliferation and differentiation of cells as different cell types 
are specified, as well as apoptosis as structures are refined and fuse with one another.  
Development of the face also requires the formation and maintenance of developmental 
boundaries that prevent the intermingling of cells between different structures. Although 
boundary formation is essential for proper craniofacial development, boundaries are also 
removed as different craniofacial prominences, such as the upper lip and secondary palate, fuse 
to generate mature structures with continuous tissue. The fusion process may occur by 
apoptosis, epithelial-to-mesenchymal transition, cell extrusion, or some combination thereof 
(Kim et al., 2015; Losa et al., 2018). Disruption of any of the components that direct boundary 
formation and maintenance or tissue fusion can result in congenital craniofacial disease. 
Although many studies of craniofacial development and disease focus on early stages involving 
NCCs, or specific events such as lip or palate fusion, these events cannot be studied in 
isolation. Other tissues in close proximity to the facial prominences contribute to growth and 
expansion of the midface and to its normal morphogenesis, and disruption of any of these 
tissues may lead to craniofacial dysmorphology. 
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Influences on growth and expansion of the midface 
The five facial prominences actively grow during development of the face, but how 
growth of NC-derived craniofacial structures and expansion of the midface are regulated to 
contribute to proper craniofacial development remains incompletely understood. This regulation 
is mediated not only by events that occur within NCC-derived mesenchymal tissues, but also by 
events in other tissues (Cox, 2004), as well as by later differentiation of cells to form cartilage 
and bone.  
One essential factor to consider in the growth and expansion of the midface is the 
growth of the brain, which can impact facial size in two important ways. First, the neural tube, 
and later the more developed brain, serve as a scaffold on which the facial prominences form 
and may exert physical forces on the facial prominences that affect their positioning or 
directional growth (Marcucio et al., 2015). Slower brain growth in comparison to growth of the 
facial prominences can lead to more prognathic facial structures, whereas increased growth of 
the brain relative to the facial prominences can lead to a wider, flatter face (Boughner et al., 
2008). Second, neural tissue and surface ectoderm also represent sources of signaling that 
affect growth and development of the facial prominences and assist in patterning neural crest-
derived mesenchyme (Marcucio et al., 2011). In the developing chicken embryo, for example, 
reducing sonic hedgehog signaling in the brain causes facial narrowing, whereas increasing it 
causes midfacial widening and even bifurcation of the frontonasal prominence (Young et al., 
2010). As the early development of the brain and face are closely related both in space and in 
time (Richtsmeier et al., 2006), the positional and signaling influences of the brain represent 
important factors contributing to early midfacial expansion.  
Later events, such as differentiation of NCC-derived mesenchyme to form cartilage and 
bone, may also contribute to the final size and shape of the midface. Between 35 days and 12 
weeks of development in humans, it has been hypothesized that directional growth of 
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craniofacial cartilages prior to craniofacial bone formation is essential for the formation of the 
face; in rats whose primary cartilages were altered due to teratogens, the size and shape of 
later bone formation was affected (Diewert, 1985). More recent studies also suggest that the 
chondrocranium can affect craniofacial growth, with structures such as the nasal septum acting 
as growth centers or supports for midface expansion (Marulanda and Murshed, 2018; 
Marulanda et al., 2017). In addition, the facial structures of different species are similar at early 
stages, such as the time prior to midline fusion, possibly to minimize the possibility of clefting. 
However, divergence to create many different facial shapes from chickens to mice to alligators 
to humans occurs after this time point (Young et al., 2014), suggesting that post-fusion events 
contribute significantly to facial shapes. Syndromes such as craniosynostosis, or premature 
fusion of one or more sutures of the skull, create imbalances in growth in different parts of the 
skull and are often accompanied by craniofacial dysmorphology (Johnson and Wilkie, 2011), 
indicating that in some cases, changes to the skull correlate with changes to the shape of the 
face. 
In considering the growth of the midface, and congenital diseases that result in its 
dysmorphology, it is essential to consider that the facial prominences have many different 
components influencing their overall structures, and therefore their function. These components 
cannot be studied in isolation (Aldridge et al., 2005), as they all contribute to the development 
and proper function of the face. Disruption of early events, such as the induction of NCCs at the 
neural plate, or migration of these NCCs, can have far-reaching effects that cause 
dysmorphology in spite of normal proceeding of following events. Similarly, defects in later 
processes, such as the development and morphogenesis of the skeletal elements of the face, 
can cause changes in facial shape even if all preceding events have occurred correctly. The 
interaction of many cell types, including the neural plate neuroepithelial cells, the non-neural 
ectoderm, NCCs, mesoderm, and later mesenchymal cell types and their derivatives, is required 
for craniofacial development, and the necessary interaction between many different molecules 
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and signaling pathways to facilitate proper morphogenesis only adds to this complexity (Chai 
and Maxson, 2006; Helms et al., 2005; Suzuki et al., 2016). These complex cellular and tissue-
level interactions require in-depth study to discover the etiology of any particular defect that 
involves expansion of the midface. 
 
Disruptions to craniofacial morphogenesis result in congenital disease 
Congenital craniofacial disease 
In the series of complex developmental events comprising craniofacial development, if 
any of the necessary processes are disrupted, the result is congenital craniofacial disease. This 
type of disruption occurs often enough that congenital craniofacial disorders make up over one-
third of all congenital birth defects ("Global Strategies to Reduce the Health Care Burden of 
Craniofacial Anomalies," 2004). These disorders are associated with significant morbidity and 
burdens not only to patients and families, but also on the healthcare system (Wehby and 
Cassell, 2010). Failure of early events in craniofacial development, such as fusion of the LNP, 
MNP, and MXP to form the lip, or midline fusion of the palatal shelves, results in cleft lip, cleft 
palate, or both (CL/P). Infants with these disorders have difficulty feeding and may be 
undernourished; they may also have difficulty with hearing and speaking and thus with social 
interaction (Dixon et al., 2011). CL/P can present as part of a wider syndromic diagnosis, or in 
isolation (non-syndromic). Although many genetic causes of CL/P have been identified, the 
causes of non-syndromic CL/P are only now beginning to be discovered, and the molecular 
events resulting in clefts are still under study (Dixon et al., 2011). Failure of later events that 
occur after craniofacial bone formation can also result in craniofacial disorders, such as 
craniosynostosis, or premature fusion of one or multiple sutures of the skull (loss of suture 
patency). Suture patency is thought to be important for passage through the birth canal and for 
accommodating growth of the brain; fusion of one or more sutures in the skull can constrain 
brain growth and result in changes to the shape of the skull and face. Children with 
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craniosynostosis often undergo multiple surgeries before the age of 2 (Johnson and Wilkie, 
2011). Indeed, for congenital craniofacial anomalies, surgery represents the only treatment 
option available for patients, and although surgical techniques are advanced and bring 
increased quality of life to these patients, the ability to detect congenital craniofacial disorders in 
utero and treat them at the cellular or molecular level remains an elusive goal. 
 
Craniofrontonasal syndrome  
Clinical and genetic features of craniofrontonasal syndrome 
One such congenital craniofacial disorder is craniofrontonasal syndrome (CFNS), an X-
linked disorder caused by mutations in EFNB1, which encodes EPHRIN-B1, a member of the 
Eph/ephrin family of signaling molecules. CFNS occurs in 1 in 120,000 individuals and is 
characterized by craniofacial phenotypes including hypertelorism, unilateral or bilateral coronal 
craniosynostosis, frontonasal dysplasia, and bifid nasal tip; patients occasionally present with 
cleft lip and palate (Cohen, 1979; Twigg et al., 2004; Wieland et al., 2004). CFNS patients may 
also have skeletal phenotypes, such as longitudinal splitting of the nails, diaphragmatic hernia, 
and occasionally, syndactyly or polydactyly; they may also present with neurological 
phenotypes, such as agenesis of the corpus callosum (Twigg et al., 2004). Unlike many X-linked 
diseases that affect male patients, CFNS is most severe in female patients heterozygous for 
mutations in EFNB1. These females are mosaic for EPHRIN-B1 expression after random X 
chromosome inactivation, a method for preserving gene dosage between the sexes. This 
mosaicism leads to aberrant segregation of ephrin-B1 expressing and non-expressing cells in a 
mouse model for CFNS, visible as large patches in the limb bud and secondary palate (Bush 
and Soriano, 2010; Compagni et al., 2003; Davy et al., 2004) of Efnb1+/Δ mouse embryos. Male 
patients with no functional EPHRIN-B1 are less severely affected, often presenting only with 
hypertelorism and occasionally with cleft lip (Twigg et al., 2004). The range of mutations in 
EFNB1 seen in CFNS patients is wide, from missense mutations to deletions to frameshift 
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mutations. There are also noncoding mutations in EFNB1 that cause CFNS; although the large 
number of observed mutations has thus far precluded an in-depth study of the individual 
consequences of each one, they are all thought to result in loss of function of EPHRIN-B1 
(Twigg et al., 2004; Twigg et al., 2006; Wieland et al., 2004). 
The discovery that mutations in EFNB1 were causative for CFNS solved a genetic 
conundrum that had long puzzled clinicians, who noted that transmission of the disease from a 
father to his daughters but not to his sons suggested X-linked inheritance, but that 
paradoxically, males were never as severely affected as females (Twigg et al., 2004; Wieland et 
al., 2004). Confirming the importance of EPHRIN-B1 mosaicism to disease pathology, rare male 
patients with severe CFNS phenotypes were found to have somatic mosaicism for EFNB1 
mutation (Twigg et al., 2013). However, the answer to this puzzle only created more questions, 
as researchers strove to determine how mosaicism for EPHRIN-B1 expression might lead to 
increased severity in craniofacial phenotypes. The connection between EPHRIN-B1 mosaicism 
and craniofacial phenotypes in female CFNS patients has remained elusive, with many 
hypotheses proposed since the genetic cause of the syndrome was discovered; although there 
is agreement that “cellular interference” occurs between ephrin-B1 expressing and non-
expressing cells (Wieacker and Wieland, 2005), the nature of this interaction remains 
incompletely understood.  
 
Cellular mechanisms of CFNS 
CFNS likely results from disrupted Eph/ephrin signaling due to mosaic loss of EPHRIN-
B1 in severely affected female heterozygotes or total loss of EPHRIN-B1 in mildly affected male 
hemizygotes. Eph/ephrin signaling and its many pathway members play important roles in cell 
positioning during embryonic development, often acting in the translation of patterning 
information into the formation and maintenance of embryonic boundaries (see Chapter 2). It is 
likely that heterozygous female patients are severely affected not only due to loss of 
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endogenous boundaries created or maintained by EPHRIN-B1, which must also be lost in 
hemizygous males, but also due to creation of ectopic EPHRIN-B1-generated boundaries 
through pathogenic cell segregation. Ectopic ephrin-B1 expression boundaries may restrict 
normal cell migration, intermingling, or orientation in mesenchymal structures during embryonic 
development to result in the wide range of CFNS phenotypes. The disruption of normal 
expression of ephrin-B1 also results in cell segregation in ephrin-B1 heterozygous mice. 
Although ectopic ephrin-B1 expression patches were initially noted in more fully developed 
structures, such as the palate (Bush and Soriano, 2010; Davy et al., 2006) and limb 
mesenchyme (Compagni et al., 2003), this process occurs much earlier, in the neural plate 
neuroepithelial cells of Efnb1+/- mice (O’Neill et al., 2016). The resulting patches of ephrin-B1 
expression and non-expression may contribute to later craniofacial and limb phenotypes in 
Efnb1+/- mice, and possibly in human CFNS patients as well. In Efnb1+/- mice, ephrin-B1-
mediated cell segregation requires kinase signaling through the EphB2 and EphB3 receptors 
(O’Neill et al., 2016). In mosaic cell mixtures, ephrin-B1 non-expressing cells upregulate actin, 
generating a cortical actin differential between ephrin-B1 expressing and non-expressing cells 
that results in segregation, with actin cables forming around aberrant patches of ephrin-B1 non-
expressing cells (O’Neill et al., 2016). This process requires the small GTPase RhoA and Rho 
kinase (ROCK); genetic disruption or pharmacological inhibition of ROCK dramatically 
decreases pathogenic cell segregation in Efnb1+/- embryos (O’Neill et al., 2016). Interestingly, 
genetic interaction studies also indicated that loss of Cdc42 or Rac1 function did not reduce 
segregation, consistent with the possibility that actomyosin contractility per se, and not cell 
migratory capacity more generally, may drive segregation. Further studies will elucidate the 
signaling partners downstream of Eph/ephrin activation that contribute to modulation of the 
cytoskeleton, as well as the biophysical differences leading to segregation of ephrin-B1 
expressing and non-expressing cells.  
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Understanding the contribution of Eph/ephrin signaling and cell segregation to CFNS 
 To better understand how mosaic loss of EPHRIN-B1 leads to craniofacial phenotypes in 
CFNS patients, it is first critical to understand the role of Eph/ephrin signaling in cell positioning 
and tissue separation as a whole (for full consideration of this topic, refer to Chapter 2). Studies 
of cellular mechanisms of CFNS are also important to contribute to the search for possible 
treatments or cures for this congenital craniofacial disease. To determine whether cell 
segregation holds the key to craniofacial phenotypes in CFNS, this work will investigate three 
essential questions (Figure 2). First, does cell segregation occur in human cell types relevant to 
craniofacial development? Second, when and where does ephrin-B1 force the segregation of 
wild type and mutant cells during development of mosaic embryos, and is it a potent regulator of 
cell positioning throughout the developing embryo? Third, how do specialized Eph/ephrin 
signaling modes contribute to ephrin-B1 mediated cell segregation? The answers to these 
questions have not been previously studied and will advance our knowledge of molecular, 
cellular, and tissue-level mechanisms of CFNS pathology as well as the role of ephrin-B1 in cell 
positioning in the developing embryo as a whole.  
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Figure 1. An overview of the development of the midface. (A) The midface develops from 
five embryonic prominences surrounding the stomodeum, or primitive mouth. The frontonasal 
prominence (FNP) is depicted in green. The two maxillary prominences (MXP) are depicted in 
yellow. By embryonic day 10.5 in mouse (equivalent to 28 days gestation in humans), the two 
mandibular prominences (MDP; depicted in blue) have fused at the midline. (B) At E11.5 in 
mouse (equivalent to 33 days gestation in humans), the lateral nasal prominence and medial 
nasal prominence surround the nasal pit, which will become the nostril. (C) Fusion of the MNP 
and LNP with the MXP at the lambdoid junction forms the upper lip between E11.5 and E12.0 in 
mouse (equivalent to 33-35 days gestation in humans). The secondary palatal shelves will 
extend from the MXP at E12.0-E12.5 in mouse (equivalent to 35-40 days gestation in humans). 
(D) Cartilage and bone differentiate from craniofacial mesenchyme to form more mature facial 
structures from E15.0-E18.0 in mouse. This figure is adapted from Moore et al., 2007. 
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Figure 2. Essential questions in the study of CFNS. (A) Does ephrin-B1-mediated 
segregation occur in human CFNS patient cells to contribute to disease pathology? (B) When 
and where does ephrin-B1 drive cell segregation during craniofacial development? Does 
segregation occur at a fixed point in development, at the neural plate between E8.0 and E8.5 
(blue bar), or does it continue in other tissues throughout development of the face (green 
arrow)? Embryo staging images adapted from eMouseAtlas, http://www.emouseatlas.org/emap/ 
ema/home.html (C) Ephrin-As inhibit EphA receptors in cis; how might ephrin-B1 interact with 
EphB receptors in cis to affect receptor signaling and cell segregation? 
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CHAPTER 2. Introduction to Eph/ephrin signaling in cell positioning during 
embryonic development 
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Eph/ephrin signaling is critical for embryonic development 
The Eph receptor tyrosine kinases were first identified based on their overexpression in 
human carcinoma (Hirai et al., 1987) and were later found to be expressed on initial outgrowths 
of neuronal axons, suggesting a role in axon guidance (Henkemeyer et al., 1994). Though their 
role in these contexts has been studied in great depth, Ephs and their signaling partners, the 
ephrins, are also expressed in most tissues during embryonic development and are essential to 
a wide variety of developmental processes (Batlle and Wilkinson, 2012; Bush and Soriano, 
2012; Egea and Klein, 2007; Kania and Klein, 2016; Klein and Kania, 2014; Kullander and Klein, 
2002; Merlos-Suárez and Batlle, 2008; Pasquale, 2008; Wilkinson, 2001). This is perhaps 
unsurprising, as the Eph receptors are the largest family of receptor tyrosine kinases found in 
mammals (Gale et al., 1996; Henkemeyer et al., 1994; Kullander and Klein, 2002).  
Ephrins, the signaling partners of the Eph receptors, are also membrane-bound, allowing 
Eph/ephrin signaling to utilize several unique signaling modes. Ephrins are separated into two 
classes: ephrin-As are membrane-bound through a GPI anchor, and ephrin-Bs are 
transmembrane molecules with a cytoplasmic domain (Gale et al., 1996). Eph receptors have 
also been separated into A and B classes based on sequence similarity and whether they bind 
to ephrin-A or ephrin-B signaling partners (Gale et al., 1996), although there is some overlap in 
binding affinity between the two classes (Himanen et al., 2004). Eph receptor oligomerization is 
necessary for propagation of a forward signal, with the size of the Eph receptor cluster 
determining the strength of the signal, such that trimers and tetramers signal maximally 
(Himanen et al., 2010; Schaupp et al., 2014; Seiradake et al., 2010). The membrane-bound 
nature of Ephs and ephrins dictates that cell-cell contact is an important part of their signal 
transduction (Davis et al., 1994; Henkemeyer et al., 1994), and in many developmental 
contexts, Eph/ephrin signaling between adjacent cells is critical. However, Eph/ephrin signaling 
via cellular protrusions may be capable of mediating signaling between nonadjacent cells 
(Cayuso et al., 2016), and release of Ephs and ephrins by exosomes also allows for the 
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possibility of signaling at greater distances (Gong et al., 2016). Whereas Eph and ephrin 
ectodomains can be proteolytically cleaved (Georgakopoulos et al., 2006; Hattori et al., 2000), 
the ectodomain alone is incapable of initiating oligomerization and is therefore unlikely to 
activate signaling; indeed, the unclustered ectodomain is often used as a competitive antagonist 
(Daar, 2012; Pegg et al., 2017), suggesting that antagonistic modulation of signaling at a 
distance by soluble Eph/ephrin ectodomains may be possible.  
Eph/ephrin signaling affects not only axon guidance, as originally hypothesized, but also 
cell proliferation, apoptosis, and cell positioning, often driving cell migration and tissue 
separation (Bush and Soriano, 2012; Kania and Klein, 2016; Laussu et al., 2014; Merlos-Suárez 
and Batlle, 2008; Pasquale, 2008; Xu and Henkemeyer, 2012). In this variety of developmental 
roles, Eph/ephrin signaling often acts as a middleman between patterning information that 
defines cell and tissue fate and the cellular movement necessary for the morphological changes 
that define the shape of these tissues.  
 
Eph/ephrin signaling modes 
Biochemically, Eph/ephrin interactions have bidirectional signaling capacity (Brückner et 
al., 1997; Holland et al., 1996; Lin et al., 1999; Torres et al., 1998). Upon binding of an ephrin to 
an Eph receptor, signaling may be transduced into the receptor-expressing cell; this classical 
forward signaling (Figure 3A) is mediated by Eph tyrosine phosphorylation followed by binding 
of partners that mediate downstream signaling, though the in vivo utilization of these binding 
partners in distinct developmental contexts is largely unknown (Bush and Soriano, 2012). An 
Eph/ephrin binding event can also result in transduction of a signal into the ephrin-expressing 
cell, known as reverse signaling (Figure 3B) (Henkemeyer et al., 1996; Holland et al., 1996). 
Therefore, in addition to Eph and ephrin expression levels and degree of oligomerization, the 
extent to which forward, reverse, and bidirectional signaling modes are utilized represents 
another layer of regulation that contributes to modulating downstream signaling.  
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Since the discovery that Eph receptor-ephrin interactions could result in signal 
transduction not only in the receptor-expressing cell, but also in the ephrin-expressing cell 
(Henkemeyer et al., 1996; Holland et al., 1996), many studies have delved into the possible 
mechanisms of ephrin reverse signaling. In biochemical studies, ephrin-Bs were found to use 
their cytoplasmic domains to mediate reverse signaling through phosphorylation of highly 
conserved tyrosines (Brückner et al., 1997) and interaction with PDZ-domain-containing 
proteins (Lin et al., 1999; Lu et al., 2001). Although ephrin-Bs themselves do not possess 
intrinsic kinase activity, therefore, they may mediate downstream signaling by recruitment of 
other signaling molecules. Ephrin-B reverse signaling may also occur by non-SH2/PDZ 
mechanisms, such as by interactions with scaffold proteins to regulate tight junctions or 
interactions with connexin-43 to regulate gap junctions (Daar, 2012; Davy et al., 2006). Although 
ephrin-As possess no intracellular domain, there is biochemical and genetic evidence for ephrin-
A reverse signaling (Dudanova et al., 2012). The precise mechanisms of this remain unclear, 
but cell culture studies indicate that ephrin-As may mediate reverse signaling through interaction 
with Src family kinases in membrane microdomains (Davy et al., 1999) and interaction with 
integrins to promote adhesion (Davy and Robbins, 2000; Huai and Drescher, 2001). In addition, 
EphA3-dependent activation of the ADAM10 metalloprotease to cleave ephrin-As allows a 
switch from adhesion to repulsion, in essence modulating the cellular response of the ephrin-
expressing cell (Hattori et al., 2000; Janes et al., 2005). Thus, upon the binding of an Eph to an 
ephrin on an adjacent cell and subsequent oligomerization, a signal can be transduced into the 
Eph-expressing cell, the ephrin-expressing cell, or into both cells simultaneously, generating a 
bidirectional signaling cascade. Which of these events is crucial to achieve the appropriate 
downstream signaling outcome seems to depend heavily on cellular context, and therefore has 
required direct evaluation in vivo in distinct cell and tissue types.  
Adding an additional layer of complexity to the regulation of Eph/ephrin signaling, there 
is evidence that expression of Eph receptors and ephrins in the same cell (in cis) can negatively 
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regulate Eph receptor signaling through ephrins in an adjacent cell (in trans) (Figure 3C) 
(Hornberger et al., 1999). Eph receptors have been proposed to interact with ephrins in cis 
using their canonical ligand-binding domain (Yin et al., 2004) as well as their membrane-
proximal fibronectin type III domain (Carvalho et al., 2006). Expression of ephrin-As in cis with 
EphA receptors in neuronal growth cones can fine-tune control of EphA receptor activation to 
accurately define the correct axon termination zone, and changing the cis-expression of ephrin-
As alters EphA phosphorylation and signaling as well as termination of axons as measured by 
growth cone collapse, demonstrating that the biochemical changes caused by cis-expression of 
ephrin-As with EphAs have a functional effect (Carvalho et al., 2006; Hornberger et al., 1999). 
Cis inhibition has been proposed to play a role in retinotectal topographic mapping and spinal 
motor axon guidance, at the synapse, and in cancer cell lines (Carvalho et al., 2006; Falivelli et 
al., 2013; Gatto et al., 2014; Hornberger et al., 1999; Kao and Kania, 2011; Marquardt et al., 
2005). The breadth of functional relevance of cis-expression of Ephs and ephrins remains 
unknown, and this has not been investigated in the context of craniofacial development. 
Moreover, cis interactions between Eph receptors and ephrins have thus far been demonstrated 
only for the A subclass; whether EphBs and ephrin-Bs interact in cis remains unknown.  
 
In vivo evidence for bidirectional signaling in the developing embryo 
The study of in vivo Eph/ephrin signaling mechanisms has been consistently active from 
the earliest studies of this signaling pathway. Our understanding of the broadly-used genetic 
tools, as well as the general principles derived from these studies, continue to evolve, providing 
us with a more nuanced understanding of in vivo signaling directionality.  
The prototypical in vivo roles for reverse signaling were first suggested by studying axon 
guidance phenotypes in mice lacking EphB receptor signaling capacity. Three receptors 
(EphB1, EphB2, EphB3), with similar affinity for B-type ephrins, and presumably similar 
intracellular signaling capabilities, are each involved in the patterning of two major 
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interhemispheric commissural axon tracts, the anterior commissure (AC) and corpus callosum 
(CC) (Figure 4A, B) (Henkemeyer et al., 1996; Mendes, 2006; Orioli et al., 1996; Robichaux et 
al., 2016). Initial genetic evidence for the existence of reverse signaling was based on 
discrepant phenotypic outcomes upon complete loss of EphB2 compared with mutants in which 
most of the intracellular domain was replaced with b-galactosidase, while maintaining the 
extracellular, transmembrane, and juxtamembrane domains (Henkemeyer et al., 1996). 
Whereas all Ephb2-/- mutant embryos exhibited defects in the posterior projection of the AC 
(ACp) and 61% exhibited defects in the CC, Ephb2LacZ/LacZ mutant embryos did not exhibit either 
of these phenotypes, leading to the conclusion that they were attributable to loss of reverse and 
not forward signaling (Henkemeyer et al., 1996; Mendes, 2006). A recent study reexamining 
these mutant alleles in guidance of the AC confirmed that null loss of EphB2 led to a higher 
penetrance of ACp phenotypes than intracellular truncation of EphB2 in Ephb2LacZ/LacZ mutant 
embryos (Figure 4D, F). Further, while complete loss of EphB1 resulted in an abnormal ACp 
approximately 30% of the time (Figure 4E), EphB1 mutants in which the intracellular domain of 
EphB1 was replaced with LacZ (EphB1T-LacZ) did not exhibit defects in ACp development 
(Figure 4C) (Chenaux and Henkemeyer, 2011; Robichaux et al., 2016). Surprisingly, however, 
loss of forward signaling through EphB1 and EphB2 together resulted in ACp defects in 80% of 
Ephb1T-LacZ/T-LacZ; Ephb2LacZ/LacZ compound mutants, demonstrating that the intracellular domains 
of EphB1 and EphB2 have redundant function. An almost identical scenario was borne out for 
the CC; loss of forward signaling through EphB1 resulted in defects in the CC in 27% of Ephb1T-
LacZ/T-LacZ mutants (Figure 4C) and 43% of Ephb2LacZ/LacZ mutants (Figure 4D), but loss of forward 
signaling through EphB1 and EphB2 resulted in CC defects in 91% of Ephb1T-LacZ/T-LacZ; 
Ephb2LacZ/LacZ compound mutants (Figure 4H). In both contexts, the penetrance upon loss of the 
intracellular domain was not as high as complete compound loss of EphB1 and EphB2 (100%) 
(Figure 4G), a discrepancy that was attributed to reverse signaling (Robichaux et al., 2016). 
However, this difference could instead be due to the retained presence of EphB3 forward 
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signaling. Indeed, the penetrance of ACp or CC phenotypes in Ephb2-/-; Ephb3-/- compound 
mutants is 100%, and higher than in either homozygous mutant alone, demonstrating their 
redundancy (Mendes, 2006; Orioli et al., 1996). Based on these studies, we conclude that in the 
case of Ephb1T-LacZ/T-LacZ; Ephb2LacZ/LacZ mutants, reverse signaling activation should still be 
retained, but these mutants still exhibit high penetrance of AC and CC defects, arguing that it is 
not necessary to evoke the existence of a reverse signal to explain differences between EphB 
null and intracellular mutant phenotypic penetrance.  
If redundant receptor forward signaling function is responsible for the bulk of ACp and 
CC phenotypes, why is complete loss of EphB1 or EphB2 receptor more severe than loss of 
only the intracellular domain? In both cases, the C-terminally truncated fusion protein retains the 
extracellular and transmembrane domains; the EphB2LacZ mutant protein also still retains the 
juxtamembrane region. Notably, Eph receptors can cocluster, or heterooligomerize, both within 
and beyond subclass, and Eph-Eph receptor interaction domains reside within the extracellular 
region and can mediate lateral propagation of signaling, independent of ephrin ligation 
(Freywald et al., 2002; Janes et al., 2011; Lackmann et al., 1998; Marquardt et al., 2005; 
Wimmer-Kleikamp et al., 2004). This raises the question of whether these intracellular mutants 
may still retain some forward signaling function, possibly as a scaffold to the larger signaling 
complex when coexpressed with other active receptors possessing redundant intracellular 
signal transduction capabilities. If so, receptor heterooligomerization and retention of some 
forward signaling capacity is a plausible explanation for the decreased phenotypic severity of 
intracellular EphB receptor mutants compared to complete receptor knockouts. To distinguish 
between this possibility and that of a reverse signaling contribution, further in vivo exploration of 
both hypotheses will be required.  
What, then, are the genetic data in support of reverse signaling in these contexts? 
Studies complementary to the above have created mouse mutants with changes to the 
intracellular domain of ephrin-Bs, either by replacing the entire domain with  b-galactosidase 
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(ephrin-B2LacZ) (Cowan et al., 2004; Dravis and Henkemeyer, 2011; Dravis et al., 2004; 
Yokoyama et al., 2001), or by making specific point mutations to the phosphorylatable tyrosines 
or the PDZ binding domain in the highly-conserved region of the cytoplasmic domain. The latter 
allows more specific assessment of phosphorylation or PDZ-dependent reverse signaling but 
does not test other potential modes of reverse signaling (Bush and Soriano, 2009; Davy and 
Soriano, 2007; Dravis and Henkemeyer, 2011; Makinen, 2005; Xu and Henkemeyer, 2009; Xu 
et al., 2011). Null loss of function of ephrin-B1, or point mutations abrogating its ability to bind to 
PDZ-domain containing proteins, results in normal ACp development, but agenesis of the CC 
(aCC), in a 129S4 genetic background (Bush and Soriano, 2009). Though a recent study 
reported that Efnb1 null mutant embryos did not exhibit CC defects in a CD1 genetic 
background, human craniofrontonasal syndrome patients harboring mutations in EFNB1 also 
exhibit aCC, indicating that although the involvement of Efnb1 is genetic background-dependent 
in mice, its requirement is conserved across species (Twigg et al., 2004). Efnb2LacZ/LacZ mutant 
mice exhibited severe defects in the formation of the ACp axon tract, suggesting that ephrin-B2 
reverse signaling is important in this context (Cowan et al., 2004). However, this allele has since 
been demonstrated to result in a gain of function of ephrin-B2 signaling in some contexts 
(described below), casting some uncertainty on the interpretation of phenotypes observed in 
these mutants (Zhang et al., 2015). Ephrin-B3 apparently regulates formation of the CC entirely 
via forward signaling, because complete loss of ephrin-B3 results in severe defects of the CC, 
whereas loss of the intracellular domain does not (Mendes, 2006). Null loss of ephrin-B3 does 
not disrupt formation of the AC, on the other hand, indicating it likely does not play a role in this 
context (Kullander et al., 2001). Together, these results support a major role for EphB forward 
signaling in formation of the AC and CC, with some reverse signaling contribution from the 
intracellular domain of B-type ephrins as well.  
In some cases, examination of ephrin-B cytoplasmic signaling mutants has made direct 
attribution of signaling directionality possible. For example, ephrin-B16FΔV mutant embryos do 
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not have the craniofacial or skeletal defects seen in ephrin-B1null embryos, indicating that 
reverse signaling by PDZ- or phosphorylation-dependent mechanisms is not necessary for 
craniofacial and skeletal development (Bush and Soriano, 2009); instead, forward signaling has 
been implicated in these processes (Bush and Soriano, 2010; Risley et al., 2009). Mice 
expressing one copy of ephrin-B2F5, in which each of the five phosphorylatable tyrosines in the 
cytoplasmic tail of ephrin-B2 is mutated to phenylalanine, on a null background (Efnb2-/F5 mice) 
do not exhibit the early embryonic phenotypes exhibited by Efnb2-/- embryos, indicating that 
these defects are not caused by lack of ephrin-B2 tyrosine phosphorylation (Davy and Soriano, 
2007). Efnb3ΔC/ΔC mice lacking the entire cytoplasmic domain of ephrin-B3 do not have the same 
corticospinal tract defects as Efnb3-/- mice, indicating that it is the forward signaling aspects of 
ephrin-B3 signaling that prevents EphA4-expressing axons from crossing the spinal cord midline 
(Yokoyama et al., 2001).  
In a study of Eph/ephrin-mediated cell segregation in CFNS, our laboratory has 
implicated unidirectional signaling in tissue separation (O’Neill et al., 2016). We showed that in 
the developing Efnb1+/- mouse embryo, a model for CFNS, ephrin-B1-mediated segregation first 
occurs in the neural plate neuroepithelium at E8.5, prior to neural tube closure. Through a series 
of genetic mouse mutants, we demonstrated that mosaic loss of reverse signaling (in Efnb1+/6FΔV 
embryos) does not result in cell segregation, indicating that mosaicism for ephrin-B1 reverse 
signaling alone is not sufficient to induce segregation. Mosaicism for loss of reverse signaling in 
an ephrin-B1 null embryo (in Efnb1Δ/6FΔV embryos), however, results in cell segregation 
indistinguishable from that seen in ephrin-B1 heterozygous embryos, indicating that the 
SH2/PDZ-dependent reverse signaling modes of ephrin-B1 are not required for segregation. 
Consistent with cell segregation being driven by forward signaling alone, ephrin-B1 
heterozygous embryos lacking forward signaling through EphB2 (Efnb1+/Δ; Ephb2LacZ/LacZ) or 
through both EphB2 and EphB3 (Efnb1+/Δ; Ephb2LacZ/LacZ; Ephb3-/-) lose segregation. This 
forward signal requires EphB kinase activity, as demonstrated by a chemical genetic approach 
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using Efnb1+/Δ mice also expressing mutant forms of EphB1, EphB2, and EphB3 engineered to 
be kinase-inhibited by the inhibitor 1-NA-PP1; these embryos exhibited robust segregation in 
the absence of 1-NA-PP1, but reduced segregation upon 1-NA-PP1 inhibition of kinase 
signaling. Therefore, reverse signaling through phosphorylation or PDZ mechanisms is neither 
necessary nor sufficient for cell segregation, whereas forward signaling is required.  
Based on mutations to ephrin-B cytoplasmic domains in mice, reverse signaling by B-
type ephrins has also been proposed in a variety of additional developmental contexts, including 
cardiac valve formation (Cowan et al., 2004), secondary palate development, foregut and 
urorectal morphogenesis (Dravis and Henkemeyer, 2011; Dravis et al., 2004), 
lymphangiogenesis (Makinen, 2005), axon pruning (Xu and Henkemeyer, 2009), and 
postsynaptic neuron maturation (Xu et al., 2011). Studies using these mutant proteins to 
interrogate reverse signaling functionality, however, have sometimes resulted in confusing 
conclusions about the role of the ephrin-B cytoplasmic domain. Ephrin-B2LacZ/LacZ embryos have 
urorectal and hindgut defects (Dravis et al., 2004), defects in cardiac development (Cowan et 
al., 2004), tracheoesophageal fistula (TEF), and cleft palate (Dravis and Henkemeyer, 2011). 
Ephrin-B2ΔV/ΔV embryos (lacking PDZ interactions) and homozygous Ephrin-B26YFΔV/6YFΔV 
embryos (lacking PDZ interactions and tyrosine phosphorylation), however, have no urorectal, 
tracheoesophageal, or palatal defects, whereas ephrin-B2LacZ/ΔV and ephrin-B2LacZ/6YFΔV embryos 
have hypospadias (Dravis and Henkemeyer, 2011). This led to the conclusion that PDZ-
dependent reverse signaling functions of ephrin-B2, in addition to a not-yet identified function of 
the intracellular domain, are important for midline closure of the embryo.  
Further investigation of the effects of ephrin-B2 cytoplasmic mutants in the context of 
lymphatic valve development resulted in the surprising discovery that these mutants may affect 
not only reverse signaling, but also forward signaling. EphB4/ephrin-B2 signaling is critical for 
lymphatic valve development, which in turn is important for maintaining tissue fluid homeostasis 
by allowing drainage of interstitial fluid and preventing backflow of lymph (Zhang et al., 2015). 
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Treating early neonatal mice (P1-P2) with antibodies that block ephrin-B2 or EphB4 function 
results in dilation of lymphatic vessels and defects in lymphatic valve structure soon thereafter, 
with complete absence of valves and death by postnatal day 8 (P8). However, Zhang and 
colleagues showed that co-administration of anti-ephrin-B2 with an antibody that is agonistic to 
EphB4 function, increasing its tyrosine phosphorylation, rescued these defects, suggesting that 
forward signaling may be sufficient in this context. These defects are similar to those seen in 
mice expressing a mutant ephrin-B2 lacking its PDZ domain interaction site (ephrin-B2ΔV) 
(Makinen, 2005) or in ephrin-B26YFΔV/6YFΔV  mice that lack PDZ- and phosphorylation-dependent 
reverse signaling (Zhang et al., 2015), but EphB4 tyrosine phosphorylation is also significantly 
reduced, at least in Efnb26YFΔV/6YFΔV embryos, indicating that this ephrin-B2 mutant also affects 
forward signaling. Treatment with the EphB4 agonist antibody also rescues the lymphatic valve 
defects in Efnb26YFΔV/6YFΔV mutants, strongly suggesting that it is ephrin-B2-driven EphB4 
forward signaling that is required for lymphatic valve development (Zhang et al., 2015). Although 
the mechanism by which mutating the cytoplasmic domain of ephrin-B2 could lead to defects in 
EphB4 forward signaling is not yet known, it has been shown that the intracellular region of 
ephrin-Bs can affect how a signal is processed in EphB expressing cells (Jorgensen et al., 
2009). Further, Efnb2LacZ/LacZ mutant mice, with the entire cytoplasmic domain of ephrin-B2 
replaced with LacZ, do not have lymphatic valve defects, and in fact have increased EphB4 
tyrosine phosphorylation, probably due to tetramerization driven by the β-galactosidase (Zhang 
et al., 2015). This suggests that the ephrin-B2LacZ allele is hypermorphic for forward signaling 
rather than a reverse signaling mutant. Zhang and colleagues inhibited EphB4 kinase signaling 
using either a small molecule inhibitor or mice expressing an analog-sensitive EphB4 kinase 
mutant and showed that inhibiting EphB4 kinase signaling results in a severe lymphatic valve 
phenotype, without any manipulation of ephrin-B2 (Zhang et al., 2015). The results from the 
above experiments suggest that a variety of cytoplasmic mutations in ephrin-B2 disrupt forward 
signaling; in combination with the data that interruption of forward signaling alone is sufficient to 
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recapitulate the lymphatic valve phenotypes under study, this work calls into question whether 
or not reverse signaling is involved in this developmental event.  
The extent to which studies using mutations of the ephrin-B cytoplasmic domain could 
lead to incorrect conclusions about the respective roles of forward and reverse signaling in 
contexts outside of lymphatic development is unclear. It is unlikely that gain-of-function activity 
of the ephrin-B2LacZ allele is responsible for all of the exhibited phenotypes, because 
Efnb2LacZ/6FΔV and Efnb2LacZ/ΔV mutants still exhibit urorectal malformations with a penetrance 
significantly higher than Efnb2LacZ/+ embryos (Dravis and Henkemeyer, 2011). Further, the 
Efnb2CR conditional loss of function model also exhibits urorectal malformations and TEF, 
indicating that these phenotypes are loss of function phenotypes that may be caused by loss of 
reverse signaling (Lewis et al., 2015). Cleft palate, on the other hand, does not occur in these 
Efnb2CR mice, suggesting that this phenotype in Efnb2LacZ/LacZ mice could be caused by 
hyperactivation of forward signaling.  
The data that have emerged regarding the effects of ephrin-B reverse-signaling mutants 
on Eph receptor forward signaling suggests that the interplay between forward and reverse 
signaling will prove to be an even more complicated subject than was previously thought. In 
determining the contributions of forward and reverse signaling to in vivo phenotypes, it will be 
essential to examine forward signaling activation in reverse signaling mutants to rule out 
contributions of cytoplasmic ephrin-B mutants to hyper- or hypo-activation of forward signaling. 
It should also be noted that very similar mutants to those described in the above section are 
frequently re-expressed, over-expressed, or mis-expressed to evaluate signaling function in 
other model systems where knock-ins are not technically straightforward. Nearly all of the 
potential caveats and complications considered above are also possible in these systems, 
which additionally must account for the consequences of exogenous expression. Thus, these 
studies highlight that our understanding of in vivo Eph/ephrin signaling mechanism is still 
evolving and will benefit from additional approaches. For example, mutations that selectively 
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block Eph receptor kinase signaling, such as those that use kinase-dead or analog-sensitive 
kinase mutant Eph receptors, have been recently used to study kinase signaling mechanisms in 
a number of contexts (O’Neill et al., 2016; Robichaux et al., 2014; Robichaux et al., 2016; 
Soskis et al., 2012). In the future, it will be valuable to identify effectors downstream of forward 
and reverse signaling activation relevant to specific contexts and demonstrate that loss of 
function of these downstream processes contributes to the observed phenotype.  
 
Eph/ephrin signaling directs cell positioning during embryonic development 
Eph/ephrin signaling is essential to axon guidance, with repulsive interactions between 
Ephs and ephrins expressed in axons and in their target zone cells mediating correct formation 
of synapses in many different areas of the developing nervous system (Egea and Klein, 2007). 
Analogous to this role in axonal pathfinding, Ephs and ephrins have also been described as 
guidance cues that mediate migration of cells over long distances by repeated short-range 
interactions. Although from a cellular perspective, Eph/ephrin signaling has been widely 
implicated in regulating cell migration, the specific functions differ somewhat across different 
developmental contexts such as neural crest migration, neuronal migration guidance pathways 
in the brain, and the migration of cells to establish left-right asymmetry. 
 
Neural crest cell migration 
Eph/ephrin signaling has repeatedly been shown to be critical for development of neural 
crest cells (NCCs). From the earliest stages, Eph/ephrin signaling regulates NCC development 
in Xenopus. Forward signaling from ephrin-B1 and ephrin-B2 in the dorsal mesoderm inhibits 
Wnt signaling required to induce NCCs; the Adam13 metalloprotease cleaves ephrin-B1 and 
ephrin-B2 to relieve this inhibition and allow NCC induction (Wei et al., 2010). Studies in chick 
and Xenopus have proposed a repulsive mode of neural crest guidance, wherein disruption of 
Eph/ephrin signaling results in invasion of NCCs into ectopic territories. Using in vitro stripe 
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assays in which soluble ephrin ligand is immobilized in narrow stripes on cover slips, cultured 
chick or rat NCCs, which express EphB receptors, avoid stripes of ephrin-B protein, instead 
preferring to migrate alongside (Krull et al., 1997; Wang and Anderson, 1997). In rat and mouse 
embryos, ephrin-B2 expression is restricted to the caudal half of the somite, whereas in chick 
embryos ephrin-B1 exhibits this pattern of expression, leading to the idea that caudally-
expressed ephrin-B guides EphB-expressing trunk NCC migration to the rostral half of the 
somite (Figure 5A). Eph/ephrin signaling has been implicated in cranial neural crest guidance 
as well. In Xenopus, rhombomeric boundaries set up by expression of EphA4 and ephrin-B2 
expression in r5 and r4, respectively, extend to migratory NCC populations derived from those 
rhombomeres, whereas EphB1 is expressed in NCCs destined for branchial arches (BA) 3 and 
4. Disruption of EphA4/EphB1 function by overexpression of truncated receptors, or by blinding 
the NCCs to the position of ephrin-B2 signal by overexpression of ephrin-B2, results in NCC 
intermingling during migration (Smith et al., 1997). In addition to a role in segmental guidance, 
Eph/ephrin signaling in Xenopus has also been demonstrated to regulate migration of NCCs 
along the ventral or dorsolateral pathways. Expression of multiple ephrins along the dorsolateral 
pathway repels and guides early-migrating NCCs expressing EphB receptors along the ventral 
pathway. Interestingly, migration of melanoblast NCCs, which also express EphB receptors, is 
promoted along the dorsoventral pathway by increasing adhesion (Santiago and Erickson, 
2002).  
In mouse, genetic disruption of ephrin-B2 also perturbs normal NCC development, with 
Efnb2null mouse embryos exhibiting both angiogenic remodeling defects and NCC defects that 
result in abnormal BA development and trunk NCC segmentation (Davy and Soriano, 2007). It 
has been difficult to assess the exact role of ephrin-B2 in NCC development in vivo, as 
angiogenic defects lead to early embryonic lethality of Efnb2null embryos. An attempt to separate 
the role of ephrin-B2 in the vasculature from its contributions to NCC migration resulted in the 
surprising discovery that rescuing expression of ephrin-B2 only in the vascular endothelium (VE) 
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is sufficient to obtain normal NCC migration and BA development (Lewis et al., 2015). In mice 
with a conditional rescue of ephrin-B2 in the vasculature in an otherwise ephrin-B2 null embryo 
(Tie2-Cre; Efnb2CR), not only angiogenesis defects, but also BA morphogenesis and cranial and 
trunk NCC defects, are rescued. Further, loss of ephrin-B2 specifically in the vasculature, again 
mediated by Tie2-Cre, resulted in angiogenic and neural crest phenotypes, as well as increased 
cell death in migrating cranial and trunk NCCs, suggesting that without proper vascular 
development, NCC survival is compromised. From these studies, it is apparent that in mouse, 
proper ephrin-B2 expression, or angiogenesis regulated by ephrin-B2, is a requirement for NCC 
development, and that ephrin-B2 may not have a role in repulsive NCC guidance as previously 
proposed. The role of the VE in regulating NCC migration, however, remains unclear. EphB4 
plays an important role in ephrin-B2 signaling in the context of angiogenesis: Ephb4-/- mice have 
similar angiogenic remodeling defects to Efnb2null mice, as well as similar NCC and BA 
morphogenesis phenotypes. However, because EphB4 is not expressed in NCCs, it seems 
unlikely that signaling to NCCs from ephrin-B2 in the VE is required (Lewis et al., 2015). Even 
without pinpointing the exact mechanism by which angiogenic remodeling contributes to NCC 
migration, it seems likely that the role of ephrin-B2 in the process is a secondary one in allowing 
the vasculature to develop and function normally, which in turn provides an as yet unknown, but 
essential, support to NCCs. It is possible that ephrin-B2 signaling from the VE may provide a 
guidance role for NCCs; further studies will be needed to determine whether this is the case, or 
whether angiogenesis plays a more permissive role in NCC survival. For example, normal 
angiogenesis may be required for delivery of oxygen, nutrients, or other signaling molecules 
required for NCC survival (Figure 5A) (Lewis et al., 2015). Interestingly, Eph/ephrin signaling 
may also have a more direct role in NCC survival. Ectopic expression of ephrin-A5-Fc in mouse 
dorsal neuroectoderm and NCCs, mediated by Wnt1-Cre, led to decreased NCC survival and 
diminished NCCs of the frontonasal prominence and BA1 and BA2 (Noh et al., 2014).  
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Like the trunk NCCs from which they are derived, the sympathetic ganglia (SG) are also 
segregated to the rostral half of each somite. This organization, however, is not the 
consequence of early migratory guidance of NCCs, which lose their segregated pattern and 
intermix along the anteroposterior axis upon arrival at the site of SG formation, but of later re-
sorting of NCCs into discrete ganglia following their arrival at sympathetic ganglia target sites 
(Kasemeier-Kulesa et al., 2005). Live imaging studies in chick have demonstrated that the 
segregation of NCCs into SG involves repulsive Eph/ephrin signaling wherein expression of 
ephrin-B1 in the rostral half of the somite expands to the mesoderm, signaling to NCCs 
expressing EphB2 to drive their condensation into discrete SG (Kasemeier-Kulesa et al., 2006). 
Disruption of this late repulsive cue disrupts SG formation even when early segmental NCC 
guidance is maintained due to loss of directionality in their repulsion.  
 
Neuronal migration 
Eph/ephrin signaling plays important roles in development of the mammalian neocortex 
and hippocampus by regulating radial and tangential neuronal migration. In the cortex, tightly 
controlled migration of neurons born at the ventricular zone leads to formation of a highly 
organized, layered structure. As the location of different excitatory neurons with different 
functions in each layer is essential to the future function of the cortex, newly born neurons at the 
proliferative ventricular zone of the cortex must migrate radially to a distinct position, with each 
successive generation of neurons migrating past older-born neurons. In the hippocampus, 
migration of neuronal precursors is also essential for the differentiation of these neurons to form 
mature structures. Interestingly, several studies have indicated that Eph/ephrin signaling 
functions together with Reelin signaling in neuronal guidance in the cortex and hippocampus 
(Bouché et al., 2013; Catchpole and Henkemeyer, 2011; Sentürk et al., 2011). Reelin is a 
secreted glycoprotein that regulates neuronal migration and cortical layering, and reeler (Reln-/-) 
mice have cortical phenotypes including “inside-out” layering, with late-born neurons aberrantly 
 31 
located in deeper layers of the cortex and earlier-born neurons in upper layers. Efnb1/b2/b3 
compound knockout mice mimic reeler cortical phenotypes, and loss of one copy of Reelin on 
an Efnb2-/- or Efnb3-/- background leads to alterations in cortical layering and hippocampal 
structures similar to those seen in reeler mice, though Reln+/- mice alone are unaffected 
(Sentürk et al., 2011). Although this suggests that Reelin and ephrin-Bs interact to facilitate 
correct radial migration of neurons to form the laminated cortex (Figure 5B), these phenotypes 
seem to depend on the Efnb3 knockout strategy used, as well as the genetic background of the 
mouse strain (Pohlkamp et al., 2016).  
In the hippocampus, loss of forward signaling from ephrin-B1 to EphB2 leads to a 
reduction in granule cell neurons in the lateral suprapyramidal blade (LSB) of the dentate gyrus, 
resulting from decreased migration of precursor cells into this area (Catchpole and 
Henkemeyer, 2011). Notably, EphB2 and ephrin-B1 mutant mice demonstrate a decrease in 
Reelin expression adjacent to the LSB, suggesting that forward signaling through EphB2 is 
necessary for Reelin expression to promote migration of precursor cells into the LSB (Catchpole 
and Henkemeyer, 2011). However, the direct mechanisms by which EphB2 and ephrin-B1 
influence the expression and secretion of Reelin in the hippocampus are unknown.  
Canonical Reelin signaling involves Reelin binding to lipoprotein receptors VLDLR and 
ApoER2, leading to tyrosine phosphorylation of Dab1, but VLDLR/ApoER2 have no intrinsic 
kinase activity, which is instead fulfilled by the recruitment of Src-family kinases (D’Arcangelo et 
al., 1999; Howell et al., 1999). Physical interactions between Reelin, EphB, and ephrin-B 
proteins have been demonstrated in both the cortex and the hippocampus, suggesting that 
EphB/ephrin-B signaling may synergize with Reelin signaling to affect neuronal migration. 
Specifically, Reelin interacts with ephrin-B2 and ephrin-B3 proteins, and stimulation of cultured 
cortical neurons with Reelin results in clustering of ephrin-Bs (Sentürk et al., 2011). Sentürk and 
colleagues point to reverse signaling through ephrin-Bs as a “missing link” that recruits Src 
family kinases to phosphorylate Dab1. Stimulation of cortical neurons with EphB3-Fc results in 
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tyrosine phosphorylation of Dab1, and Efnb1/b2/b3 knockout mice have decreased Dab1 
phosphorylation (Sentürk et al., 2011), though genetic evidence supporting the involvement of 
the ephrin-B cytoplasmic domain in Dab1 phosphorylation has not yet been shown. Reelin also 
coimmunoprecipitates with recombinant EphB1, EphB2, and EphB3 in cultured neurons and 
induces EphB tyrosine phosphorylation, proteolytic processing, and cytoskeletal responses in 
Cos1 cells (Bouché et al., 2013). These effects are independent of the canonical Reelin 
receptors (Bouché et al., 2013). However, the in vivo relevance of these biochemical 
interactions to cortical lamination, and the mechanisms of synergy between Eph/ephrin 
signaling and Reelin signaling, remain uncertain. Loss of EphB2 kinase signaling results in 
aberrant cell dispersal in the CA3 region of the hippocampus (Figure 5B), demonstrating that 
EphB forward signaling is required for this in vivo event. However, these studies face a 
challenge in distinguishing Reelin-to-Eph signaling from ephrin-to-Eph signaling. Bouché and 
colleagues argue that the hippocampal CA3 defects in compound Ephb1; Ephb2 mutant mice 
are a result of Reelin-mediated forward signaling, not ephrin-B1-mediated forward signaling, 
because ephrin-B1 knockout mice have a much milder CA3 phenotype than the Ephb1; Ephb2 
mutants, whereas the reeler mouse phenotype is similar to the Ephb1; Ephb2 mutant phenotype 
(Bouché et al., 2013). However, although neither ephrin-B2 nor ephrin-B3 were found to be 
expressed in the CA3 region during hippocampal neuronal migration, it is impossible to rule out 
the contribution of ephrin-B1 or as yet unknown contributions from other ephrins that may bind 
to and activate EphB1/EphB2. In the future, studies that examine compound EphB 
receptor/Reelin mutant mice, probe EphB receptor signaling changes in reeler mice, or 
differentiate the downstream signaling pathways of EphB receptors activated by ephrins vs. 
activated by Reelin, may shed further light on the in vivo relevance of these interactions. 
Although the mechanism of Reelin interactions with EphBs or ephrinBs to facilitate neuronal 
migration remains unclear, it is apparent that Reelin can interact genetically and biochemically 
with several members of this pathway, demonstrating that Eph/ephrin signaling molecules are 
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able to integrate with Reelin signaling to assist in mediating signaling outcomes that lead to 
correct positioning of neurons.  
Ephrin-B1 also plays an early role in maintenance of the structural integrity of the apical 
surface of the developing cortex, which is necessary for correct cortical lamination. Maintenance 
of apical attachment of neural progenitors at the ventricular zone and attachment of neighboring 
apical progenitors to each other via adherens junctions are regulated by ephrin-B1 signaling, 
and Efnb1+/- and Efnb1-/- embryos demonstrate abnormal folding of the apical surface of the 
neuroepithelium (Arvanitis et al., 2013). Efnb1 mutant embryos demonstrate changes in cell-
ECM adhesion at the apical surface, with decreases in apical localization, but not mRNA or 
protein expression of integrin-b1. Notably, cell-cell adhesion, examined via N-cadherin 
expression, and cell polarity, marked by the apical distribution of b-catenin, are unaffected in 
these mutants. In ex vivo cortical slices, acute loss of ephrin-B1 results in loss of elongated cell 
morphology and detachment of cells from the apical surface of the ventricular zone. Ephrin-B1 
tyrosine phosphorylation and the PDZ interaction domain of the ephrin-B1 intracellular domain 
are not necessary for maintenance of apical adhesion, as expression of ephrin-B1 lacking its 
cytoplasmic domain rescues the cell-ECM adhesion defects (Arvanitis et al., 2013). By 
synergizing with integrin-b1 signaling to maintain the integrity of the apical surface of the 
ventricular zone of the cortex, therefore, ephrin-B1 signaling plays a critical role in coordinating 
the development of the cortex. Here, ephrin-B1 does not serve directly as a guidance cue, but 
rather plays an indirect role, serving as a structural support system for neural progenitors to 
allow maintenance of apical adhesion during the early development of the cortex. Future studies 
defining the mechanisms of Eph/ephrin support of neuronal migration, through Reelin signaling 
or other pathways, will provide more insight into the roles of this pathway in defining correct cell 
positioning in the developing brain.  
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Guidance of cell migration to establish left-right asymmetry 
Eph/ephrin signaling has recently been implicated in establishing left-right asymmetry in 
the developing zebrafish embryo. The dorsal forerunner cells (DFCs), precursor cells to the 
Kupffer’s vesicle (KV), the left-right organizer in zebrafish, express EphB4b, while the 
surrounding mesendodermal cells express ephrin-B2b, and signaling between them maintains 
DFC cluster integrity as the cells migrate past each other (Zhang et al., 2016). These 
interactions are mediated by extension of protrusions from DFCs that are then repulsed by the 
neighboring cells, and loss of EphB4b leads to loss of RhoA and pMLC expression at the DFC-
mesendoderm boundary, slowing of this repulsive response, and subsequent dispersal of DFCs, 
ultimately resulting in a smaller or absent KV and defects in later asymmetric positioning of 
organs (Zhang et al., 2016). Eph/ephrin signaling is also involved in epithelial-mesenchymal 
interactions that control asymmetrical positioning of the liver (Cayuso et al., 2016). Cayuso and 
colleagues demonstrate that EphB3b/ephrin-B1 signaling between the lateral plate mesoderm 
(LPM) and the hepatoblasts of the forming liver results in hepatoblast repulsion that is critical for 
correct asymmetric positioning of the liver (Figure 5C), challenging the existing model that the 
LPM actively pushes hepatoblasts, which are passively corralled into place. Hepatoblasts form 
long cellular protrusions that are lost in ephrin-B1 morpholino-treated embryos but increased 
with loss of direction in ephb3b morphants (Cayuso et al., 2016). Expressing reverse signaling 
mutant ephrin-B1 proteins in an ephrin-B1-deficient background has varying effects on 
protrusion formation. Adding ephrin-B16F rescues hepatoblast protrusion formation, whereas 
adding ephrin-B1ΔV does not. The authors conclude that PDZ-dependent reverse signaling 
mediates protrusion formation, independent of tyrosine phosphorylation of the cytoplasmic 
domain of ephrin-B1, to permit hepatoblast movement away from the midline and facilitate 
asymmetric positioning of the liver. Though no examination of possible changes to forward 
signaling in EphB3b-expressing LPM cells was made, ectopic expression of EphB3bΔICD (lacking 
the intracellular domain) in the left LPM, where there is little endogenous EphB3b, resulted in 
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movement of the hepatoblasts to the right side, consistent with a role of reverse signaling in 
repulsion of hepatoblasts from the LPM and establishing the asymmetric positioning of the liver. 
Further studies of the role of Eph/ephrin signaling in liver positioning, as well as in the 
establishment of asymmetry in other organ systems, will elucidate the signaling mechanisms 
involved in these processes.  
 
Eph/ephrin signaling translates patterning cues to separation between embryonic tissues 
Establishing and maintaining separation between tissues during development is a 
multifaceted process requiring patterning to establish cell fate, segregation of different cell types 
to form boundaries, and prevention of cell migration and intermingling across these boundaries. 
A classical view of Eph/ephrin-mediated tissue separation involves reciprocal expression of 
Ephs and ephrins in separate compartments, with bidirectional signaling across the Eph/ephrin 
expression boundary preventing intermingling (Kania and Klein, 2016). This model stems from 
studies of Eph receptors and ephrins in the organization of the developing embryo: in the brain, 
spinal cord, branchial arches, limb buds, and somites, Eph receptor and ephrin expression 
appeared mutually exclusive and restricted to defined domains, leading to the proposal that 
Ephs may encounter ephrins only at the boundaries between these domains (Gale et al., 1996). 
Further study suggested that reciprocal expression can contribute to tissue separation and 
maintenance of boundaries between morphologically defined compartments, such as the 
rhombomeres of the zebrafish hindbrain (Xu et al., 1999). More recent evidence demonstrates 
the existence of more complex patterns of Eph/ephrin expression and signaling during 
development (Barrios et al., 2003; O’Neill et al., 2016; Rohani et al., 2014). Eph/ephrin signaling 
has long been studied as a mediator of boundary formation and maintenance in early neural 
development, gastrulation, and somitogenesis. Recently, increased complexity of Eph/ephrin 
expression patterns and signaling has been demonstrated in each of these contexts, providing 
evidence for a more nuanced role of Eph/ephrin signaling at tissue boundaries that depends 
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both on context and on the combinatorial expression of Eph receptors and ephrins in the tissue 
in question. In each of these situations, Eph/ephrin signaling is a downstream effector of 
boundary formation and maintenance, translating patterning information to physical separation. 
The mechanisms by which tissue separation is achieved are still under study, but include 
changes to adhesion, cytoskeletal dynamics, cellular repulsion, and cell migration.  
 
Eph/ephrin-mediated boundary formation during early neural development 
The first discovery of Eph/ephrin signaling in cell segregation and boundary formation 
was in the developing nervous system. Segmentation of the vertebrate hindbrain during 
development leads to the formation of compartments termed rhombomeres, which demarcate 
boundaries between different areas of the hindbrain that will eventually develop into different 
adult structures. Importantly, the organization of the rhombomere separates precursor cells of 
different neuronal subtypes and contributes to the later organization of hindbrain neurons 
(Moens and Prince, 2002); inappropriate cell mixing must therefore be prevented to preserve 
normal adult hindbrain function. Eph receptors are expressed in odd-numbered rhombomeres, 
and ephrins are expressed in even-numbered rhombomeres, leading to the proposal that 
signaling mediates repulsive interactions at rhombomere boundaries (Figure 6A) (Xu et al., 
1999) or differential adhesion between cells of different rhombomeres (Cooke et al., 2005; 
Kemp et al., 2009).  
In the developing zebrafish hindbrain, gene expression boundaries become 
morphological boundaries, which manifest as shallow indentations between rhombomeres by 
15h post fertilization. Morpholino knockdown of EphA4a, which is usually expressed in 
rhombomeres r3 and r5, resulted in jagged edges to rhombomere boundaries, with krx20-
expressing cells from r3 and r5 invading into the adjacent even-numbered rhombomeres 
(Calzolari et al., 2014). Invading cells do not immediately change their fate, suggesting that 
Eph/ephrin signaling acts downstream of patterning cues, and indeed, Eph/ephrin expression 
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patterns in rhombomeres are established in part through the transcription factors Krox20 and 
HoxB4. In zebrafish, Krox20 binds and drives expression from an r3/r5 enhancer element 
harbored by EphA4 and deletion of this binding site leads to loss of r3/r5 enhancer activity, 
suggesting that EphA4 is directly regulated by Krox20 (Theil et al., 1998). Krox20 also directly 
regulates the expression of multiple Hox genes, suggesting a means of coupling downstream A-
P cell fate specification with physical separation of rhombomeres (Theil et al., 1998). More 
recently, it has been suggested that coupling cell fate with tissue separation in the hindbrain 
may entail a more complicated hierarchy that also depends on A-P specification; indeed, loss of 
Hox genes disrupts not only A-P identity, but also rhombomere boundaries (Prin et al., 2014). In 
mouse and chick, Hoxb4 and Hoxd4 share their anterior expression border at the r6/r7 
boundary, and loss of both resulted in loss of the r6/r7 boundary. In addition, widespread 
misexpression of Hoxb4 also disrupted rhombomere boundaries, and mosaic misexpression of 
Hoxb4 or any of several other Hox genes caused aberrant segregation within a rhombomere, 
indicating that a differential in Hoxb4 (and its targets) drives rhombomere formation. One such 
target may be EphA7: upon loss of Hoxb4 and Hoxd4, EphA7 was upregulated caudal to the 
site of the r6/r7 border, while ectopic expression of Hoxb4 resulted in EphA7 repression rostral 
to this border. Functional evidence for a requirement of EphA7 in r6/r7 boundary formation is so 
far lacking, however, and complementary ephrin expression at this boundary has not been 
identified. Mosaic expression of several different Hox proteins induced cell segregation, but the 
segregating effect of Krox20 expression predominated, suggesting that a hierarchy of 
combinatorial regulation of Eph/ephrin genes by multiple transcription factors couples A-P cell 
fate specification to tissue separation.  
As the morphological changes that define rhombomere boundaries take place, actin and 
myosin II accumulate to form a cable between rhombomeres (Calzolari et al., 2014), suggesting 
a mechanism by which Eph/ephrin signaling may direct both cell segregation and the formation 
of a physical barrier to cell intermingling. Work in Drosophila, Xenopus, and mouse, as well as 
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in human cell culture, similarly support the broad idea that regulation of actomyosin contractility 
contributes to Eph/ephrin-mediated segregation (Aliee et al., 2012; Monier et al., 2010; O’Neill 
et al., 2016; Rohani et al., 2011; Umetsu et al., 2014). In the rhombomere, cells can move past 
a boundary via cell division but are rapidly pushed back into their proper position, perhaps by 
the elastic boundary formed by the actomyosin cable (Calzolari et al., 2014). The actomyosin 
cables appear to colocalize with EphA4a in r3/r5, and disrupting actin or myosin II using ROCK 
inhibitors or Blebbistatin results in dismantling of the cables and invasion of r3/r5 cells into even-
numbered rhombomeres, creating jagged rhombomere boundaries. Conversely, stabilizing 
phosphorylated myosin by treatment with calyculin A results in even more pronounced 
rhombomere boundaries. Importantly, morpholino knockdown of EphA4a disrupts actomyosin 
cable formation in a similar manner to ROCK inhibition or Blebbistatin treatment, and the jagged 
boundaries that form can be rescued by treatment with calyculin A (Calzolari et al., 2014), 
indicating that EphA4a acts upstream of myosin to modulate formation of this physical 
boundary. Further, ectopic activation of EphA4a in even-numbered rhombomeres results in 
accumulation of actomyosin in EphA4a-expressing cells only if they are surrounded by ephrin-
expressing cells, suggesting that Eph/ephrin signaling acts to upregulate actomyosin. Boundary 
sharpening appeared to begin before actomyosin enrichment could be observed, however 
(Calzolari et al., 2014), suggesting that additional mechanisms may be at play in initial 
rhombomere boundary sharpening. 
Eph/ephrin signaling also acts downstream of patterning cues during forebrain 
development in zebrafish. During neurulation, the cells of the prospective eye field evaginate to 
form the optic vesicles, which must remain separated from the cells of the prospective 
telencephalon and diencephalon for proper eye development. Eph receptor expression in the 
telencephalon and ephrin expression in the eye field are essential to this process, as 
morpholino knockdown or misexpression of these molecules results in delayed optic vesicle 
evagination and aberrant localization of eye field cells within the telencephalon (Cavodeassi et 
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al., 2013). In addition, misexpression of the normally telencephalon-restricted EphB4a in eye 
field cells causes them to segregate into the telencephalon while retaining eye field markers, 
indicating that Eph/ephrin expression determines their movement regardless of fate 
(Cavodeassi et al., 2013). In zebrafish mutants that have lost expression of the eye field 
transcription factor Rx3, Eph receptor expression expands into the eye field while ephrin 
expression remains normal, placing Eph/ephrin signaling downstream of patterning (Cavodeassi 
et al., 2013). Although the boundary between the eye field and the telencephalon is enriched in 
both F-actin and pMLCII, this study does not investigate whether Eph/ephrin signaling directly 
regulates the cytoskeleton in this context.  
Pathogenic cell segregation in the neural plate neuroepithelium in the mouse model for 
CFNS also depends on modulation of the cytoskeleton (Figure 6B). Genetic disruption of 
ROCK using a dominant-negative allele in Efnb1+/- mice or pharmacological inhibition using the 
ROCK inhibitor Y-27632 in a cell culture model for segregation dramatically decreased the size 
of aberrant ephrin-B1 expression patches in each context (O’Neill et al., 2016). Interestingly, 
genetic interaction studies indicated that loss of Cdc42 or Rac1 function did not reduce 
segregation in Efnb1+/- embryos, consistent with the possibility that actomyosin contractility per 
se, and not cell migratory capacity more generally, may drive segregation in CFNS.  
 
Eph/ephrin signaling in germ layer separation during gastrulation 
Gastrulation represents one of the earliest tissue separation events in the embryo. The 
propensity for separation between cells of the germ layers is so strong that in the classic 
experiments of Townes and Holtfreter, even when cells of the amphibian germ layers were 
dissociated into single cells and forcibly mixed, they segregated from one another in culture to 
re-aggregate in groups of like cells (Townes and Holtfreter, 1955). Eph/ephrin signaling is 
required to maintain the boundary between the ectoderm and mesoderm during Xenopus 
gastrulation. Recent studies of the formation and maintenance of these boundaries have added 
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a layer of complexity to our understanding of Eph/ephrin regulation of these early tissue 
separation processes.  
In the Xenopus gastrula, the mesoderm translocates across the ectodermal blastocoel 
roof (BCR), producing a paradox whereby mesoderm cells must be prevented from integrating 
into the ectoderm as they adhere to it while migrating. This process can be reconstituted in vitro 
using explant culture experiments, and live imaging of the mesoderm-ectoderm explant 
boundary reveals fast cell detachment and reattachment events, which may enable the 
adhesive contacts that mediate the collective migration of the mesoderm along the BCR, while 
preventing intermingling (Rohani et al., 2011). Multiple EphB and ephrin-B proteins are 
expressed in both the mesoderm and the ectoderm, and morpholino knockdown of ephrin-B1, 
ephrin-B2, or EphB4 in either the mesoderm or the ectoderm leads to increased integration of 
mesoderm cells into the BCR, suggesting a more complex situation than in the classical 
complementary expression model. Competitive inhibition of forward signaling by overexpression 
of truncated EphB4 resulted in diminished separation, and while combinatorial morpholino 
knockdown of ephrin-B expression in one explant and EphB expression in the opposing explant 
did not further decrease segregation, loss of both ephrin-B and EphB expression in the same 
explant does. These data have led to the conclusion that ectoderm-mesoderm separation is 
likely governed by multiple antiparallel forward signaling pathways across the boundary (Figure 
6C) (Rohani et al., 2011; Rohani et al., 2014). Addition of preclustered ephrin-B-Fc fusion 
proteins to activate forward signaling can rescue attachment-detachment cell behaviors and 
separation from ephrin-B knockdown mesoderm or endoderm, further indicating that activation 
of Eph receptors in both tissues mediates segregation. This result is surprising in that it 
suggests that positional information conferred by cellular ephrin signaling in each cell population 
may not be important; activation of Eph receptor signaling in all cells in the explant results in 
tissue separation only at the explant boundaries. It seems, therefore, that activation of Eph 
receptor signaling in either population renders the populations somehow less miscible. The 
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outcome of Eph/ephrin signaling across the ectoderm-mesoderm boundary is at least partly 
mediated by activation of RhoA and Rac and results in enrichment of F-actin at the boundary 
(Rohani et al., 2011). In contrast to reciprocal Eph/ephrin expression, these data demonstrate 
that more complex mechanisms involving multiple coexpressed Ephs and ephrins may be 
required to localize cytoskeletal and cell behavioral changes to a boundary. These results also 
indicate that unidirectional signaling is sufficient to produce separation, although in this case it is 
required in both tissues (Rohani et al., 2011).  
If Ephs and ephrins are expressed throughout both the ectoderm and mesoderm, how is 
tissue separation restricted only to their interface? Whereas complete specificity of Eph/ephrin 
pair binding, with signaling only at the boundary, is unlikely based on known receptor-ligand 
affinities, completely promiscuous binding would result in repulsion within both the ectoderm 
and mesoderm, leading to complete dissolution of the tissue. Instead, work by Rohani and 
colleagues suggests that an intermediate situation exists, in which antiparallel signaling 
between complementary pairs of Ephs and ephrins creates the strongest signaling interface at 
the heterotypic mesoderm-ectoderm boundary (Rohani et al., 2014). Importantly, although 
complete specificity is not necessary for separation in this model (both ephrin-B2 and ephrin-B3 
can signal through EphA4, for example), neither are the Ephs and ephrins functionally 
redundant. Only ephrin-B2 signals through EphB4, and the phenotypes of morpholino 
knockdown of one Eph/ephrin family member are not rescued by expression of another. Further, 
chimeric Eph receptors composed of the extracellular domain of one receptor and the 
intracellular domain of another can only rescue depletion of the Eph whose extracellular domain 
they possess, indicating that specificity depends on differential Eph/ephrin binding occurring at 
the boundary, which may activate different downstream signaling cascades. A baseline level of 
adhesion between homotypic cell pairs of the ectoderm and mesoderm, provided by cadherin 
expression, is required to maintain the homotypic tissue cohesivity required for border 
sharpening (Rohani et al., 2014; Taylor et al., 2017). Whether homotypic repulsion is simply 
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overcome by differential adhesive forces provided by cadherins, or whether other mechanisms, 
such as cis inhibition of signaling, also contribute to blunting homotypic signaling outcomes, is 
not yet known. 
An important remaining question involves the mechanisms that establish the differential 
expression of Eph and ephrin proteins in different germ layers. It is possible that transcription 
factor patterning alone maintains Eph/ephrin expression domains, but transcription factors that 
affect Eph/ephrin expression in the Xenopus ectoderm and mesoderm are not yet known. 
However, during gastrulation, Eph/ephrin protein stability is regulated through degradation of 
ephrin-B1 by ubiquitination, which is mediated by Smad ubiquitin regulatory factors (Smurfs). 
Interactions between ephrin-B1 and Smurf2 lead to ephrin-B1 ubiquitination and degradation, 
whereas interactions between ephrin-B1 and Smurf1 prevent its interaction with Smurf2, 
forestalling degradation (Hwang et al., 2013). Smurf2-mediated degradation of ephrin-B1 
prevented separation between the endoderm and mesoderm, but Smurf1 binding to ephrin-B1 
inhibits this interaction to allow separation. Loss of separation upon loss of Smurf1 can be 
rescued by subsequent knockdown of Smurf2 (Hwang et al., 2013). This reveals that 
modulating protein stability is one mechanism by which ephrin-B1 can be regulated to eventuate 
tissue separation during gastrulation.  
 
Eph/ephrin signaling in the separation between forming somites 
The formation of somites is a key step in the axis elongation and segmentation of the 
vertebrate embryo. The cells of the somites are precursors to vertebral and rib structures, as 
well as to skeletal muscle and dermis of the skin. Segmentation must be tightly regulated to 
ensure that segment number is strictly maintained, which is essential to further normal 
development; although the number of somites may vary between species, it is generally fixed 
within a species (Bénazéraf and Pourquié, 2013). Somites form with a defined period, the length 
of which is dependent on the species (Bénazéraf and Pourquié, 2013). To achieve this, Wnt, 
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FGF, and Notch signaling pathways are activated in pulses in the presomitic mesoderm (PSM), 
leading to a “traveling wave” of mRNA expression of their transcriptional targets. Many of these 
targets encode negative-feedback inhibitors of Wnt, FGF, and Notch signaling, which may 
explain the periodic control of signaling through these pathways (Bénazéraf and Pourquié, 
2013). Downstream of this feedback loop, expression of segmentation genes such as Mesp2 is 
seen in the PSM of the future somite, preceding the morphological changes that mediate somite 
boundary formation.  
After the future somite is defined by patterning of segmentation genes, intercellular 
signaling is required to translate these cues into the morphogenetic processes that result in 
boundary formation and separation. Several Eph receptors and ephrins are expressed in the 
somites in developing mouse embryos (Gale et al., 1996), and expression of ephrin-A1, ephrin-
B2, and EphA4 in segmented patterns in the zebrafish PSM suggested that these signaling 
molecules may play a role in somite formation (Durbin et al., 1998). Indeed, overexpression of 
truncated Eph or ephrin proteins, which serve a dominant-negative function by binding their 
cognate ephrin or Eph and blocking downstream signaling, disrupted somite boundary 
formation, resulting in absent or abnormally-shaped somites (Durbin et al., 1998). Perturbation 
of Eph/ephrin signaling did not affect segmental prepatterning, but downstream markers of 
somite differentiation reflected the organization of the ectopic somite, indicating that Eph/ephrin 
signaling mediates the translation of segmental prepattern into physical somite separation. 
Activation of Eph/ephrin signaling is sufficient for boundary formation, because exogenous 
expression of EphA4 in zebrafish fss- mutants, which lack segmental expression of several 
Eph/ephrins and fail to form somites, was sufficient to induce somite boundary formation at the 
interface between clusters of EphA4-expressing and -nonexpressing cells (Barrios et al., 2003; 
Durbin et al., 2000). Separation was also induced when cells expressed a truncated EphA4 that 
lacks the intracellular tyrosine kinase domain, indicating that tissue separation can be induced in 
the absence of kinase signaling in this context (Barrios et al., 2003). These data suggest that 
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Eph/ephrin signaling may be directly involved in the morphogenetic processes that occur at the 
somite boundary, which include the formation of an indentation or furrow between adjacent 
somites; mesenchymal-to-epithelial transition of cells at either side of the boundary, which 
assume a columnar shape; accumulation of adhesion complex components, such as beta-
catenin, at the apical pole of the cell; basal movement of cell nuclei towards the somite 
boundary; and apical movement of centrosomes. Whereas initial gap formation requires reverse 
signaling, several of the subsequent epithelialization changes require forward signaling through 
either direct or non-cell-autonomous means (Barrios et al., 2003).  
Later work in chicken embryos suggests that both forward and reverse Eph/ephrin 
signaling may act in initial formation of the somite gap (Watanabe et al., 2009). In a gap-
inducing assay, transplantation of a cMeso-1-expressing explant into the PSM of a host chick 
embryo results in upregulation of EphA4 and formation of a gap at the cMeso-1 expression 
boundary (Watanabe et al., 2009). Likewise, overexpression of EphA4 or ephrin-B2 is sufficient 
to induce an ectopic gap. Overexpression of EphA4 lacking its intracellular domain also creates 
an ectopic gap, indicating that the intracellular domain of EphA4 is dispensable for somitic gap 
formation. Consistent with this, overexpression of ephrin-B2 lacking its intracellular domain or 
ephrin-B2YF (lacking three phosphorylatable tyrosines) does not induce an ectopic gap, 
indicating that phosphorylation-dependent ephrin-B2 reverse signaling is necessary for gap 
formation (Watanabe et al., 2009). Overexpression of constitutively active Cdc42 with ephrin-B2 
negates the ability of ectopic ephrin-B2 expression to induce an ectopic somite gap, but 
suppression of Cdc42 alone is not sufficient to induce the gap, though it is sufficient to rescue 
cell epithelialization. Inhibition of Cdc42 in conjunction with overexpression of ephrin-B2YF 
rescues both gap formation and cell epithelialization (Watanabe et al., 2009). The authors 
conclude that tyrosine phosphorylation of ephrin-B2 likely regulates Cdc42 to enable somite gap 
formation. Although it is clear that some portion of the cytoplasmic domains of both Ephs and 
ephrins are required for various aspects of the somite gap formation and cell epithelialization 
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process, the consequences of these mutations must be considered in light of new knowledge of 
the effects of ephrin cytoplasmic mutants on forward signaling, and much remains to be learned 
about the underlying mechanism. In particular, it remains to be determined whether somites, like 
the ectoderm and mesoderm in Xenopus gastrulation, require antiparallel forward signaling in 
addition to bidirectional signaling across a boundary.  
Changes in adhesion molecules and extracellular matrix interactions are key outcomes 
of Eph/ephrin signaling to promote somite separation (Figure 6D). As somites form and 
boundary cells undergo MET, a fibronectin (FN) matrix is assembled along the somite boundary. 
Both FN and its receptor, the heterodimer Integrina5b1, are required for somite formation 
(Koshida et al., 2005). Live imaging and genetic studies in transgenic zebrafish expressing the 
Itga5-GFP fusion protein show that Itga5 clustering occurs along the basal side of cells during 
formation of the somite border followed by the emergence of a FN matrix (Jülich et al., 2009). 
“Inside-out” signaling (that is, cellular signaling to integrins resulting in clustering and 
crosslinking of FN to form a matrix), rather than “outside-in” signaling (signaling from 
accumulated FN to the integrins inducing integrin clustering) is therefore likely required for 
somite separation (Jülich et al., 2009). Forward signaling through EphA4/ephrin-B2a induced 
Itga5 clustering, FN matrix assembly, and the formation of “actin belts” in mosaic experiments, 
implicating Eph/ephrin signaling as a candidate regulator for inside-out activation of Itga5 in 
somite separation (Jülich et al., 2009). However, the signaling mechanisms by which ephrin-B2 
reverse signaling might drive Itga5 clustering remain unknown.  
 
Cellular mechanisms of Eph/ephrin-mediated segregation 
In each of these systems, a common underlying question exists regarding the cellular 
mechanisms of segregation mediated by Eph/ephrin signaling. Generally, cell segregation was 
originally hypothesized to result from differences in affinities between two cell types that could 
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be driven by quantitative or qualitative differences in adhesiveness conferred by distinct 
constellations or levels of adhesion molecule expression (Nose et al., 1988; Steinberg, 1970; 
Townes and Holtfreter, 1955). The differential adhesion hypothesis (DAH) proposes the specific 
case in which a quantitative difference in cell adhesion between two cell populations drives the 
segregation of randomly-migrating cells (Steinberg, 1970). Indeed, multiple studies have 
implicated direct regulation of cell adhesion by Eph/ephrin signaling as a driver of cell 
segregation. In the intestinal epithelium, EphB activation by ephrin-B1 results in the recruitment 
of the ADAM10 metalloproteinase, which cleaves E-cadherin and therefore presumably results 
in differential adhesion at the Eph/ephrin signaling interface (Cortina et al., 2007; Solanas et al., 
2011).  
As opposed to differential adhesion, Eph/ephrin-mediated segregation is more widely 
attributed to a “repulsive” mechanism, though the cell biological definition and biophysical 
consequences of repulsive Eph/ephrin cellular interactions are varied. In many contexts, 
Eph/ephrin signaling guides cell migration by a repulsion mechanism analogous to axon 
guidance in which cellular collapse and disengagement of Eph- and ephrin-expressing cells is 
followed by directional migration, as in contact inhibition of locomotion (Astin et al., 2010; 
Pasquale, 2005; Poliakov et al., 2004). In cell segregation, this guidance activity would result in 
a repeated redirection of cells away from their heterotypic partners, resulting in segregation of 
the heterotypic populations by a trial and error process that would be predicted to result in a 
greater distance traveled over the course of segregation compared to other models of 
segregation. Indeed, in cell segregation assays in low density HEK293 cell culture, EphB2 
expressing cells exhibit collapse and directional migration away with an increased migration 
speed and travel a greater total distance than cells not undergoing segregation (O’Neill et al., 
2016; Poliakov et al., 2008; Taylor et al., 2017). However, at high density, EphB2 cells 
undergoing segregation do not exhibit an increased distance travelled, probably due to 
constraints imposed by the confluent culture conditions (O’Neill et al., 2016). Nevertheless, cells 
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segregate robustly at high density, consistent with the fact that cell segregation in the embryo is 
a behavior that occurs at high cell densities, which leads to the question of whether directional 
migratory guidance is required for Eph/ephrin cell segregation in the embryo (O’Neill et al., 
2016; Taylor et al., 2017).  
A separate model, the differential interfacial tension hypothesis (DITH), has proposed 
that differences in cortical tension, driven primarily by actomyosin contractility, oppose cell 
adhesion and drive differences in the ability of cells to establish and maintain stable contacts 
(Brodland, 2002; Krieg et al., 2008). Based on elevated Lifeact-RFP signals in EphB2 cells 
during live imaging of cell segregation, and on the apparently highly conserved involvement of 
actomyosin contractility in cell segregation, we previously proposed that cellular collapse upon 
ephrin-B activation of Eph receptor signaling may result in a change in cortical tension, leading 
to minimization of heterotypic contacts in favor of homotypic contacts (O’Neill et al., 2016). In 
cases where Eph and ephrin populations begin fully intermixed, as in cell mixing assays or in 
CFNS, the “signaling interface” initially includes all EphB2 cells. In other situations, such as 
Xenopus gastrulation, however, the signaling interface is limited to a patterned interface where 
Eph/ephrin signaling sharpens and maintains the existing boundary. A recently proposed 
heterotypic interfacial tension (HIT) model that relates to this specific case observes that there 
need not be differences in cortical tension or homotypic adhesion between the entirety of two 
populations if local differences in these properties occur specifically at heterotypic cell contacts 
(Canty et al., 2017). Such a local difference would, of course, be the case in boundaries 
generated by Eph/ephrin signaling, which relies on cell contact for signaling. Interestingly, 
atomic force microscopy to infer cortical tension showed that in fact ectoderm cells were stiffer 
than mesoderm cells, but levelling these differences by myosin depletion in the ectoderm or 
overexpression of constitutively active Rho in the mesoderm had no effect on separation. 
Similarly, a dissociation assay indicated that ectoderm cells were more adherent than 
mesoderm cells, and in this case, levelling these differences decreased separation only 
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modestly. These data led to the conclusion that tissue separation in Xenopus gastrulation is 
governed by local Eph/ephrin-mediated repulsion leading to reduced contact at the heterotypic 
interface, though whether cortical tension is changed specifically at that interface remains 
untested (Canty et al., 2017).  
In contrast, at the Xenopus notochord-PSM boundary, Eph/ephrin signaling may 
regulate both adhesion and cortical tension (Fagotto et al., 2013). Cadherin clustering at 
interfaces between heterotypic notochord-PSM cell pairs at the boundary is less pronounced 
than that at interfaces between homotypic cell pairs, which possess larger cadherin clusters. 
Smaller or absent cadherin clusters at the heterotypic interface allow for cell protrusions and 
blebbing at the boundary. This cadherin pattern is dependent on myosin, which in turn depends 
on Eph/ephrin signaling between notochord and PSM cells at the boundary (Fagotto et al., 
2013). This suggests that separation at this boundary does not depend on differing levels of 
expression of cadherin complexes between cells of the different tissue types, but rather on 
differences in recruitment at different cell interfaces. Differences in heterotypic and homotypic 
Eph/ephrin signaling therefore result in differential cell contractility at the notochord-PSM 
boundary, with protrusions and blebbing of the boundary cells, which then inhibits cadherin 
clustering between heterotypic cell pairs.  
Importantly, these studies reinforce the idea that a boundary cannot be defined simply 
by examining the adhesive or contractile properties of each individual tissue. Instead, the 
interaction between heterotypic cell pairs at the boundary must somehow differ from that of 
homotypic cell pairs within each individual tissue. This requires an intricately regulated interface 
with many small interactions between cells of each tissue, resulting in dynamic changes to the 
cytoskeleton and to adhesion complexes that mediate boundary maintenance. The Eph/ephrin 
signaling family, with its large variety of molecules and complex regulatory abilities, is a perfect 
fit for this role. Further investigation of this complex interplay at other embryonic boundaries will 
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reveal the mechanisms by which Eph/ephrin signaling mediates tissue separation in different 
contexts.  
 
Evolving perspectives on Eph/ephrin signaling mechanism and directionality 
It is readily apparent that Eph/ephrin signaling acts to regulate cell movement and 
positioning to effect tissue morphogenesis in a wide variety of developmental processes (Table 
1), perhaps unsurprising considering the expression of pathway members in almost every tissue 
during development. Eph/ephrin signaling is unique among major signaling pathways that direct 
developmental processes on a large scale, in that it generally appears to have relatively little 
influence on establishing transcription of downstream target genes in the contexts studied so 
far. Instead, the members of this pathway act more directly to define tissue architecture by 
acting as a “middleman” between upstream transcription factor patterning and the cell physical 
and behavioral changes required to direct cells to their correct positions. Specifically, a major 
role for this pathway has been identified in regulation of cytoskeletal changes. This mediation of 
cellular changes downstream of transcription factor expression can be aided by the ability of 
Ephs and ephrins to signal in both the receptor and ephrin-expressing cells and is essential for 
Eph/ephrin signaling to mediate cell migration and tissue separation. Here, we have 
summarized a number of challenges addressed by recent developments in the field: these 
include analysis of the complexity of signaling directionality and signaling mechanisms in vivo, 
identification of new contexts for Eph/ephrin regulation of cell migration, the role of combinatorial 
expression of Ephs and ephrins in tissue separation, and the role for differing cellular 
mechanisms of segregation to effect tissue separation in a variety of contexts. The results of 
these recent studies have deepened our understanding of how Eph/ephrin signaling regulates 
cell position and have made clear the need for continuing studies in these areas to fully 
understand how this complex pathway regulates developmental morphogenesis. 
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The complexity of Eph/ephrin signaling has led to longstanding challenges in 
understanding signaling mechanisms in vivo; these challenges may also impact our 
consideration of cellular mechanisms. Whereas genetic evidence for bidirectional signaling in 
development remains, refinement of this understanding continues, causing us to reevaluate the 
relevance of this paradigm in specific situations. While Eph/ephrin signaling mutants are 
tremendously valuable for determining signaling mechanisms involved in the formation and 
maintenance of boundaries, they must also be interpreted with care, especially when 
overexpression is employed. It has become clear that a simple complementary expression 
model, with bidirectional signaling across the expression divide, will no longer be sufficient in 
most developmental scenarios. First and foremost, in many developing tissues, both Eph 
receptors and ephrins are co-expressed. For example, both EphB receptors and ephrin-Bs are 
expressed in the early mouse neural plate neuroepithelium prior to induction of the neural crest 
(O’Neill et al., 2016), as well as in mouse palatal shelves later in development (Bush and 
Soriano, 2010). It is also clear that co-expression of EphAs and ephrin-As, such as in the 
developing chick retina (Hornberger et al., 1999), can play critical roles in axon guidance. In 
addition, recent evidence indicates that unidirectional Eph/ephrin signaling is sufficient to drive 
the formation of boundaries during development, calling into question the idea that bidirectional 
signaling is necessary for Eph/ephrin signaling-mediated processes. Rather, parallel or anti-
parallel combinations of Eph- and ephrin-expression may work together to drive separation of 
tissues. 
Studies of tissue separation in disparate contexts often seem to converge on Eph/ephrin 
regulation of the cytoskeleton, firmly establishing the paradigm of this signaling pathway as a 
“middleman” between transcription factor patterning and the cellular changes necessary for 
morphogenetic processes to occur. What then are the upstream mechanisms by which 
differential Eph/ephrin expression is determined? Often, it seems that expression patterns of 
these signaling molecules are determined in parallel to the definition of cell fate by upstream 
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transcription factors. For example, tbx24 (fss) in the zebrafish PSM, cMeso-1 in forming chick 
somites, Krox20 in rhombomeres 3 and 5 in the mouse (Theil et al., 1998), val in rhombomeres 
5/6 in zebrafish (Cooke et al., 2001), and rx3 in the zebrafish eye field (Cavodeassi et al., 2013) 
can all affect the proper expression of Ephs and ephrins that is necessary for later boundary 
formation. Loss of Eph/ephrin expression does not seem to affect expression of these 
transcription factors, suggesting that gene expression patterning is not generally an important 
outcome of Eph/ephrin signaling. In considering complementary expression domains, we must 
also consider the effect of post-transcriptional mechanisms. In some cases, what appears as 
reciprocal expression of Eph and ephrin proteins could be caused by signaling leading to 
cleavage or endocytosis of receptor-ligand complexes, this high signaling turnover appearing as 
a reduction in Eph receptor expression in populations of cells with high ephrin expression, or 
vice versa. 
How Eph/ephrin signaling leads to cell segregation and boundary formation has long 
been under debate, with differential adhesion, repulsive migration, and differential cortical 
tension all accumulating evidence to support these various hypotheses. Whether the outcome of 
Eph/ephrin signaling is tissue-specific, or whether one of these hypotheses will dominate in all 
contexts in which Eph/ephrin-mediated tissue separation occurs, remains to be determined by 
future careful studies of these processes. 
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Table 1. Eph/ephrin relationships and roles in cell positioning in the developing embryo 
Page 1 of 2 
 Signaling 
partner(s) 
Role in cell 
positioning 
Signaling 
directionality 
References 
ephrin-
B1 
EphB1, 
EphB2, 
EphB3 
Axon guidance of the 
corpus callosum 
Forward 
Reverse - ? 
(Henkemeyer et al., 
1996; Mendes, 2006; 
Orioli et al., 1996; 
Robichaux et al., 2016) 
 EphB2, 
EphB3 
Craniofacial and 
skeletal development 
Forward (Bush and Soriano, 
2010; O’Neill et al., 
2016) (see Chapter 3) 
 EphB2, 
EphB3 
Cell segregation Forward (O’Neill et al., 2016) 
 EphB2 Sorting of neural crest 
cells into sympathetic 
ganglia 
Forward (Kasemeier-Kulesa et al., 
2005) 
 EphB2 Apical attachment of 
neural progenitor cells 
Forward (Arvanitis et al., 2013) 
 EphB1, 
EphB2 
Migration of precursor 
cells in the 
hippocampus 
Forward* (Bouché et al., 2013; 
Catchpole and 
Henkemeyer, 2011) 
 EphB3 Cortical neuronal 
migration 
Reverse (Sentürk et al., 2011) 
 EphB3 Asymmetric liver 
positioning 
Bidirectional (Cayuso et al., 2016) 
 EphA4, 
EphB2 
Xenopus ectoderm-
mesoderm separation 
during gastrulation 
Forward (Rohani et al., 2014) 
ephrin-
B2 
EphB1, 
EphB2, 
EphB3 
Axon guidance of the 
anterior commissure 
Reverse - ? (Cowan et al., 2004; 
Robichaux et al., 2016) 
 EphB2, 
EphB3, 
EphB4 
Midline closure of the 
embryo 
Reverse - ? (Cowan et al., 2004; 
Dravis et al., 2004; 
Dravis and Henkemeyer, 
2011) 
 EphB3 Cortical neuronal 
migration 
Reverse (Sentürk et al., 2011) 
 EphB4 Lymphatic valve 
development 
Forward 
Reverse - ? 
(Makinen, 2005; Zhang 
et al., 2015) 
 EphB4 Neural crest migration 
(indirect); angiogenic 
remodeling 
Forward (Davy and Soriano, 
2007; Lewis et al., 2015) 
 EphB4 Dorsal forerunner cell 
migration to form the 
Kupffer’s vesicle 
Bidirectional - 
? 
(Zhang et al., 2016) 
 EphB2, 
EphB4 
Xenopus ectoderm-
mesoderm separation 
during gastrulation 
Forward (Rohani et al., 2011, 
2014) 
 EphA4 Somite formation Reverse (Jülich et al., 2009; 
Watanabe et al., 2009) 
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Table 1. Eph/ephrin relationships and roles in cell positioning in the developing embryo  
Page 2 of 2 
 Signaling 
partner(s) 
Role in cell 
positioning 
Signaling 
directionality 
References 
ephrin-
B3 
EphB1, 
EphB2, 
EphB3 
Axon guidance of the 
corpus callosum 
Forward (Kullander et al., 2001; 
Mendes, 2006) 
 EphB3 Cortical neuronal 
migration 
Reverse (Sentürk et al., 2011) 
 EphA4 Axon guidance in the 
spinal cord 
Forward (Yokoyama et al., 2001) 
 EphA4 Xenopus ectoderm-
mesoderm separation 
during gastrulation 
Forward (Rohani et al., 2014) 
*Bouché et al. also propose a role for Reelin-to-Eph forward signaling in hippocampal progenitor 
migration in the CA3 region. 
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Figure 3. Eph/ephrin signaling modes. Binding of an Eph receptor to an ephrin in an adjacent 
cell can initiate (A) forward signaling through receptor tyrosine phosphorylation in the Eph-
expressing cell, (B) reverse signaling through ephrin tyrosine phosphorylation or binding to PDZ 
domain-containing proteins in the ephrin-expressing cell, or both (bidirectional signaling). Some 
forms of Eph/ephrin forward signaling do not require the kinase domain of the Eph receptor 
(kinase-independent signaling). (C) Coexpression of an EphA receptor and an ephrin-A in the 
same cell has been shown to attenuate receipt of signals from adjacent cells, a process that has 
been termed cis inhibition. The mechanism of signal attenuation is unknown. Green color of the 
Eph receptor indicates activation of forward signaling, whereas blue color of the Eph receptor 
indicates no activation. Red color of the ephrin indicates activation of reverse signaling, whereas 
purple color indicates no activation. Ephrin-Bs are transmembrane proteins (shown in A, B); 
ephrin-As are membrane-linked through a GPI anchor (shown in C).  
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Figure 4. Differentiating Eph/ephrin forward and reverse signaling in the development of 
two axon tracts, the corpus callosum and the anterior commissure. (A) Key to 
representations of a normal corpus callosum (CC) and agenesis of the corpus callosum (aCC). 
(B) Key to representations of a normal posterior branch of the anterior commissure (ACp) and of 
ACp misprojections. (C–F) Mice expressing a truncated version of EphB1 in which the 
intracellular domain is replaced with LacZ (EphB1T ⁠-LacZ) (C) have a 20% penetrance of aCC and 
no ACp defects. Similarly, mice expressing EphB2L⁠acZ (D) have a 43% penetrance of aCC and a 
10% penetrance of ACp defects. However, mice with total loss of EphB1 (E) or EphB2 (F) have 
a higher incidence of CC and ACp defects, raising the question of whether functional 
redundancy can truly explain the low penetrance of phenotypes in the truncated mutants. 
Functional redundancy should allow one receptor to compensate for both loss and truncation of 
the other. (G–H) EphB1; EphB2 double knockout mice have 100% penetrance of severe ACp 
misprojection defects (G), while mice in which the intracellular domain of both receptors has 
been replaced with LacZ (H) have only 80% incidence of moderate-to-severe phenotypes. How 
can the difference between these cases be explained? It is possible that the maintenance of 
reverse signaling via receptor extracellular domains in (H) allows preservation of some function, 
though it is unlikely that reverse signaling plays a dominant role in CC or ACp formation, as the 
phenotype in (H) is still quite severe. Although EphB3 forward signaling may compensate 
somewhat, this should be the case in both mutants, and is unlikely to explain the difference. The 
most likely explanation is the possibility that truncated EphB1 and EphB2 receptors maintain the 
capacity to hetero-oligomerize with full-length Eph receptors, such as EphB3, to contribute to 
forward signaling and preserve a small amount of function. 
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Figure 5. Eph/ephrin signaling provides support and guidance for migrating cells during 
development. (A) Ephrin-Bs have been implicated in both cranial and trunk neural crest cell 
(NCC) migration. Recent genetic evidence in mice suggests that the role of ephrin-B2 in cranial 
NCC migration is secondary to its role in the vasculature, and therefore that ephrin-B2 signaling 
in this context acts not as a guidance cue, but rather as a supplier of support and nutrients 
critical to NCC survival. During trunk NCC migration, ephrin-B1 (in chick) or ephrin-B2 (in 
mouse) is thought to act as a guidance cue for migrating cells, with their expression in the 
posterior half of the somite restricting migration of EphB-expressing NCCs to the anterior half of 
the somite. (B) The secreted neuronal guidance cue Reelin interacts biochemically with Eph 
receptors, and compound EphB receptor mutant mice as well as compound ephrin-B mutant 
mice have reeler (Reln-⁠/-)-like neuronal migration phenotypes in both the cortex and 
hippocampus. Although many Eph or ephrin compound mutant phenotypes are not as severe as 
Reln-⁠/- phenotypes, this raises the intriguing possibility that Eph/ephrin signaling and Reelin 
signaling may synergize to promote neuronal migration in the cortex and hippocampus. (C) 
EphB/ephrin-B signaling, with EphB3b expressed in the lateral plate mesoderm (LPM) and 
ephrin-B1 expressed in the hepatoblasts, is essential for correct asymmetric positioning of the 
liver during zebrafish development. NCC, neural crest cell; LPM, lateral plate mesoderm. 
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Figure 6. Eph/ephrin signaling mechanisms in developmental tissue separation. (A) A 
classical view of Eph/ephrin signaling mechanisms in the rhombomeres of the zebrafish hind- 
brain involves complementary expression of Eph receptors and ephrins in adjacent rhombomere 
compartments, with bidirectional signaling mediating repulsive migration of Eph-expressing cells 
away from the ephrin-expressing compartment and vice versa. (B) Mosaicism for ephrin-B1 
expression in the congenital craniofacial disease craniofrontonasal syndrome (CFNS) leads to 
aberrant cell segregation, which is characterized by unidirectional signaling from ephrin-B1 
expressing cells (magenta) to ephrin-B1 non-expressing (EphB-expressing) cells (green), 
leading to upregulation of actin and formation of an actin cable in the EphB-expressing cells. (C) 
In the Xenopus gastrula, the mesoderm migrates along the ectodermal blastocoel roof without 
integrating into the ectoderm. This simultaneous migration and separation is mediated by 
antiparallel Eph/ephrin forward signaling across the ectoderm-mesoderm boundary, leading to 
repeated attachment and detachment of the migrating mesoderm cells. (D) Bidirectional 
signaling between ephrin-B2 in the posterior region of a newly formed somite and EphA4 in the 
anterior region of a forming somite contributes to somite gap formation and subsequent cell 
epithelialization at the somite border. While gap formation requires reverse signaling but not 
forward signaling, cell epithelialization requires both reverse signaling and forward signaling 
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through direct or cell-non-autonomous mechanisms. CFNS, craniofrontonasal syndrome; FN, 
fibronectin. 
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CHAPTER 3. EPHRIN-B1 mosaicism drives cell segregation in 
craniofrontonasal syndrome hiPSC-derived neuroepithelial cells 
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Summary 
 Although human induced pluripotent stem cells (hiPSCs) hold great potential for the 
study of human diseases affecting disparate cell types, they have been underutilized in seeking 
mechanistic insights into the pathogenesis of congenital craniofacial disorders. 
Craniofrontonasal syndrome (CFNS) is a rare X-linked disorder caused by mutations in EFNB1 
and characterized by craniofacial, skeletal, and neurological anomalies. Heterozygous females 
are more severely affected than hemizygous males, a phenomenon termed cellular interference 
that involves mosaicism for EPHRIN-B1 function. Although the mechanistic basis for cellular 
interference in CFNS has been hypothesized to involve Eph/ephrin-mediated cell segregation, 
no direct evidence for this has been demonstrated. Here, by generating hiPSCs from CFNS 
patients, we demonstrate that mosaicism for EPHRIN-B1 expression induced by random X 
inactivation in heterozygous females results in robust cell segregation in human neuroepithelial 
cells, thus supplying experimental evidence that Eph/ephrin-mediated cell segregation is 
relevant to pathogenesis in human CFNS patients.   
 
Introduction  
Congenital craniofacial disorders represent over one-third of all birth defects ("Global 
strategies..." 2004). While the genetic causes of many syndromes are known, how these 
mutations lead to abnormal cellular mechanisms underlying these disorders is incompletely 
understood. A better understanding of the underlying etiology of these disorders is needed to 
develop new treatment strategies targeted to the cellular and molecular basis of disease. The 
emergence of hiPSCs as a tool for human disease modeling (Takahashi and Yamanaka, 2006; 
Takahashi et al., 2007; Tiscornia et al., 2011; Yu et al., 2007) holds great promise for improving 
our cellular understanding of craniofacial diseases, as hiPSCs can be differentiated into patient-
specific, disease-relevant cell types. However, perhaps due to the challenge of modeling 
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structural aspects of craniofacial disease in two dimensions in cell culture, hiPSC models for 
these disorders are not yet widely used.  
 Craniofrontonasal syndrome (CFNS; OMIM #304110) is an X-linked disorder caused by 
mutations in EFNB1 and characterized by craniofacial, skeletal, and neurological anomalies 
(Twigg et al., 2004; Wieland et al., 2004). The most common clinical findings include 
hypertelorism, frontonasal dysplasia, coronal synostosis, bifid nasal tip, longitudinal splitting of 
the nails, and wiry or frizzy hair; other less frequent symptoms include cleft lip and palate, 
diaphragmatic hernia, agenesis of the corpus callosum, syndactyly, and polydactyly (Twigg et 
al., 2004; Twigg et al., 2006; Twigg et al., 2013; Wieacker and Wieland, 2005; Wieland et al., 
2004). CFNS is an unusual X-linked disorder in that heterozygous females are more severely 
affected than hemizygous male patients, who are usually unaffected or mildly affected and often 
present only with hypertelorism (Wieacker and Wieland, 2005). This counterintuitive inversion of 
severity has been termed cellular interference, a phenomenon whereby random X chromosome 
inactivation (XCI) in heterozygous female CFNS patients results in mosaicism for EFNB1 
expression, leading to abnormal cellular interactions (Twigg et al., 2013; Wieacker and Wieland, 
2005). Consistent with this notion, rare severely-affected male CFNS patients have somatic 
mosaic mutations in EFNB1 (Twigg et al., 2013), reinforcing mosaicism as an important aspect 
of CFNS pathogenesis. 
EFNB1 encodes EPHRIN-B1, a member of the Eph/ephrin family of membrane-linked 
signaling molecules, and abnormal signaling between cells expressing wild-type EPHRIN-B1 
and cells that are functionally EPHRIN-B1-null may occur in the mosaic state (Compagni et al., 
2003; Wieacker and Wieland, 2005). During development, Eph/ephrin signaling plays an 
important role in boundary formation, an essential process that requires signaling between 
adjacent cells and often involves segregation between different cell types (Batlle and Wilkinson, 
2012; Cayuso et al., 2015; Fagotto, 2014; Fagotto et al., 2014). Differential expression of Eph 
receptors and ephrins in vivo can restrict cell intermingling in the vertebrate hindbrain (Xu et al., 
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1999), limb bud (Compagni et al., 2003; Davy et al., 2004), eye (Cavodeassi et al., 2013), 
somites (Barrios et al., 2003; Durbin et al., 1998; Durbin et al., 2000), cranial sutures (Merrill et 
al., 2006; Ting et al., 2009), and intestinal crypts (Holmberg et al., 2006), as well as in the 
Drosophila wing disc (Umetsu et al., 2014). In culture, expressing an Eph receptor in one 
population of cells and an ephrin in another restricts intermingling of cells from the two 
populations (Jorgensen et al., 2009; Mellitzer et al., 1999; Poliakov et al., 2008). Further, cell 
segregation occurs in developing Efnb1+/- mouse limb (Compagni et al., 2003) and secondary 
palate (Bush and Soriano, 2010), supporting the idea that XCI-induced mosaicism leads to 
segregation of Ephrin-B1 expressing and non-expressing cells.  
 The role of Eph/ephrin signaling in boundary formation and supporting data from mouse 
models suggest that mosaicism for EPHRIN-B1 expression may lead to aberrant cell 
segregation in human CFNS patients (Compagni et al., 2003; Twigg et al., 2004; Twigg et al., 
2006; Twigg et al., 2013; Wieacker and Wieland, 2005; Wieland et al., 2004). However, it has 
proven difficult to determine the mechanism of cellular interference, and EPHRIN-B1-mediated 
cell segregation has not been demonstrated in CFNS patients. Here, we report the generation of 
an hiPSC model to study defects in morphogenesis in a congenital craniofacial disorder. We 
demonstrate that cell segregation is a consequence of EPHRIN-B1 mosaicism in CFNS, 
providing evidence that this cell behavior is relevant to CFNS pathogenesis in humans. The 
CFNS hiPSC model provides proof of principle that hiPSC-derived cell types can be used both 
to model structural anomalies and to gain valuable insights into fundamental cellular 
mechanisms of morphogenesis in patient cells. 
 
Results 
Isolation of CFNS human dermal fibroblasts and reprogramming to hiPSCs 
To investigate cellular mechanisms of CFNS, we established human dermal fibroblast 
(HDF) cultures from a 10-month-old female CFNS patient with a heterozygous mutation in exon 
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5 of EFNB1 (EFNB1+/c.712delG) (Byrne et al., 2009; Hogue et al., 2010). We also established HDF 
cultures from skin biopsies of the patient’s father, a hemizygous carrier of the mutation 
(EFNB1Y/c.712delG), and her unaffected mother (EFNB1+/+). We generated hiPSC lines from low-
passage HDFs of each individual using non-integrating episomal vectors (Bershteyn et al., 
2014; Okita et al., 2011) and selected three hiPSC lines from each individual for further analysis 
and experimentation (from the patient, lines CFNShet-1, -2, and -3; from the patient’s father, 
lines CFNShemi-1, -2, and -3; and from the patient’s mother, lines wt-1, -2, and -3). Sequencing 
of exon 5 of EFNB1 confirmed the expected genotypes (Figures 7A and S1). All nine hiPSC 
lines were free of reprogramming plasmid integration by PCR (data not shown) and had normal 
G-banded karyotypes (Figure S1).  
 
Characterization of CFNS hiPSC pluripotency and differentiation potential 
CFNShet and CFNShemi HDFs were reprogrammed to generate hiPSCs, which 
possessed embryonic stem cell-like morphology similar to that of wild-type hiPSCs. All lines, 
regardless of genotype, possessed differentiation potential to ectoderm (bIII tubulin), endoderm 
(a-fetoprotein), and mesoderm (muscle actin) in an embryoid body protocol (Figures 7B and 
S2) and expressed the endogenous pluripotency markers OCT4, SOX2, NANOG, TRA-1-60 
and TRA-1-81 (Figures 7C and S3).  
XCI-induced mosaicism in females plays a central role in CFNS (Twigg et al., 2004; 
Twigg et al., 2006; Twigg et al., 2013; Wieacker and Wieland, 2005; Wieland et al., 2004). 
However, XCI status of female hiPSCs can vary across different lines (Lessing and Lee, 2013), 
depending on conditions used for reprogramming (Tchieu et al., 2010; Tomoda et al., 2012; 
Wutz, 2012). To model CFNS, we used reprogramming conditions that favor maintenance of 
XCI rather than X reactivation (Wutz, 2012) and characterized XCI status of CFNShet HDFs and 
each CFNShet hiPSC line using the human androgen receptor assay (HUMARA) (Kiedrowski et 
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al., 2011). CFNShet HDFs showed an expected XCI ratio close to 50%, as in earlier studies that 
indicated no skewed X inactivation in female CFNS patients (Table 2) (Twigg et al., 2004; 
Wieland et al., 2004; Wieland et al., 2007). All three CFNShet hiPSC lines showed complete 
inactivation of the maternal, wild-type X chromosome, consistent with the clonal XCI expected 
from female hiPSC lines derived from a single fibroblast under conditions that favor XCI 
maintenance (Tchieu et al., 2010). Therefore, only the paternal, mutant copy of EFNB1 is 
expressed in these lines (Table 2), and they are not expected to express functional EPHRIN-
B1.  
 
Differentiation and characterization of CFNS neuroepithelial cells 
CFNS affects multiple structures derived from neural crest cells (NCCs), a multipotent 
population of stem cells that are induced at the neural plate border, delaminate, and migrate 
ventrolaterally to populate the craniofacial structures and contribute to skeletal, connective, 
neural, and vascular tissues. In mice, Ephrin-B1-mediated cell segregation occurs in the NE 
prior to NCC emigration (O’Neill et al., 2016). We therefore reasoned that NE cells are a good 
model for testing whether cell segregation occurs in CFNS, and we began by differentiating 
CFNS and control hiPSCs to human neuroepithelial cells (hNE). We adapted a monolayer 
protocol that uses dual-SMAD inhibition to improve neural differentiation efficiency through 
inhibition of activin and nodal signaling (Chambers et al., 2009). All hNE cells, regardless of 
genotype, had neuroepithelial morphology and expressed the neural progenitor cell markers 
PAX6, SOX1, and OTX2 (Figure 8A). These data indicate that CFNS patient hiPSCs are able 
to differentiate into hNE cells independently of EPHRIN-B1 expression. hNE cells of all 
genotypes, but not hiPSCs, expressed EFNB1 mRNA (Figure 8B), and over the course of 
differentiation to hNE cells, expression of mRNA transcripts of both EFNB1 and PAX6 increased 
in a similar manner in cells of each genotype (Figure 8C). hNE cells of all three genotypes 
expressed EFNB2, a closely related B-type ephrin, as well as EPHB2 and EPHB3, signaling 
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partners of EPHRIN-B1 that are involved in craniofacial development (Orioli et al., 1996) 
(Figure S4A-S4C). Wild-type hNE cells expressed EPHRIN-B1 protein, whereas CFNShet and 
CFNShemi EFNB1 mutant hNE cells did not (Figure 8D).  
 
EPHRIN-B1 mosaicism results in cell segregation in CFNS hNE cells 
To model EFNB1 mosaicism and determine whether it results in segregation, we 
generated mixed cultures of fluorescently labeled hNE cells of different genotypes at a 1:1 ratio. 
Control mixed cultures in which all cells expressed EPHRIN-B1 (wt-3 + wt-3, N=11/11 trials) or 
in which no cells expressed EPHRIN-B1 (CFNShet-3 + CFNShet-3, N=7/7 trials; CFNShemi-1 + 
CFNShemi-1, N=4/4 trials) resulted in hNE cells commingling freely, with no notable 
segregation after 48 hr (Figures 9A-9C). However, in hNE cell populations mosaic for EPHRIN-
B1 expression, EPHRIN-B1-expressing cells segregated dramatically from EPHRIN-B1 non-
expressing cells, forming distinct boundaries between the two different cell types by 48 hr 
(Figures 9D and 9E) (wt-3 + CFNShet-3, N=10/10 trials; wt-3 + CFNShemi-1, N=4/4 trials). To 
ensure that this segregation depended on EPHRIN-B1 expression and not on differences 
between independent hNE cell lines, we mixed hNE lines derived from different hiPSC lines of 
the same genotype and also observed intermixing of cells (wt-3 + wt-2, Figure 9F; CFNShet-3 + 
CFNShet-1, Figure 9G) (N=3/3 trials, each condition). Further, mixing hNE lines derived from 
different genotypes lacking EPHRIN-B1 expression (CFNShet-3 + CFNShemi-1, N=3/3 trials) 
did not result in cell segregation (Figure 9H), demonstrating that hNE cells segregate based on 
the presence or absence of EPHRIN-B1 expression and not some other factor associated with 
individual variability.  
 To observe the process of cell segregation over time, we used live cell imaging to 
capture the first 25 hr after cell mixing in both mosaic and EPHRIN-B1 non-expressing cell 
mixtures. Both cell mixtures were intermingled at time of mixing (t=0, Figures S5A and S5G). 
Cells in both mixtures continued to interact with each other over time, and EPHRIN-B1 non-
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expressing mixtures remained freely commingled at each time point (Figures S5B-S5E). 
However, the EPHRIN-B1 mosaic population of cells segregated progressively over 25 hr 
(Figures S5H-S5L), indicating that segregation is a continuous process that occurs over time. 
These data provide evidence that EPHRIN-B1-mediated cell segregation can occur in human 
CFNS. 
 
Discussion 
Here, we have generated an hiPSC model of a human craniofacial condition and have 
used it to address an outstanding question: does mosaicism for EFNB1 expression result in cell 
segregation in human CFNS? The c.712delG mutation found in this CFNS family occurred 5’ to 
the transmembrane domain-encoding region of EFNB1, and we found that EFNB1 mutant hNE 
cells did not express EPHRIN-B1, indicating that this mutation results in an unstable EPHRIN-
B1 protein and most likely null loss of function. To enable us to model CFNS, it was essential 
that loss of EFNB1 function not prevent CFNS patient-derived HDFs from undergoing 
reprogramming to hiPSCs. We did not observe differences in reprogramming ability between 
EFNB1 mutant and control HDFs, leading us to conclude that EPHRIN-B1 expression is not 
necessary for reprogramming. Further, we found that both control and CFNS hiPSCs possessed 
differentiation potential to all three germ layers; loss of EPHRIN-B1 expression does not 
apparently prevent differentiation. This is consistent with our qRT-PCR data demonstrating that 
transcripts of EFNB1 and several other Eph/ephrin signaling family members are expressed at 
very low levels in hiPSCs relative to hNE cells, suggesting that these signaling molecules may 
not play critical roles in hiPSCs.  
Previous human genetic studies have indicated that mosaicism for EFNB1 mutation is 
central to CFNS pathology, a phenomenon termed cellular interference suggested to result in 
cell segregation based on evidence from model organisms (Compagni et al., 2003; Twigg et al., 
2004; Twigg et al., 2006; Twigg et al., 2013; Wieacker and Wieland, 2005; Wieland et al., 2004). 
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Whether cell segregation occurs in CFNS, however, and in what cell types, was not known. 
Based on evidence of cell segregation in the neural plate NE in Efnb1+/- mice (O’Neill et al., 
2016), we differentiated hiPSCs to hNE cells to address this question.  
 Both wild-type and CFNS patient-derived hNE cells expressed neural stem cell markers 
and several members of the Eph/ephrin gene family, including EFNB1. Expression of EFNB1 
varied between hNE lines, as well as between independent differentiations of the same hiPSC 
line, indicating that there was inherent variability in the differentiations. Consistently, however, 
hNE cells expressed higher levels of EFNB1 than hiPSCs, indicating that increased EFNB1 
expression is a characteristic of the hNE cell type. In addition, EFNB1 expression decreased as 
hNE cells were maintained over time, suggesting that higher levels of EFNB1 expression may 
mark a progenitor stage in the differentiation program.  
As hiPSCs are clonally derived cell lines, CFNShet hNE lines are not mosaic for EFNB1 
expression, necessitating a different approach to model cellular interference. Upon mixing wild-
type and EPHRIN-B1 non-expressing hNE cells to generate EPHRIN-B1 mosaicism, the 
EPHRIN-B1 expressing and non-expressing cells segregated to form ectopic boundaries in 
culture. This robust segregation occurred in mosaic mixtures of wild-type + CFNShet cells and 
wild-type + CFNShemi cells, but not in mixtures of two different populations of EPHRIN-B1 
expressing cells, or two different populations of EPHRIN-B1 non-expressing cells, even if these 
two populations were derived from different hiPSC lines. We therefore conclude that 
segregation is not an effect of mixing different hNE lines, but rather an effect of mosaicism for 
EPHRIN-B1 expression, and that cellular interference through EPHRIN-B1-mediated cell 
segregation occurs in CFNS cells. This finding informs our understanding of the etiology of 
CFNS and indicates that cell segregation contributes to cellular interference. How cell 
segregation leads to more severe disease phenotypes is not yet clear; the hiPSC model we 
have developed is a highly relevant system in which to answer remaining questions about 
CFNS pathology. 
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An hiPSC model is an important resource because patient cells can be differentiated into 
multiple disease-relevant cell types, overcoming the challenge of isolating primary cells from 
patients. It is notable that cell segregation occurs in the neuroepithelium in models of CFNS; 
recent studies have indicated that Treacher Collins syndrome, another neurocristopathy, also 
exhibits cellular defects originating in the neuroepithelium and ongoing in the NCC (Jones et al., 
2008). Our hiPSC model of CFNS will facilitate further studies of cell segregation, such as 
investigating whether it occurs in hNCCs and their descendants. This will contribute to a better 
understanding of the developmental timing of CFNS etiology and will provide the ability to study 
aspects of the disease that are less well understood. For example, mutations in EFNB1 that 
cause CFNS are responsible for approximately 7% of cases of craniosynostosis in which a 
genetic cause is known (Johnson and Wilkie, 2011), and studies in mice have demonstrated 
that suture boundary formation is regulated by A-type Eph/ephrin signaling (Merrill et al., 2006; 
Ting et al., 2009). However, how EPHRIN-B1 affects boundary formation and maintenance at 
the suture is unknown, because EFNB1 mutant mice do not exhibit craniosynostosis. Further, in 
CFNS, other organ systems not derived from NCCs are also affected; patients exhibit limb 
anomalies and defects of the axial skeleton that may be attributable to cell segregation 
(Compagni et al., 2003; Davy et al., 2004; Davy et al., 2006). Differentiation of hiPSCs into 
these various cell types is a method for testing the importance of EPH/EPHRIN-mediated cell 
segregation in various tissues. 
hiPSC models of congenital craniofacial disease will also facilitate targeted molecular 
therapies for these disorders. As we have shown that cell segregation resulting from EPHRIN-
B1 mosaicism occurs in human CFNS cells, therapeutic benefits may be derived from 
preventing segregation. Additional research to determine the mechanism by which hNE cell 
segregation leads to craniofacial phenotypes in CFNS patients is likely to identify molecular 
candidates that could be targeted to achieve this goal. A human model system of EPHRIN-B1-
mediated cell segregation could then serve as a high-throughput system for testing candidate 
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therapeutic molecules. Finally, this CFNS hiPSC model system may encourage the use of 
hiPSC-based systems to model structural aspects of other congenital craniofacial anomalies in 
which self-organization of cells may play a role. Such studies have the potential to inform 
therapeutic approaches for congenital craniofacial anomalies, as well as to increase our 
understanding of cell self-organizing properties to facilitate tissue engineering and cell 
replacement therapies for patients with these disorders. 
 
Materials and Methods 
hiPSC generation and culture. All human tissue collection, stem cell studies, procedures, and 
written consents were approved by the UCSF Committee on Human Research and the UCSF 
Gamete, Embryo, and Stem Cell Research Committee. Prior to their inclusion in this study, 
written informed consent was obtained from all participants or from their parents. A small dermal 
tissue sample was collected from an excess specimen at the time of a surgical procedure of the 
10-month-old female CFNS proband. Punch biopsies were obtained from the proband’s father 
and mother. Primary human fibroblast cultures were established and cultured on plastic culture 
dishes in DMEM high glucose (Life Technologies) containing 10% FBS (HyClone), 2 mM L-
glutamine, 1 mM sodium pyruvate, 0.1 mM MEM non-essential amino acids, and penicillin-
streptomycin-fungizone. Human iPSCs were generated using episomal reprogramming 
(Bershteyn et al., 2014; Okita et al., 2011). Briefly, one microgram of each of the Y4 
combination of episomal reprogramming factors (Addgene 27078, 27080, 27082) was 
electroporated into 3 x 105 fibroblasts (passage 5-6) with the Neon Electroporation Device 
(Invitrogen) using the 100-uL kit and conditions of 1650 V, 10 ms, and three pulses. Cells were 
detached 6 days after electroporation and seeded at 1.5 x 105 cells per 10-cm dish onto 
irradiated mouse embryonic fibroblasts (Globalstem). On day 7, media was changed from 
fibroblast media to KnockOutTM ESC/hiPSC culture media containing 4 ng/mL bFGF (Life 
Technologies), and cells were cultured for a further 18-25 days. Colonies with hiPSC-like 
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morphology were manually selected under a dissecting microscope and subcultured on 
irradiated MEFs. By passage four, hiPSCs were transferred to feeder-free conditions and 
cultured in mTeSR1 medium (STEMCELL Technologies) on dishes coated with hESC-qualified 
Matrigel (Corning). 
 
hiPSC characterization. G-banded karyotype analysis of hiPSC lines was performed after 
passage 9 by WiCell Research Institute (Madison, WI). To confirm EFNB1 genotypes, DNA 
samples were isolated from both HDF and hiPSC lines with a DNeasy Blood and Tissue Kit 
(Qiagen) and sequenced by SeqWright, Inc. (Houston, TX). To assay for plasmid integration, 
DNA samples were amplified by PCR with EBNA-1 plasmid backbone-specific primers and 
normalized to GAPDH as a loading control (Table 7). PCR products were resolved against a 
positive control plasmid diluted to the equivalent of 1 and 0.2 copies plasmid/diploid genome. 
Female HDF and hiPSC cultures were assayed for relative inactivation of each X-chromosome 
with the HUMAR assay (Kiedrowski et al., 2011). Briefly, capillary electrophoresis was 
performed on genomic DNA samples both digested and undigested with the methylation-
sensitive restriction enzyme HpaII, which selectively digests the active X chromosome. Each 
allele is represented as a separate peak in the capillary electrophoresis trace based on the 
differential number of CAG repeats at the human androgen receptor locus on each X-
chromosome. Areas under the peak for each allele were measured on Peak Scanner™ (Applied 
Biosystems) for both undigested and digested samples, and these peak areas were used to 
calculate XA (fraction of expression from a given X chromosome). 
 
hNE cell differentiation and culture. hNE cell differentiations from hiPSCs were performed using 
a monolayer dual-SMAD inhibition protocol (Chambers et al., 2009), with some modifications. 
hiPSCs were plated on hESC-qualified Matrigel (Corning)-coated dishes at a density of 2.5 x 
105 cells/cm2 (day 0) in STEMdiff Neural Induction Medium (NIM; STEMCELL Technologies) 
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supplemented with penicillin-streptomycin (P/S) and 10 μM Y-27632 (Santa Cruz 
Biotechnology) to increase cell survival as single cells (Watanabe et al., 2007). Daily media 
changes were made with NIM supplemented with P/S, 10 μM SB-431542 (Santa Cruz 
Biotechnology), and 5 μM DMH1 (Sigma) (Neely et al., 2012) on days 1-3 and NIM + P/S alone 
on days 4 onward. After 8-10 days in culture, cells were dissociated to a single-cell suspension 
in Accutase and replated on Matrigel-coated dishes at a 1:1 dilution in NIM supplemented with 
P/S and 10 μM Y-27632. hNE cell cultures were maintained in NIM with or without SB-431542 
and DMH1 and split at ratios of 1:1 to 1:3 until experimentation. 
 
hNE cell segregation assays. EPHRIN-B1-expressing and EPHRIN-B1-non-expressing hNE 
cells were either labeled with CellTracker dye CMFDA (Molecular Probes) for 45 minutes at a 
concentration of 5 μM in NIM supplemented with penicillin-streptomycin (P/S) or infected with 
adenovirus Ad-CMV-eGFP or Ad-CMV-mCherry (Vector Biolabs) overnight at a concentration of 
1-5 x 106 IFU/cm2 in NIM + P/S, followed by incubation in NIM + P/S for 2 additional days. hNE 
cells from differentially labeled lines were mixed at a concentration of 5 x 105 cells/line and 
plated on Matrigel-coated 24-well glass-bottom dishes (MatTek), for a total of 1 x 106 cells per 
well. Cells were imaged at 48 hours after mixing on a Zeiss Cell Observer spinning disc 
confocal microscope to assess cell segregation. For live imaging of cell segregation, cell mixing 
experiments were set up as described above and plated in 4-chamber glass-bottom dishes 
(Greiner Bio-One), with cell number adjusted to achieve the same density. 15 mM HEPES 
(UCSF Cell Culture Facility) was added to cell media to facilitate buffering outside the CO2 
incubator during the imaging process. Cell mixtures were imaged at twenty-minute intervals 
over 25 hours after mixing using a Zeiss Cell Observer spinning disc confocal microscope.  
 
Immunocytochemistry. Cells were plated on Matrigel-coated glass coverslips and fixed in 2% 
paraformaldehyde in PBS at room temperature. The cells were washed with PBS, blocked in 
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5% normal donkey serum (Jackson ImmunoResearch) and 0.1% Triton-X-100 in PBS, 
incubated in primary antibody (Table 6) for 1 hour at room temperature or overnight at 4°C, 
washed with PBS, and incubated in secondary antibody (Table 6) at room temperature. Cells 
were counterstained in 0.1 μg/mL DAPI (Millipore) in PBS for 20 minutes at room temperature 
and mounted on slides using Aquamount (Thermo Scientific) for imaging. 
 
Immunoblotting. Cells were lysed in NP-40 lysis buffer (20 mM Tris-HCl, 137 mM NaCl, 10% 
glycerol, 1% NP-40, 2 mM EDTA) supplemented with 1 mM dithiothreitol (Sigma) and the 
following protease and phosphatase inhibitors: aprotinin, 2 μg/mL; leupeptin, 5 μg/mL; 
pepstatin, 1 μg/mL; PMSF, 1 mM; NaF, 10 mM; and NaVO4, 1 mM. Protein quantification was 
performed using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Immunoblotting 
was performed according to standard procedures using Odyssey® TBS blocking buffer (LI-
COR) for blocking and dilution of antibodies (Table 6) and TBS with 0.1% Tween-20 for 
washing. Imaging of immunoblots was performed using an Odyssey® Infrared Imaging System 
(LI-COR), and analysis was carried out using Image Studio™ software (LI-COR). 
 
qRT-PCR of hiPSCs and neuroepithelial cells. Total RNA was extracted from cells using TRIzol 
(Life Technologies). RNA was reverse transcribed using a SuperScript™ II First-Strand 
Synthesis System for RT-PCR (Life Technologies). qRT-PCR was performed using iTaq 
Universal SYBR Green and a CFX96 Real Time System (Bio-Rad), with primer pairs that span 
exon-intron boundaries (Table 7). 
 
Statistics. For analysis of qRT-PCR data, GraphPad Prism 6 was used to plot mean expression 
± standard deviation of technical replicate reactions, indicated by error bars. Biological 
replicates (different hiPSC lines or different hNE differentiations), if applicable, are shown as 
separate bars on the graph. 
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Table 2. HUMARA demonstrates clonal inactivation of maternal (wild type) X 
chromosome in each CFNShet hiPSC line  
 Peak Areas Peak Areas Possible Values 
of XA 
(Fraction of X 
activation) 
Ratio of XAwt to 
XAmut 
(Average % X 
activation) 
 Undigested 
Samples 
Digested Samples 
 Maternal Paternal Maternal Paternal XA, 
maternal 
XA, 
paternal 
XA, 
maternal 
XA, 
paternal 
CFNS 64276 61770 9880 19316 0.65 0.35 61 39 
het 51069 43431 16592 24562 0.56 0.44 
HDF     0.63 0.37 
     0.58 0.42 
CFNS 59768 205805 28403 0 0.00 1.00 0 100 
het-1 17428 57018 4606 0 0.00 1.00 
hiPSCs     0.00 1.00 
     0.00 1.00 
CFNS 69895 230728 183006 0 0.00 1.00 0 100 
het-2 41823 157233 173086 0 0.00 1.00 
hiPSCs     0.00 1.00 
     0.00 1.00 
CFNS 50731 158352 42899 0 0.00 1.00 0 100 
het-3 53890 163248 94864 0 0.00 1.00 
hiPSCs     0.00 1.00 
     0.00 1.00 
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Figure 7. Reprogramming of wild-type, CFNShet, and CFNShemi HDFs to hiPSCs. (A) 
CFNShet-3 and CFNShemi-1 hiPSCs possess the EFNB1c.712delG mutation compared with wt-3 
hiPSCs. See also Figure S1. (B) wt-3, CFNShet-3, and CFNShemi-1 hiPSCs possess 
differentiation potential to ectoderm (bIII-tubulin), endoderm (alpha-fetoprotein, AFP), and 
mesoderm (muscle actin). Samples were counterstained with DAPI (blue). Scale bars, 20 μm. 
See also Figure S2. (C) wt-3, CFNShet-3, and CFNShemi-1 hiPSCs express the endogenous 
pluripotency markers OCT4, SOX2, and NANOG, as well as the surface markers TRA-1-60 and 
TRA-1-81 (counterstained with DAPI (blue)). Scale bars, 20 μm. See also Figure S3. 
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Figure 8. Differentiation and characterization of hNE cells from hiPSCs. (A) 
Immunostaining reveals that wt-3, CFNShet-3, and CFNShemi-1 hNE cells express the hNE cell 
markers PAX6, SOX1, and OTX2. Scale bars, 50 μm. (B) EFNB1 mRNA expression 
(normalized to GAPDH mRNA expression) in hiPSCs and wild-type, CFNShet, and CFNShemi 
hNE cells. Numbers following underscores represent separate hNE differentiations. Error bars 
represent the standard deviation of n = 3 technical replicate qRT-PCR reactions per hiPSC or 
hNE line. See also Figure S4. (C) Relative EFNB1 and PAX6 expression (normalized to 
GAPDH expression) increase over the course of hNE cell differentiation of wt-3, CFNShet-3, 
and CFNShemi-1 hiPSCs. Error bars represent the standard deviation of n = 3 technical 
replicate qRT-PCR reactions per condition. Data shown are one of n = 2 biological replicates of 
each wt-3 and CFNShet-3 or one of n = 3 biological replicates of CFNShemi-1 (n = 2) and 
CFNShemi-3 (n = 1). (D) Immunoblotting reveals expression of EPHRIN-B1 protein in wild-type 
but not CFNShet or CFNShemi hNE cells or in hiPSCs of any genotype. 
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Figure 9. Robust cell segregation in neuroepithelial cells mosaic for EPHRIN-B1 
expression. (A–C) Mixing two populations of wild-type EPHRIN-B1 expressing hNE cells (A), 
two populations of CFNShet hNE cells not expressing EPHRIN-B1 (B), or two populations of 
CFNShemi hNE cells not expressing EPHRIN-B1 (C) results in cell intermingling over 48 hours. 
(D and E) Cell mixing to generate cultures mosaic for EPHRIN-B1 expression (wt-3 + CFNShet-
3 (D); wt-3 + CFNShemi-1 (E)) results in robust segregation of EPHRIN-B1 expressing and non-
expressing hNE cells over 48 hours. See also Figure S5. (F–H) Mixing two different wild-type 
(EPHRIN-B1 expressing) hNE cell lines (wt-3 + wt-2) (F), two different CFNShet (EPHRIN-B1 
non-expressing) hNE cell lines (CFNShet-3 + CFNShet-1) (G), or two EPHRIN-B1 non-
expressing hNE cell lines of different genotypes (CFNShet-3 + CFNShemi-1) (H) results in cell 
intermingling without cell segregation. Adjustments to gamma were made to better visualize 
independent cell populations. Scale bars, 50 μm. 
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Figure S1. Genetic characterization of CFNS patient-derived hiPSCs. (A) Sequencing 
chromatograms show retention of G712 in wt hiPSC lines, heterozygous deletion of G712 in 
CFNShet lines, and deletion of G712 in CFNShemi lines. (B) G-banded karyotype analysis 
shows that all nine hiPSC lines have normal karyotypes (46, XX for female wild-type and CFNS 
heterozygous lines and 46, XY for male CFNS hemizygous lines).  
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Figure S2. CFNS patient-derived hiPSCs possess differentiation potential to all three 
germ layers. Upon in vitro embryoid body differentiation, EFNB1+/+ lines (wt-1, -2), 
EFNB1+/c.712delG lines (CFNShet-1, -2), and EFNB1Y/c.712delG lines (CFNShemi-2, -3) demonstrated 
differentiation potential to ectoderm (bIII tubulin), endoderm (alpha-fetoprotein, AFP), and 
mesoderm (muscle actin). Samples were counterstained with DAPI (blue). Scale bars, 20 μm. 
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Figure S3. CFNS patient-derived hiPSCs express pluripotency markers. Immuno-
cytochemical characterization of EFNB1+/+ lines (wt-1, -2), EFNB1+/c.712delG lines (CFNShet-1, -2), 
and EFNB1Y/c.712delG lines (CFNShemi-2, -3) reveals positive staining for the nuclear factors 
OCT4, SOX2, and NANOG, as well as the surface antigens TRA-1-60 and TRA-1-81 
(counterstained with DAPI (blue)). Scale bars, 20 μm.   
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Figure S4. Expression of additional EphB/ephrin-B signaling family members in hiPSCs 
and hNE. qRT-PCR demonstrates relative expression levels of (A) EFNB2, (B) EPHB2, and (C) 
EPHB3 in hNE cells of all three genotypes. Very low expression of each of these Eph/ephrin 
signaling family members is seen in hiPSCs. Expression of each Eph/ephrin signaling family 
member in each sample was normalized to expression of GAPDH. Error bars represent the 
standard deviation of three technical replicates per hiPSC or hNE line. 
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Figure S5. Time lapse imaging of hNE cell mixing experiments. (A-F) Live imaging of a 
mixture of EPHRIN-B1 non-expressing cells (CFNShet-3 + CFNShet-3) over 25 hours 
demonstrates that EPHRIN-B1 non-expressing cells remain intermixed as they continue to 
interact with each other and are not segregating at 25 hours (F). (G-L) Live imaging of a cell 
mixture mosaic for EPHRIN-B1 expression (CFNShet-3 + wt-3) shows that cells are intermixed 
at the beginning of the experiment (G), but segregate from each other over time, and are 
already forming patches of EPHRIN-B1 expressing and non-expressing cells at 25 hours (L). 
Adjustments to gamma were made to better visualize independent cell populations. Scale bars, 
50 μm.    
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CHAPTER 4. Aberrant cell segregation in craniofacial primordia and the 
emergence of facial dysmorphology in craniofrontonasal syndrome 
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Summary 
Craniofrontonasal syndrome (CFNS) is a rare X-linked disorder characterized by 
craniofacial, skeletal, and neurological anomalies and caused by mutations in EFNB1. 
Heterozygous females are observed to be more severely affected than hemizygous male 
patients, a phenomenon called cellular interference that has been attributed to cell segregation 
resulting from EPHRIN-B1 mosaicism and that can be recapitulated in Efnb1 mutant mice. 
However, the developmental origin of craniofacial dysmorphology and its spatiotemporal 
relationship with cell segregation is unknown, and the role of cell segregation in CFNS etiology 
therefore remains poorly understood. Here, we couple geometric morphometric techniques with 
interrogation of cell segregation to quantitatively relate facial shape to cell segregation in an 
Efnb1 mutant mouse model of CFNS. We show that differences in the development of the face 
emerge early but continue to become more dramatic during critical stages of craniofacial 
morphogenesis, correlating with the progression of cell segregation. Whereas craniofacial 
shape changes are qualitatively similar in Efnb1 heterozygous and hemizygous mutant 
embryos, heterozygous embryos are more severely affected, indicating that Efnb1 mosaicism 
exacerbates phenotypes rather than having a neomorphic affect. Further, by generating ephrin-
B1 mosaicism in specific cell populations, we find that ephrin-B1 is a potent regulator of cell 
segregation throughout craniofacial development and that emergence of differences in face 
shape between control and ephrin-B1 mutant embryos correlates with occurrence of 
segregation in craniofacial primordia. Together, these data suggest that cell segregation in post-
migratory neural crest-derived mesenchyme progressively drives dysmorphology in CFNS.   
 
Introduction 
Congenital craniofacial anomalies account for one third of all birth defects (“Global 
Strategies to Reduce the Health Care Burden of Craniofacial Anomalies,” 2004). Advances in 
craniofacial genetics have identified many genes involved in craniofacial syndromes (Twigg and 
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Wilkie, 2015), but an understanding of the underlying etiology and progression over 
developmental time for each condition will be necessary for improved therapies for this large 
group of disorders. Craniofrontonasal syndrome (CFNS, OMIM #304110) is a subgroup of 
frontonasal dysplasia that is caused by mutations in EPHRIN-B1 (EFNB1), which is located on 
the X chromosome (Cohen, 1979; Twigg et al., 2004; Wieland et al., 2004). Paradoxically, this 
X-linked syndrome is associated with more severe disease phenotypes in heterozygous females 
than hemizygous males, a phenomenon termed “cellular interference” (Twigg et al., 2004; 
Wieacker and Wieland, 2005; Wieland et al., 2004). Whether this “increased severity” 
represents increased disease severity (additional phenotypes in female patients) or an 
increased degree of severity of the same disease, or both, has not been rigorously examined. 
Heterozygous female patients frequently display a combination of orbital hypertelorism (based 
on measurements of inner canthal and interpupillary distances or on computed tomography 
(CT) scans), a short and wide upper face, facial asymmetry, unilateral or bilateral coronal 
craniosynostosis, a short nose, bifid nasal tip, and a broad nasal bridge (Twigg et al., 2004; van 
den Elzen et al., 2014; Wieland et al., 2004). In a subset of cases, cleft lip and palate, agenesis 
of the corpus callosum (Twigg et al., 2004), and maxillary hypoplasia (van den Elzen et al., 
2014) have also been noted. In addition to craniofacial defects, patients present with axial 
skeletal defects including syndactyly and polydactyly.  
CFNS has been termed a neurocristopathy, and it has been hypothesized that CFNS 
phenotypes may be partly attributable to impacts on early neural crest cell (NCC) migration or to 
later bone differentiation defects (Davy et al., 2004; Davy et al., 2006; Nguyen et al., 2016; 
Twigg et al., 2004); however, the precise developmental etiology of this disorder remains 
unknown. Because CFNS patients are clinically evaluated postnatally but craniofacial 
development occurs very early during embryogenesis, it is difficult to pinpoint the developmental 
timing and tissue origin of the craniofacial phenotypes, and therefore this remains a subject of 
debate. Hypertelorism, a key defining phenotype of female CFNS patients that is also seen at a 
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milder level in males with hemizygous mutations in EFNB1, as well as frontonasal dysplasia and 
widened midface, are phenotypes that may have a variety of tissue origins. It is possible that 
these changes are due to defects in NCCs or their derivatives, but they may also be secondary 
to changes in brain shape, or to craniosynostosis that restricts the growth of the skull vault. 
Changes to the shape of the brain can cause changes to facial shape by several described 
mechanisms (Marcucio et al., 2011; Marcucio et al., 2015); for example, reduction of brain size 
in Crf4 mutant mice is associated with more advanced fusion in the developing face, leading to 
a narrower and more prognathic face (Boughner et al., 2008). There is also some evidence for 
the idea that increases in brain size may underlie clefting phenotypes by increasing separation 
of the facial prominences to an extent that they can no longer make contact, even if their 
outgrowth is normal (Parsons et al., 2011; Young et al., 2007). Changes in brain morphology 
have also been proposed to contribute to hypertelorism (Young et al., 2010), but hypertelorism 
could also be secondary to expansion of the midface in CFNS patients. Previous data has 
shown that cell segregation between ephrin-B1 expressing and non-expressing cells occurs in 
the early neural plate (O’Neill et al., 2016), but it is unknown whether this phenomenon 
contributes to changes in the brain that may affect the face, or whether segregation or other 
changes to different tissues underlie these phenotypes. A detailed quantification of CFNS 
phenotypes and assessment of their developmental etiology will be required to determine when 
and where changes in the shape of the face arise in these patients. 
Ephrin-B1 is a member of the Eph/ephrin family of membrane-linked signaling 
molecules; signaling between Eph receptors and ephrins is important for boundary formation, 
cell migration, axon guidance, vascular development, and neurogenesis (Batlle and Wilkinson, 
2012; Fagotto et al., 2014; Kania and Klein, 2016; Klein and Kania, 2014; Kullander and Klein, 
2002; Pasquale, 2005; Pasquale, 2008; Wilkinson, 2001) (see Chapter 2). Ephrins are 
classified into two types: ephrin-As, which are anchored to the cell membrane, and ephrin-Bs, 
which are transmembrane proteins, while Eph-A and Eph-B receptors are classified by their 
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binding affinity to ephrin-As or ephrin-Bs. No specific mutations in EFNB1 or aberrant patterns 
of X-inactivation have been associated with variation in severity or type of dysmorphology, 
though mutations in the region of the fifth exon encoding the intracellular domain have been 
identified less frequently (Twigg et al., 2004; van den Elzen et al., 2014). Analysis of several 
tissue types indicate that X-inactivation is not biased by presence of an EFNB1 mutation (Twigg 
et al., 2004; Wieland et al., 2008), suggesting that loss of gene function does not impact cell 
survival. Supporting the idea that mosaicism for ephrin-B1 expression results in more severe 
dysmorphogenesis, rare male patients with severe CFNS phenotypes exhibit somatic 
mosaicism for EFNB1 mutations (Twigg et al., 2006; Twigg et al., 2013; Wieland et al., 2008). 
Studies of the role of ephrin-B1 in development and the mechanism by which ephrin-B1 
mosaicism results in more severe developmental phenotypes have often been carried out using 
Efnb1 mutant mice as a model for CFNS.  
The Efnb1 mutant mouse has largely been accepted as a good model for CFNS, as 
Efnb1+/Δ mice share many of the same phenotypic characteristics as human EFNB1+/- CFNS 
patients. Efnb1+/Δ embryos are overall less affected than hemizygous (Efnb1Δ/Y) or homozygous 
(Efnb1Δ/Δ) embryos (Bush and Soriano, 2010; Compagni et al., 2003; Davy et al., 2004), 
mirroring the situation seen in female heterozygous CFNS patients. Although this mouse model 
has been widely used to study CFNS, the craniofacial phenotypes associated with heterozygous 
or hemizygous loss of Efnb1 have not been characterized beyond the report of relatively high 
frequency of cleft palate and shorter skulls with altered bone formation (Compagni et al., 2003; 
Davy et al., 2004; Davy et al., 2006; Nguyen et al., 2016), and it remains unknown to what 
extent face shape changes in Efnb1+/Δ embryos mirror those of CFNS patients. The mild 
phenotypes seen in Efnb1Δ/Y mice also inspire the question of whether Efnb1 heterozygosity 
represents a neomorphic state, or a more severe version of the hemizygous state. If mouse 
phenotypes can be shown to quantitatively mirror human phenotypes, the Efnb1+/Δ model will be 
a valuable tool for determining the developmental etiology of CFNS phenotypes; the timing and 
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tissues in which facial shape changes first become apparent in Efnb1+/Δ embryos will shed light 
on the important question of when and where these phenotypes may arise in human patients. 
Increased severity in heterozygous females has been proposed to stem from “cellular 
interference” between cells that express a mutant allele and cells that do not after random X 
inactivation (Wieacker and Wieland, 2005). Cellular interference has been shown to involve cell 
segregation in the developing limb buds of heterozygous female mice, where ectopic borders 
between ephrin-B1 expression and non-expression coincide with the development of additional 
digits (Compagni et al., 2003; Davy et al., 2004), and in the developing craniofacial complex 
(Bush and Soriano, 2010; Davy et al., 2006; O’Neill et al., 2016). Ephrin-B1-mediated cell 
segregation in Efnb1+/- mice can be seen as early as E8.5 in neural plate neuroepithelial cells 
(O’Neill et al., 2016), and this aberrant cellular behavior also occurs in CFNS patient hiPSC-
derived neuroepithelial cells (see Chapter 3), indicating that cell segregation is likely to occur in 
human CFNS patients. How ephrin-B1-mediated segregation contributes to facial 
dysmorphogenesis remains mysterious, however, as the timing and tissue specificity of cell 
segregation and phenotypic progression of CFNS craniofacial phenotypes have not been 
documented. For example, it is unknown whether segregation in precursor cells at the neural 
plate stage is ultimately responsible for the large ephrin-B1 expression patches visible later in 
development in craniofacial structures, or whether ephrin-B1 mosaicism continues to drive 
segregation in multiple cell types throughout the development of these structures. It is also 
unknown whether dysmorphogenesis is directly driven by segregation or is a secondary 
consequence of the inappropriate Eph/ephrin boundaries that are established. Further, though 
ephrin-B1 mosaicism and cell segregation likely play a pivotal role in the cellular etiology of 
CFNS, it remains unclear whether and how aberrant ephrin-B1 expression domains contribute 
to dysmorphic facial shape. 
Here, we use mouse models of CFNS to understand the cellular and developmental 
etiology of craniofacial phenotypes. First, we compare the facial form of Efnb1 heterozygous 
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female and hemizygous male embryos with control embryos to quantify the specific effects of 
Efnb1 loss on facial growth and development to better understand how CFNS dysmorphology 
develops. Next, we demonstrate that ephrin-B1 is a potent regulator of cell segregation in 
multiple cell types across craniofacial development and that the timing of segregation in 
craniofacial primordia correlates with the onset and progression of facial phenotypes in 
developing embryos. These results indicate that cell segregation occurring in the craniofacial 
primordia may be the principal driver of cellular interference and severe facial 
dysmorphogenesis in CFNS. 
 
Results 
Ephrin-B1 has a significant effect on embryonic facial shape from E11.5 to E14.5 that mirrors 
CFNS 
 Robust quantitative methods will be required to investigate how early the effects of 
mosaic expression of ephrin-B1 on facial morphology appear, whether the earliest facial shape 
effects parallel later facial shape effects and how these change in severity over time, and 
whether phenotypic severity varies between heterozygous females and hemizygous males. We 
therefore quantified mouse embryo facial shape between E11.5 and E14.5 using geometric 
landmark-based morphometrics analysis based on micro-computed tomography (µCT) scans of 
heads of Efnb1+/Δ and Efnb1Δ/Y embryos as well as a pooled control sample of Efnb1+/lox and 
Efnb1lox/Y embryos. To determine the significance and relative contribution of facial size 
(estimated as centroid size) and Efnb1 genotype in determining facial shape, we carried out a 
Procrustes ANOVA analysis on E11.5 embryos using a published landmark set (Percival et al., 
2014). The shape change vectors of each landmark were illustrated separately for each 
genotype and plotted alongside µCT surfaces of specimens that are representative of mean 
genotype facial shapes (Figure 10A). Within the E11.5 analysis, facial size and Efnb1 genotype 
both contribute significantly to facial shape (Table 3), explaining approximately 23% and 11% of 
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the variation, respectively. Genotype effect comparisons based on the E11.5 Procrustes 
ANOVA model can be analyzed to pinpoint specific differences between genotypes. Nasal and 
mouth landmarks between facial prominences illustrate increased relative width and decreased 
relative height of the face. A relatively wide face is noted, and the eye and facial prominences 
appear to be relatively posterior, while the anterior vault landmarks are relatively anterior, 
suggesting a lack of facial prominence outgrowth. Overall, the faces of affected specimens 
show a lack of anterior outgrowth, combined increased relative width, and decreased relative 
height. The significant genotype effect indicates that ephrin-B1 mosaicism or loss influences 
facial shape as early as E11.5. With a few exceptions, including at the mandibular prominence, 
the facial effects noted in Efnb1Δ/Y males are largely less severe versions of Efnb1+/Δ 
dysmorphology at E11.5. 
To determine the significance and relative contribution of facial size (estimated as 
centroid size), embryonic age, and Efnb1 genotype in determining facial shape from E12.5-
E14.5, we completed a Procrustes ANOVA analysis using a novel landmark set defined for the 
E12.5-E14.5 age group. Each factor within the E12.5-E14.5 analysis, in addition to the 
interaction between age and genotype, had significant effects on facial shape (Table 4). 
Variation in Efnb1 genotype explained almost 7% of facial shape variation, indicating that 
ephrin-B1 has a significant effect on facial morphology. As expected for a sample covering 
multiple embryonic days, size explained a very large percentage of facial shape variation (77%, 
based on Rsq; see Table 4). The much higher percentage of variation explained by size in 
comparison with the E11.5 analysis occurs because the E11.5 analysis includes samples from a 
much shorter range of developmental time than the E12.5-E14.5 analysis. This is driven by the 
correlation of facial size and shape across development, also known as allometry. Even after 
size is accounted for, embryonic age and the interaction of age and genotype factors are 
significantly associated with a small amount of facial variation (<1% each).  
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 The first principal component (PC) of a principal components analysis (PCA) of facial 
shape across E12.5-E14.5 largely clusters specimens by embryonic age, which is strongly 
correlated with size; this is expected from the large percentage of variation explained by size. A 
multivariate linear model was used to estimate the allometric component that is common across 
the sample regardless of genotype. The residuals of this regression are interpreted as facial 
shape after accounting for allometry. The first PC of a PCA of these facial shape residuals 
largely separates genotypes, regardless of age (Figure 10B). Control shapes are found on the 
positive end, Efnb1Δ/Y males are found in the middle, and Efnb1+/Δ females are found at the 
negative end. This PC represents a common axis of facial shape covariation that separates the 
genotypes, suggesting major similarities in a genotype’s effect on facial shape at E12.5, E13.5, 
and E14.5. It also suggests that hemizygous male embryos have less severe, but qualitatively 
similar, facial dysmorphology to heterozygous female embryos.  
Although individual PCs illustrate broad patterns of facial shape covariation, they each 
represent only part of overall covariation. Therefore, we calculated Procrustes distances 
between mean control and affected genotype facial shapes to confirm the significance of facial 
shape differences between genotypes and estimate the relative severity of affected facial shape 
dysmorphology. There were significant differences in mean facial shape between control and 
each affected genotype at each embryonic age (Table 5). In addition, the mean facial shapes of 
Efnb1+/Δ embryos were always more different from controls than were Efnb1Δ/Y facial shapes, 
confirming that female heterozygotes display more severe dysmorphology. Comparisons of 
typical E14.5 genotype-specific facial shapes, estimated from the E12.5-E14.5 Procrustes 
ANOVA analysis multivariate linear model, indicate overall similarities in the effects of Efnb1Δ/Y 
and Efnb1+/Δ genotypes on facial shape, but also a few differences. Shape change vectors for 
each landmark at E14.5 can be illustrated for each genotype and plotted alongside 
representative µCT surfaces indicating mean genotype facial shape (Figure 10C). These 
genotype effect comparisons are similar to those used with the E11.5 model and indicate that 
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parallel genotype effects present at E11.5 are still present at E14.5. Both affected genotypes 
display hypertelorism, represented by an increased relative width between anterior eye 
landmarks. They also have a relatively inferior-posterior nose, anterior ear, and superior-lateral-
posterior lip corners. Altogether, these shared patterns of dysmorphology indicate hypertelorism 
and facial shortening in both male hemizygotes and female heterozygotes.  
There are also some noted differences in the effect of each genotype on facial shape. 
Although both males and females display increased relative width at the eyes, only Efnb1+/Δ 
embryos display increased relative width of the posterior whisker margins and a posterior 
inferior corner of the whisker region. This suggests a larger increase in relative width of the 
midfacial region in the female heterozygotes that is not matched by the male hemizygotes. In 
addition, the degree of facial shortening in the females is more extreme, as seen by longer 
vectors at the ear and nose landmarks. Finally, the female heterozygotes display a much higher 
point of maxillary prominence fusion at each embryonic age, suggesting reduced midline lip 
fusion. These results quantitatively demonstrate that in the mouse, as in human CFNS patients, 
female heterozygotes possess more severe facial dysmorphology than hemizygous male 
patients; they also suggest that increased midface expansion underlies more severe 
phenotypes in female heterozygotes.  
Our shape analysis indicates that the anterior canthus of the eye is relatively lateral in 
Efnb1+/Δ embryos compared to control mice (Figure 10C), with Efnb1Δ/Y mice in between. This 
suggests that our affected mice display hypertelorism, as is seen in humans with CFNS. 
However, because overall scale and size-correlated shape variation was removed prior to the 
final PCA analysis, the same result might be achieved with an absolutely shorter snout or an 
absolutely wider biorbital breadth. A comparison of bicanthic breadth was completed to confirm 
whether our affected embryos display hypertelorism. Kruskal-Wallis tests indicate that there are 
significant differences in relative bicanthic breadth (bicanthic breadth/whisker region length) 
between genotypes at each age. Pairwise Wilcoxan tests were completed to determine how 
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they differed. At E11.5 and E12.5, Efnb1+/Δ mice have significantly wider relative bicanthal 
breadth than control mice, but Efnb1Δ/Y mice do not. At E13.5 and E14.5, both Efnb1+/Δ and 
Efnb1Δ/Y mice have significantly wider relative bicanthal breadth than control mice. These results 
confirm that Efnb1+/Δ mice display hypertelorism at all ages tested, and Efnb1Δ/Y mice display 
hypertelorism at E13.5 and E14.5; this earlier difference may contribute to the increased 
severity in heterozygous embryos. Overall, our analyses of facial shape indicated the presence 
of CFNS-like facial dysmorphology as early as E11.5 in Efnb1+/Δ and Efnb1Δ/Y embryos.  
 
Sox1Cre mediates cell segregation independently in the brain, but this does not affect NCC-
derived craniofacial mesenchyme or facial shape 
 Cell segregation has been proposed to underlie increased severity in heterozygous 
female CFNS patients with ephrin-B1 mosaicism (Bush and Soriano, 2010; Compagni et al., 
2003; O’Neill et al., 2016; Wieacker and Wieland, 2005) (see Chapter 3). We have previously 
shown that ephrin-B1 mediates segregation in the neural plate neuroepithelium (O’Neill et al., 
2016), but it was not known whether this segregation in neural progenitors, leading to large 
patches of ephrin-B1 expression and non-expression later in the brain, can mediate changes in 
facial shape. There is some evidence that disruption of neuroepithelial cells can negatively 
affect NCCs, resulting in abnormal craniofacial development in Treacher-Collins syndrome 
patients (Jones et al., 2008; Sakai et al., 2016), and changes to the shape of the brain can 
cause changes to facial shape (Marcucio et al., 2011; Marcucio et al., 2015). We therefore 
wondered whether ephrin-B1 mosaicism in neural progenitor cells alone could result in ephrin-
B1-mediated changes to facial shape later in development.  
 To determine whether early neural progenitor segregation contributes to later 
segregation in the brain and craniofacial structures, we generated neural progenitor-specific 
ephrin-B1 mosaic Sox1Cre/+; Efnb1+XGFP/Δ embryos and compared frontal sections through the 
brain, FNP, and palatal shelves to matched control Efnb1+XGFP/lox sections at E13.5. These 
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embryos express a GFP transgene from one (wild-type) X chromosome (Hadjantonakis et al., 
1998; Hadjantonakis et al., 2001), which we use to monitor X chromosome inactivation (XCI). 
Control embryos demonstrate high ephrin-B1 expression in the brain and a fine-grained mosaic 
pattern of XGFP expression, as expected after random XCI (Figure 11A, A’). Full heterozygous 
Efnb1+XGFP/Δ embryos (mediated by b-actin-Cre) have robust segregation in the brain at E13.5, 
visible as large ephrin-B1/GFP positive and negative patches (Figure 11B, B’). Likewise, the 
brains of Sox1Cre/+; Efnb1+XGFP/Δ embryos show large patches of ephrin-B1/GFP positive and 
negative cells (Figure 11C, C’), indicating that ephrin-B1 mosaicism restricted to neural 
progenitor cells leads to robust segregation in the brain. 
 We next wished to determine whether neural progenitor cell segregation has any effect 
on craniofacial structures later in development. Sox1Cre-mediated recombination of the ROSA26 
locus in Sox1Cre/+; ROSA26mTmG/+ reporter embryos leads to widespread membrane GFP 
expression throughout the brain at E13.5 (Figure 12A, A’) without expression in craniofacial 
structures such as the palatal shelves (Figure 12B, B’) and FNP (Figure 12C, C’). We 
therefore did not expect to see segregation in these structures, and indeed, XGFP expression 
patterns in Sox1Cre/+; Efnb1+XGFP/Δ palatal shelves (Figure 12D, D’) and FNP (Figure 12E, E’) 
appeared evenly distributed throughout the craniofacial mesenchyme, with ephrin-B1 
expression indistinguishable from that seen in control Efnb1+XGFP/lox embryos (Figures 16-17). 
Facial shape comparison between Sox1Cre/+; Efnb1+/Δ and control embryos using µCT scans of 
E14.5 embryo heads, followed by a Procrustes ANOVA analysis using the landmark set 
developed for E12.5-E14.5 embryos, indicated that there was no overall effect of genotype 
between the two groups. Calculation of Procrustes distances between mean control and 
affected genotype facial shapes also showed no significant difference in mean shape between 
Sox1Cre/+; Efnb1+/Δ and control embryos (data not shown). From these data, we can conclude 
that ephrin-B1 mosaicism in neural progenitor cells does drive segregation that is later visible in 
the brain, but this process is independent from facial shape changes seen in full Efnb1+/Δ mouse 
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embryos. Instead, it is possible that early neural plate segregation is maintained through NCC 
induction and migration, or that later stages of cell segregation occur in NCCs and their 
derivatives. Either mechanism could result in changes to craniofacial structures; if ephrin-B1 
mosaicism in NCCs and their derivatives leads to segregation in these cell types, these later 
segregation events may contribute to the facial shape changes we have demonstrated. 
 
Ephrin-B1-mediated cell segregation occurs in post-migratory neural crest cells correlating with 
upregulation of ephrin-B1 expression in craniofacial primordia 
To better understand how cell segregation contributes to facial shape changes, we 
sought to determine where and when ephrin-B1 mediates segregation throughout 
developmental time. Because NCCs are migratory stem cells that populate the structures of the 
face (Bhatt et al., 2013; LaBonne and Bronner-Fraser, 1998), we first tested the ability of ephrin-
B1 mosaicism in NCCs to induce cell segregation in these cells. We generated NCC-specific 
ephrin-B1 mosaic Sox10-CreTg/o; Efnb1+XGFP/Δ embryos and examined them for NCC 
segregation. At E10.5, Sox10-Cre-mediated recombination of the ROSA26 locus in Sox10-
CreTg/o; ROSA26mTmG/+ reporter embryos was robust in the post-migratory NCCs of the maxillae 
and FNP (Figure 13A-B). Like control Efnb1+XGFP/lox embryos (Figure 13C-D), however, neither 
NCC-specific Sox10-CreTg/o; Efnb1+XGFP/Δ embryos nor full Efnb1+XGFP/Δ (mediated by b-actin-
Cre) embryos exhibited cell segregation in the maxillae at this stage (Figure 13E, G), 
suggesting that if cell segregation occurs in migratory NCCs, it does not carry through to post-
migratory NCC-derived mesenchyme of the maxillary prominences. Ephrin-B1 expression was 
low in the maxillae at this stage (Figure 13C, E, G), indicating that perhaps its upregulation in 
post-migratory craniofacial mesenchyme is required for segregation. Very small groups of 
ephrin-B1/XGFP expressing and non-expressing cells could be seen in the LNP of each group 
of mosaic embryos at E10.5 (Figure 13F, H), indicating either that cell segregation in pre-
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migratory NCCs can carry through to the LNP, or (more likely) that segregation occurs in the 
LNP earlier than in the MXP due to earlier upregulation of ephrin-B1 in this structure.  
To test whether an increase in ephrin-B1 expression in post-migratory NCC-derived 
mesenchyme leads to cell segregation at later stages, we next examined NCC-specific ephrin-
B1 mosaic Sox10-CreTg/o; Efnb1+XGFP/Δ embryos at E11.5, an embryonic stage at which 
phenotypic differences in Efnb1+/Δ embryos are first apparent (Figure 10A) and ephrin-B1 
begins to exhibit robust expression in the maxillary prominences (MXP) and lateral nasal 
prominences (LNP). In control Efnb1+XGFP/lox embryos, ephrin-B1 expression and a fine-grained 
mosaic pattern of XGFP expression are visible in the MXP and LNP at this stage (Figure 14A-
B). However, in Sox10-CreTg/o; Efnb1+XGFP/Δ NCC mosaic embryos, distinct patches of ephrin-
B1/XGFP expression and non-expression are visible in both structures (Figure 14C-D), 
indicating both that ephrin-B1 drives segregation in the neural crest and that segregation occurs 
in the maxilla after migration of NCCs to populate the craniofacial prominences. Notably, the 
upregulation of ephrin-B1 expression in the FNP prior to the maxilla may provide a plausible 
explanation for why segregation may be seen earlier in the FNP, but we cannot rule out the 
possible contribution of pre-migratory NCC segregation. Together, these data indicate that 
multiple distinct phases of cell segregation occur; in addition to early cell segregation in the 
headfold, a second phase of cell segregation begins in the post-migratory NCC-derived 
craniofacial mesenchyme upon upregulation of ephrin-B1 expression in this population.   
 
Post-migratory neural crest cell segregation results in local dysmorphogenesis in craniofacial 
structures  
 The finding that segregation occurs in post-migratory NCCs demonstrates that ephrin-B1 
mediates this process after the headfold stage; we next wished to determine whether 
segregation continues in later post-migratory NCC-derived craniofacial mesenchyme. Ephrin-B1 
has strong expression in the anterior secondary palate (Bush and Soriano, 2010), the study of 
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which has implications for cleft palate in CFNS patients. We therefore asked whether cells of the 
palate mesenchyme mosaic for ephrin-B1 expression can undergo segregation mediated by 
ephrin-B1. We generated palate mesenchyme-specific ephrin-B1 mosaic Shox2IresCre/+; 
Efnb1+XGFP/Δ embryos and compared them to control Efnb1+XGFP/lox embryos at E11.5, before 
palatal shelf extension, and at E12.5, a stage at which the palatal shelves are extending from 
the maxillary prominences. As expected, prior to the onset of Shox2-mediated recombination in 
the secondary palate mesenchyme, no cell segregation was observed in Shox2IresCre/+; 
Efnb1+XGFP/Δ embryos, which instead resembled controls (Figure 15A-B). Although Shox2IresCre 
mediated some recombination of the ROSA26 locus in Shox2IresCre/+; ROSA26mTmG/+ reporter 
embryos in the maxilla at E11.5, almost all membrane GFP-positive cells (Figure 15C, C’) 
coexpressed neurofilament (2H3) (Figure 15D, D’), indicating that these are likely nerve cells of 
the maxillary trigeminal ganglion. By embryonic day 12.5, however, palate-specific ephrin-B1 
mosaic Shox2IresCre/+; Efnb1+XGFP/Δ embryos exhibited small patches of ephrin-B1/GFP 
expression and non-expression that were not observed in control embryos (Figure 15E-F), 
indicating that segregation is beginning to take place in this tissue. By this embryonic timepoint, 
Shox2IresCre recombination of the ROSA26 locus in Shox2IresCre/+; ROSA26mTmG/+ reporter 
embryos led to mesenchyme-specific membrane GFP expression (Figure 15G, G’) that does 
not overlap with 2H3 expression (Figure 15H, H’). Ephrin-B1 is therefore a powerful driver of 
segregation not only in progenitor cells, such as neuroepithelial cells or NCCs, but also in more 
differentiated cell types of the craniofacial mesenchyme. These data also demonstrate that 
ephrin-B1-mediated cell segregation is not a single event in developmental time; rather, it likely 
continues through development of craniofacial structures. 
We have demonstrated that differences in facial shape are evident in female 
heterozygous embryos as early as E11.5, but these shape changes continue to develop over 
time and increase in severity through E14.5. To investigate the extent of segregation later in 
development and to determine whether there are visible changes to craniofacial tissue 
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morphology at later stages, we examined embryos with ephrin-B1 mosaicism in specific cell 
types at E13.5. In addition to the anterior secondary palate, the developing frontonasal 
prominence (FNP) also has strong Efnb1 expression and may contribute to CFNS phenotypes 
such as midface expansion and frontonasal dysplasia. We therefore focused on the effects of 
segregation within these two embryonic structures. We examined full Efnb1+XGFP/Δ embryos 
(mediated by b-actin-Cre) as well as NCC-specific ephrin-B1 mosaic Sox10-CreTg/o; Efnb1+XGFP/Δ 
embryos and palate mesenchyme-specific ephrin-B1 mosaic Shox2IresCre/+; Efnb1+XGFP/Δ embryos 
and compared both palatal shelves and FNP to control Efnb1+XGFP/lox embryos at E13.5.  Control 
embryos have strong ephrin-B1 expression in the tips of the anterior palatal shelves and lateral 
FNP, while XGFP is visible in a fine-grained mosaic pattern in each structure (Figure 16A, A’; 
Figure 17A, A’). In full Efnb1+XGFP/Δ heterozygotes, large ephrin-B1/GFP expressing and non-
expressing patches are apparent in the palatal shelves (Figure 16B, B’) and FNP (Figure 17B, 
B’). In these embryos, regions of local dysmorphogenesis correlate with aberrant ephrin-B1 
expression boundaries, including smaller and abnormally shaped palatal shelves and bifurcation 
of the nasal concha.  
Neural crest specific mosaic Sox10-CreTg/o; Efnb1+XGFP/Δ embryos also have visible 
ephrin-B1/GFP positive and negative patches in the palate, which correspond with local 
dysmorphology of shelf structure including less extension of the palatal shelves (Figure 16C, 
C’). Comparable to full heterozygotes, these embryos also exhibit segregation in the FNP and 
often have bifurcations of the nasal conchae (Figure 17C, C’). This indicates that restricting 
ephrin-B1-mediated segregation to the NCCs is sufficient to create dysmorphology similar to 
that seen in full ephrin-B1 heterozygotes and further highlights the importance of segregation in 
the neural crest.  
In palate mesenchyme-specific Shox2IresCre/+; Efnb1+XGFP/Δ heterozygotes, small ephrin-
B1/GFP expressing and non-expressing patches are apparent in the palate mesenchyme 
(Figure 16D, D’). These patches appear smaller than those in full or NCC-specific mosaic 
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embryos, and the palatal shelves appear normally sized and not as dramatically dysmorphic. 
However, there is still some local dysmorphogenesis correlating with aberrant ephrin-B1 
expression boundaries. No segregation is present in the lateral FNP of these embryos (Figure 
17D, D’), although some segregation can be seen in the nasal septum and upper lip 
mesenchyme, where Shox2IresCre-mediated recombination and ephrin-B1 expression overlap. As 
expected, upon examining the brains of these embryos with Cre-restricted ephrin-B1 
heterozygosity, ephrin-B1 mosaicism in NCCs or secondary palate mesenchyme alone does not 
result in cell segregation in the brain at E13.5 (Figure 11D-E). In total, these data demonstrate 
that ephrin-B1 mediates segregation within the post-migratory NCC-derived mesenchyme in 
structures key to CFNS pathology and suggest that aberrant ephrin-B1 expression patches may 
contribute to craniofacial dysmorphology by mediating tissue structure changes at their ectopic 
boundaries.  
 
Discussion 
The results of our analyses illuminate the developmental basis for craniofacial 
dysmorphogenesis in craniofrontonasal syndrome (CFNS). Using landmark analysis, we have 
determined the exact locations of facial changes across Efnb1 mutations from the heterozygous 
to null state and defined the timing of onset of these changes during embryonic development; 
the critical period is from E11.5-E14.5, which approximately corresponds to weeks 5-8 in human 
embryonic development. During this period, both ephrin-B1 null hemizygote and ephrin-B1 
mosaic heterozygous embryos demonstrate changes in facial shape relative to control embryos, 
but the changes are more pronounced in mosaic heterozygous embryos, suggesting that the 
increased severity seen in heterozygous female CFNS patients is a quantitatively more severe 
version of the hemizygous phenotype. In addition, we have shown that cell segregation occurs 
in the post-migratory NCCs that populate the craniofacial mesenchyme at E11.5, which 
correlates both with the onset of ephrin-B1 expression in these tissues and with the first 
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changes we observe in facial shape. When restricted to the NCCs or the secondary palate 
mesenchyme, ephrin-B1 mosaicism drives segregation to generate ectopic expression borders 
that correlate with local dysmorphology in craniofacial structures. When restricted to neural 
progenitor cells, ephrin-B1 mosaicism drives segregation independently in the brain, but this 
does not cause changes in facial shape, indicating that it is ephrin-B1 mosaicism in a different 
tissue that predominantly drives dysmorphology in CFNS. Future studies will determine the 
contribution of ephrin-B1 mosaicism and segregation in other tissues to changes in facial shape 
and the requirement for individual EphB receptors to mediate these changes. To work towards 
therapeutic strategies for these patients, it will also be essential to investigate whether or not 
cell segregation can be blocked or reversed, as it appears to hold the key to increased severity 
in female CFNS patients.  
Using Efnb1+/Δ mice, a model for heterozygous CFNS patients, as well as Efnb1Δ/Y mice, 
their ephrin-B1 null counterparts, we have quantified the nature, severity, and progress of facial 
dysmorphogenesis during the embryonic days subsequent to NCC migration to populate the 
facial prominences. Significantly wider and shorter faces in Efnb1 null mice were noted as early 
as E11.5 and maintained through E14.5, even as the face continues to develop. Additionally, 
female heterozygotes displayed more severe dysmorphology than hemizygous males 
throughout this period. The quantitative characterization of phenotypic changes in these 
embryos revealed that dysmorphology analogous to CFNS phenotypes seen in humans with 
EFNB1 mutations arose very early during facial morphogenesis, including hypertelorism and 
midfacial hypoplasia, and these phenotypes were more severe in heterozygous females from 
the earliest stages. This further establishes Efnb1+/Δ mice as a useful system for modeling facial 
dysmorphogenesis in CFNS and allows for direct connection between Efnb1 mutation on an 
inbred background and changes to face shape.  
Aberrant ephrin-B1-mediated cell segregation, or “cellular interference,” has long been 
posited as the causative mechanism for producing craniofacial and skeletal phenotypes in 
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CFNS patients (Compagni et al., 2003; O’Neill et al., 2016; Twigg et al., 2013; Wieland et al., 
2008) (see Chapter 3). It has remained difficult, however, to definitively demonstrate the 
connection between cell segregation and craniofacial dysmorphogenesis. To begin to address 
this question, it is necessary to understand both when (in developmental time) and where (in 
relevant tissues to CFNS) cell segregation occurs. We have shown that in addition to an early 
wave of segregation in the neural plate neuroepithelium, where ephrin-B1 expression is high, a 
second wave of segregation occurs upon upregulation of ephrin-B1 in NCC-derived craniofacial 
mesenchyme of the MXP and LNP at E11.5. As dramatic segregation is not apparent in these 
structures at E10.5, we propose that this segregation is not maintained or established 
throughout NCC migration, but rather represents a separate segregation event occurring after 
migration is complete. Furthermore, if ephrin-B1 mosaicism is restricted to postmigratory NCCs 
of the palate mesenchyme, segregation still occurs in these cells, indicating that later derivatives 
of NCCs are also subject to ephrin-B1-mediated segregation and suggesting that even more 
differentiated cell types might possess the potential to undergo this process. Future studies will 
determine whether aberrant ephrin-B1 expression boundaries, or failure of endogenous 
boundary maintenance, caused by ephrin-B1 mosaicism contribute to CFNS phenotypes that 
arise later in development, such as craniosynostosis.  
The combination of careful histological and morphometric analyses suggests that the 
etiology of craniofacial phenotypes in CFNS patients occurs early in development of the face, as 
aberrant ephrin-B1-mediated segregation begins in post-migratory neural crest cells of the MXP 
and LNP. Our data represent a first step towards establishing a connection between cell 
segregation and craniofacial dysmorphogenesis; local changes in craniofacial structures are 
evident even when ephrin-B1 mosaicism is restricted to NCCs or to the palate mesenchyme, 
suggesting that later segregation in these cell types contributes to craniofacial phenotypes. We 
have also shown that although segregation occurs dramatically in neural precursor cells at the 
neural plate and is present in the brains of Efnb1+/Δ embryos, restriction of ephrin-B1 mosaicism 
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to neural progenitor cells in Sox1Cre/+; Efnb1+/Δ embryos does not result in changes to 
craniofacial structures or changes to face shape, although segregation in the brain remains 
equally robust in these embryos. Although previous studies have shown that changes to the 
structure of the brain can alter the shape of the face (Marcucio et al., 2011; Marcucio et al., 
2015), we demonstrate that this is not the case for the developmental etiology of craniofacial 
dysmorphology in CFNS. Further studies will be required to continue investigating the 
connection between ephrin-B1 mosaicism, cell segregation, and changes in facial shape; in 
particular, it will be important to determine whether ephrin-B1 mosaicism in NCCs causes 
differences in facial shape between Sox10-CreTg/o; Efnb1+/Δ and control embryos.  
Future experiments will use geometric morphometrics-based analysis to determine 
whether ephrin-B1 mosaicism specifically in neural crest cells in Sox10-CreTg/o; Efnb1+/Δ 
embryos creates significant changes in facial shape, thereby shedding light on the tissue origins 
of craniofacial dysmorphology. In addition, it will be important to determine which EphB 
receptors are required for signaling that results in both segregation and changes to facial shape. 
For a better understanding of how cell segregation creates craniofacial dysmorphology, it will 
also be essential to identify the cellular mechanisms that drive changes in craniofacial structures 
in response to the presence of aberrant ephrin-B1 boundaries. Finally, given the importance of 
cell segregation to CFNS and the fact that it is not a fixed event early in development of the 
neural plate, we are actively working on experiments to block or genetically reverse cell 
segregation in vivo. If this is feasible, these experiments will serve as proof of principle that this 
cell behavior is dynamic and reversible, and CFNS patients may benefit from molecular 
therapies to reduce or eliminate segregation in the future.  
 
Materials and Methods 
Mouse lines. All animal experiments were performed in accordance with the protocols of the 
University of California, San Francisco Institutional Animal Care and Use Committee. Mice were 
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socially housed under a twelve-hour light-dark cycle with food and water ad libitum. If single 
housing was required for breeding purposes, additional enrichment was provided. All alleles 
used for the experiments herein have been previously described. All mice were backcrossed 
and maintained on a congenic C57Bl/6J genetic background. Efnb1lox, MGI: 3039289 (Davy et 
al., 2004); XGFP, MGI: 3055027 (Hadjantonakis et al., 1998); b-actin-Cre, MGI: 2176050 
(Lewandoski et al., 1997); Sox10-Cre, MGI: 3586900 (Matsuoka et al., 2005); Shox2IresCre, MGI: 
5567920 (Dougherty et al., 2013); Sox1Cre, MGI: 3807952 (Takashima et al., 2007); 
ROSA26mTmG, MGI: 3716464 (Muzumdar et al., 2007). For a full description of genetic crosses 
used to generate embryos; strain background, sex, and stage of embryos; and numbers of 
embryos analyzed, please refer to Table 8.  
 
Generation of embryos for immunofluorescence analysis of cell segregation. An X-linked beta-
actin GFP transgene (XGFP) that demonstrates a fine-grained mosaic pattern of GFP 
expression after random X chromosome inactivation (XCI) in female embryos (Compagni et al., 
2003; Hadjantonakis et al., 1998; Hadjantonakis et al., 2001) was used to visualize XCI as well 
as cell segregation in all mosaic embryos. Full ephrin-B1 heterozygotes were generated using 
b-actin-Cre mice. b-actin-CreTg/o; XGFP/Y male mice were crossed to Efnb1lox/lox female mice to 
generate both b-actin-CreTg/o; Efnb1+XGFP/Δ and Efnb1+XGFP/lox control embryos. Embryos mosaic 
for ephrin-B1 expression specifically in the neural crest cell (NCC) lineage were generated using 
Sox10-Cre mice (Matsuoka et al., 2005), which were crossed to Efnb1lox/lox female mice to 
generate both Sox10-CreTg/o; Efnb1+XGFP/Δ heterozygous mutant and Efnb1+XGFP/lox control 
embryos. Embryos mosaic for ephrin-B1 expression specifically in the palate and limb 
mesenchyme were generated using Shox2IresCre (Dougherty et al., 2013). Shox2IresCre/+; XGFP/Y 
male mice were crossed to Efnb1lox/lox female mice to generate both Shox2IresCre/+; Efnb1+XGFP/Δ 
heterozygous mutant and Efnb1+XGFP/lox control embryos. Embryos mosaic for ephrin-B1 
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expression in early neural progenitor cells were generated using Sox1Cre, which drives 
recombination in neural plate neuroepithelial cells at E8.5 (Takashima et al., 2007). Sox1Cre/+; 
XGFP/Y male mice were crossed to Efnb1lox/lox female mice to generate both Sox1Cre/+; 
Efnb1+XGFP/Δ heterozygous mutant and Efnb1+XGFP/lox control embryos. 
 
Morphometrics specimen and data acquisition. Embryos mosaic for ephrin-B1 expression in all 
tissues (full heterozygotes) were collected at embryonic days E11.5, E12.5, E13.5, and E14.5 
from crosses of Efnb1lox/lox mice and b-actin-Cre mice. This sample includes hemizygote males 
(Efnb1Δ/y), heterozygote females (Efnb1+/Δ), and control specimens that were sometimes 
littermates of affected specimens and sometimes came from separate crosses of b-actin-Cre 
and C57BL/6J mice to control for possible effects of Cre transgene insertion. Embryos were 
fixed in a mixture of 4% PFA and 5% glutaraldehyde in PBS. After approximately an hour 
soaking in Cysto-Conray II (Liebel-Flarsheim Canada), micro-computed tomography (µCT) 
images of embryo heads were acquired with a Scanco µ35 at the University of Calgary with 
45kV/177µA for images of 0.012 mm3 voxel size. All facial landmarks were collected on 
minimum threshold based ectodermal surfaces (downsampled x2) from the µCT images in 
Amira (FEI). Because of striking changes in the morphology of the face between E11.5 and 
E14.5, two different landmark sets were required to quantify facial shape across this period. 
Previously defined ectodermal landmarks (Percival et al., 2014), minus those previously 
identified as problematic (i.e. landmarks 2, 7(24), 10(27), 13(30), 17(34), 18(35), 21(38), 22), 
were used to quantify facial form of E11.5 embryos.  A modified and reduced version of this 
published landmark set was developed to allow for comparison of ectodermal facial form 
between E12.5 and E17.5, which we used to quantify facial form of our E12.5, E13.5, and E14.5 
embryos.   
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Morphometric analysis E12.5-E14.5. Procrustes superimposition was performed on landmarks 
collected from E12.5, E13.5, and E14.5 specimens to align each specimen and remove scale 
from analysis. Superimposition and subsequent geometric morphometric analysis was 
completed using geomorph (Adams and Otárola-Castillo, 2013) in R Statistical Software (R 
Developmental Core Team, 2008). Procrustes ANOVA analysis, with permutation-based tests 
for significance, was used to determine whether size (numeric; centroid size), genotype (factor; 
+/Δ, Δ/y, control), age (numeric; 12.5, 13.5, 14.5) and their interactions have a significant 
influence on facial shape (α=0.05). We visualized the effects of Efnb1+/Δ and Efnb1Δ/y genotypes 
on facial shape by plotting differences between genotype specific shapes estimated from the 
Procrustes ANOVA multivariate linear model (assuming E14.5 age and average E14.5 centroid 
size). Given the strong changes in facial shape that normally occur between E12.5 and 14.5, we 
completed a multivariate regression of facial shape on centroid size to estimate allometry and 
used the rescaled residuals of that regression as “allometry corrected” coordinates for further 
analysis. Principal components analyses of coordinate values were completed both before and 
after “allometry correction” to visualize patterns of specimen clustering along major axes of 
facial shape covariation within the sample. Procrustes distances between mean control and 
affected facial shapes were calculated from residual landmark coordinates at each age to 
determine whether genotypes displayed significantly different facial shapes. Significance was 
determined by comparing Procrustes distances to 95% age-specific confidence intervals that 
were estimated with 1000 permutations of distances between two randomly selected control 
groups of 15 specimens.   
 
Morphometrics analysis E11.5. Procrustes coordinate based analyses were completed for 
E11.5 facial landmarks in much the same way they were performed for the E12.5-14.5 sample. 
The major difference is that all analyses were completed without allometry correction, because 
only one age was under analysis. The Procrustes distance values, Procrustes ANOVA output 
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values, and other values are not directly comparable between the E11.5 and the E12.5-E14.5 
analysis, because a different set of landmarks undergoing independent Procrustes 
superimpositions were completed for each age group. However, comparisons of the type of 
facial shape changes associated with genotype within each age group are valuable to determine 
if affected phenotypes like those noted in older specimens exist as early as E11.5. 
 
Immunofluorescence. Embryos were fixed in 4% PFA in PBS, dehydrated through sucrose, 
embedded in OCT, and frozen in dry ice/ethanol. 12 µm sections were cut using an HM550 
(Thermo Scientific) or a CM1900 (Leica) cryostat. Slides were washed with PBS, blocked in 5% 
normal donkey serum (Jackson ImmunoResearch) and 0.1% Triton-X-100 in PBS, incubated in 
primary antibody overnight at 4°C, washed with PBS, and incubated in secondary antibody at 
room temperature (for antibody information, please refer to Table 6). Slides were 
counterstained in DAPI (Millipore) in PBS and coverslips were mounted on slides using 
Aquamount (Thermo Scientific) for imaging. Images were obtained on an Axio Imager.Z2 
upright microscope using an AxioCamMR3 camera and AxioVision Rel.4.8 software (Zeiss). 
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Table 3. Significant influences on facial shape at E11.5 
 Df SS MS Rsqc F Z Pr(>F) 
Sizea 1 0.141 0.141 0.229 24.719 6.274 0.001* 
Genotypeb 2 0.069 0.034 0.111 6.005 5.970 0.001* 
Residuals 74 0.406 0.006     
Total 77 0.615      
aOutput of a multivariate linear ANOVA to estimate the influence of overall size (estimated as 
centroid size) on facial shape. 
bOutput of a multivariate linear ANOVA to estimate the influence of genotype (as a factor) on 
facial shape. 
cRsq provides an estimate of how much facial shape variance a given covariate explains.  
* indicates a significant effect on facial shape, as calculated using a permutation test. 
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Table 4. Significant influences on facial shape from E12.5-E14.5  
 Df SS MS Rsqe F Z Pr(>F) 
Sizea 1 1.706 1.706 0.772 1083.475 7.158 0.001* 
Genotypeb 2 0.145 0.072 0.066 46.005 13.728 0.001* 
Agec 1 0.011 0.011 0.005 7.287 9.243 0.001* 
Genotype:Aged 2 0.016 0.008 0.007 5.207 10.914 0.001* 
Residuals 210 0.331 0.002     
Total 216 2.210      
aOutput of a multivariate linear ANOVA to estimate the influence of overall size (estimated as 
centroid size) on facial shape. 
bOutput of a multivariate linear ANOVA to estimate the influence of genotype (as a factor) on 
facial shape. 
cOutput of a multivariate linear ANOVA to estimate the influence of age (as continuous) on facial 
shape across E12.5-E14.5 specimens.  
dGenotype:Age is the interaction effect of genotype and age.  
eRsq provides an estimate of how much facial shape variance a given covariate explains.  
* indicates a significant effect on facial shape, as calculated using a permutation test. 
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Table 5. Age-specific comparisons of the Procrustes distances between the mean shape 
of affected and control genotypes, after accounting for allometry  
  Efnb1 genotype 
 Control (95% CI) Δ/ya +/Δa 
E11.5^ 0.07-0.18^ 0.22*^ 0.32*^ 
E12.5 0.04-0.09 0.15* 0.23* 
E13.5 0.03-0.06 0.19* 0.28* 
E14.5 0.03-0.06 0.18* 0.29* 
aHigher values represent a greater difference in facial shape, a proxy for severity of 
dysmorphology. 
* indicates a significantly different facial shape than control, based on the 95% control 
confidence intervals produced by bootstrapping the control sample.  
^ indicates that E11.5 Procrustes distance values cannot be directly compared to E12.5-E14.5 
values, because they are based on a different landmark set and separate Procrustes 
superimposition. However, the pattern of the ordering of Procrustes distance values within ages 
can be compared and show similar patterns of significance. 
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Figure 10. Ephrin-B1 has a significant effect on embryonic facial shape from E11.5 to 
E14.5 that mirrors CFNS. (A) A representative control E11.5 specimen surface from the 
anterior and lateral views, with landmarks identified. Plot of the predicted facial shape landmark 
positions for control (black points), Efnb1Δ/Y (red points), and Efnb1+/Δ (cyan points) from the 
anterior and lateral views. The lengths of these shape difference vectors are magnified three 
times to allow for easy comparison of directions of shape changes associated with the two 
affected genotypes. Thin black lines are placed for anatomical reference. (B) Specimens plotted 
along PC1 and PC2 of facial shape variation residuals of the multivariate regression of facial 
shape on size. These residuals can be interpreted as facial shape coordinates after accounting 
for a common allometric component associated with growth. Control, Efnb1Δ/Y, and Efnb1+/Δ 
clusters are shown as black, red, and cyan symbols, respectively; circles indicate E12.5, 
squares indicate E13.5, and triangles indicate E14.5.  (C) Representative control, Efnb1Δ/Y, and 
Efnb1+/Δ E14.5 specimen surfaces from the anterior and lateral views, with landmarks 
superimposed on all three genotypes. Plots of the predicted facial shape landmark positions are 
also shown from the anterior and lateral views: control (black points), Efnb1Δ/Y (red points), and 
Efnb1+/Δ (blue points). The lengths of these shape difference vectors are magnified three times 
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to allow for easy comparison of directions of shape changes associated with the two affected 
genotypes. Thin black lines are placed for anatomical reference.  
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Figure 11. Ephrin-B1 mosaicism in neural progenitors produces cell segregation in the 
brain, whereas neural crest-specific mosaicism does not. (A, A’) Control embryos 
demonstrate high ephrin-B1 expression in the brain, with no cell segregation as shown by a 
fine-grained mosaic pattern of XGFP expression. (B, B’) In embryos with ubiquitous mosaicism 
for ephrin-B1 expression mediated by b-actin-Cre, cell segregation is evident throughout the 
brain as large patches of ephrin-B1 and GFP expression. (C, C’) Generation of ephrin-B1 
mosaicism specifically in neural progenitor cells using Sox1Cre results in dramatic segregation 
throughout the brain at E13.5, visible as large patches of ephrin-B1 and GFP expression. 
However, ephrin-B1 mosaicism generated in neural crest cells using Sox10-Cre (D, D’) or in 
post-migratory neural crest cells of the palate mesenchyme using Shox2IresCre (E, E’) does not 
lead to segregation in the brain, as demonstrated by an evenly distributed pattern of XGFP 
expression. Scale bars, 200 μm.  
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Figure 12. Ephrin-B1-mediated cell segregation in the brain does not affect development 
of craniofacial structures. (A, A’) Recombination of the ROSA26 locus in Sox1Cre; 
ROSA26mTmG/+ embryos leads to widespread membrane GFP expression throughout the brain 
at E13.5, but minimal membrane GFP expression in (B, B’) anterior palatal shelves or (C, C’) 
anterior frontonasal prominence (FNP). (D, D’) Ephrin-B1 mosaicism in early neural progenitor 
cells mediated by Sox1Cre does not drive segregation in neural crest-derived craniofacial 
structures such as the anterior palatal shelves or (E, E’) FNP. Ephrin-B1 expression and 
craniofacial morphology appear normal in these embryos, indicating that neural progenitor cell 
segregation is an independent process. Scale bars, 200 μm. 
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Figure 13. Craniofacial cell segregation first occurs in the post-migratory neural crest-
derived mesenchyme, correlating with the onset of upregulation of ephrin-B1. (A, A’) 
Sox10-Cre drives recombination in the maxillary prominences and (B, B’) frontonasal 
prominence (FNP) of Sox10-CreTg/o; ROSA26mTmG/+ embryos at E10.5. (C, C’) Efnb1+XGFP/lox 
control maxillary prominences and (D, D’) FNP demonstrate a fine-grained mosaic pattern of 
XGFP expression at E10.5. Ephrin-B1 expression is not strong in the maxillae but has begun to 
be upregulated in the FNP at this stage. (E, E’) Likewise, neural crest-specific Sox10-CreTg/o; 
Efnb1+XGFP/Δ heterozygous embryos demonstrate a fine-grained mosaic pattern of XGFP 
expression in the maxillary prominences at E10.5, indicating that segregation is not carried 
through from migratory NCCs. (F, F’) The FNP of E10.5 Sox10-CreTg/o; Efnb1+XGFP/Δ 
heterozygous embryos show a small amount of segregation, visible as patches of ephrin-
B1/GFP expression and non-expression, likely because ephrin-B1 has begun to be expressed 
in the FNP at this stage. (G, G’) The maxillae of full ephrin-B1 heterozygotes (mediated by b-
actin-Cre) are also not segregated at E10.5, but segregation can be seen in the neural tissues 
of these embryos. (H, H’) Segregation is visible in the developing LNP and in neural tissues of 
full ephrin-B1 heterozygotes. 
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Figure 14. Neural crest cells mosaic for ephrin-B1 expression undergo cell segregation in 
craniofacial primordia. (A, A’) At E11.5, Efnb1+XGFP/lox control embryos demonstrate a fine-
grained mosaic pattern of XGFP expression, and ephrin-B1 expression is strong in both the 
maxillary prominences and (B, B’) the lateral FNP. (C, C’) Sox10-CreTg/o; Efnb1+XGFP/Δ embryos 
with ephrin-B1 mosaicism specifically in NCCs show dramatic cell segregation in the maxillary 
prominences and (D, D’) the lateral FNP, indicating that NCCs are capable of undergoing 
ephrin-B1-mediated segregation resulting in aberrant ephrin-B1 expression patterns in 
craniofacial mesenchyme. Scale bars, 200 μm.   
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Figure 15. Palate-specific ephrin-B1 mosaicism results in cell segregation in the anterior 
palate mesenchyme after E11.5. (A, A’) At E11.5, the maxillae of Efnb1+XGFP/lox control and (B, 
B’) Shox2IresCre/+; Efnb1+XGFP/Δ heterozygous embryos are indistinguishable; both genotypes 
demonstrate a fine-grained mosaic pattern of XGFP expression in the maxillary prominences, 
indicating that no cell segregation has taken place. (C, C’) Shox2IresCre drives minimal 
recombination in the maxillary prominences of Shox2IresCre/+; ROSA26mTmG/+ embryos at E11.5. 
(D, D’) Most membrane GFP-expressing cells also express neurofilament (2H3) and are likely 
nerve cells of the maxillary trigeminal ganglion; only a few mesenchymal cells have undergone 
recombination at this stage (white arrows). (E, E’) At E12.5, control palatal shelves show a fine-
grained mosaic pattern of XGFP expression. (F, F’) Small patches of ephrin-B1/XGFP 
expressing and non-expressing cells are visible in the palatal shelves of Shox2IresCre/+; 
Efnb1+XGFP/Δ heterozygous embryos at E12.5, demonstrating that post-migratory neural crest 
cells are also subject to segregation mediated by ephrin-B1 mosaicism. (G, G’) By E12.5, 
Shox2IresCre/+; ROSA26mTmG/+ embryos express membrane GFP in the palatal shelf mesenchyme 
as well as (H, H’) in the nerve cells of the maxillary trigeminal ganglion. Scale bars, 200 μm. 
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Figure 16. Post-migratory neural crest cell segregation correlates with local 
dysmorphology in the secondary palate. (A, A’) Ephrin-B1 protein is strongly expressed in 
the anterior-middle palatal shelves. Evenly distributed XGFP expression in control Efnb1+XGFP/lox 
embryos indicates that no cell segregation has occurred. (B, B’) Cell segregation is visible in the 
palatal shelves of full ephrin-B1 heterozygotes (mediated by b-actin-Cre) as large patches of 
ephrin-B1 and GFP expression in these structures. The palatal shelves are smaller and 
dysmorphic, with changes in shape occurring at boundaries between ephrin-B1 expressing and 
non-expressing domains (white arrow). (C, C’) Generation of ephrin-B1 mosaicism specifically 
in neural crest cells using Sox10-Cre results in dramatic cell segregation in the palatal shelves, 
which are smaller and dysmorphic, with regions of dysmorphogenesis correlating with ephrin-B1 
expression boundaries (yellow arrow). (D, D’) Ephrin-B1 mosaicism in Shox2IresCre-expressing 
cells results in cell segregation in the palatal shelves, which express both ephrin-B1 and Shox2. 
Areas of dysmorphogenesis are visible at the interface between ephrin-B1 expression and non-
expression domains (blue arrow). Scale bars, 200 μm. 
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Figure 17. Post-migratory neural crest cell segregation correlates with dysmorphology in 
the nasal conchae of the frontonasal prominence. (A, A’) In frontal sections of control 
Efnb1+XGFP/lox embryos at E13.5, ephrin-B1 protein expression is strong in the LNP lateral to the 
nasal concha of the anterior frontonasal prominence (FNP). XGFP expression is uniformly 
distributed in a mosaic pattern, indicating that random X inactivation has taken place, but no cell 
segregation is evident. (B, B’) In embryos with ubiquitous mosaicism for ephrin-B1 expression 
mediated by b-actin-Cre, cell segregation is evident throughout the anterior FNP, and bifurcation 
of the nasal concha occurs at an aberrant ephrin-B1 expression boundary (white arrowhead). 
(C, C’) Generation of ephrin-B1 mosaicism specifically in neural crest cells using Sox10-Cre 
results in cell segregation visible throughout the anterior FNP and bifurcation of the nasal 
concha visible at ephrin-B1 expression boundaries (yellow arrowhead). (D, D’) Restriction of 
ephrin-B1 mosaicism to post-migratory neural crest cells using Shox2IresCre does not cause cell 
segregation or dysmorphology in the nasal concha of the anterior FNP, as Shox2 is not 
expressed in this region. Scale bars, 200 μm. 
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CHAPTER 5. Mechanisms of ephrin-B1 cis regulation of EphB receptor 
signaling 
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Summary 
Much of our perception of the mechanisms of Eph/ephrin signaling is based on the 
situation in which binding of an ephrin in one cell to an Eph receptor in an adjacent cell results in 
bidirectional signaling between the cells. Reciprocal expression patterns of Eph receptors and 
ephrins can be observed in some regions of the developing embryo, such as the brain and 
spinal cord, somites, and limb buds, reinforcing the concept that trans signaling occurs across 
Eph/ephrin expression boundaries to achieve downstream functions. However, ephrin-B1, a 
signaling pathway member important for maintenance of normal tissue boundaries and 
associated with pathogenic boundary formation in congenital craniofacial disease, is often 
coexpressed with its receptors EphB2 and EphB3 during craniofacial development. Generally, it 
remains mysterious how coexpression impacts signaling differently from complementary 
expression. During axon guidance, coexpression of ephrin-As and EphA receptors modulates 
EphA activation in response to external stimuli, a process known as cis inhibition. Cis inhibition 
has not been reported for B-type ephrins, and it is not known how cis-expression affects normal 
ephrin-B1-EphB signaling outcome or aberrant ephrin-B1 boundary formation in craniofacial 
disease. Here, we demonstrate that ephrin-B1 does not inhibit EphB receptors in cis as 
described for A-type ephrins. Rather, coexpression of ephrin-B1 with EphB receptors regulates 
signaling outcome through desensitization of EphB-expressing cells by receptor downregulation 
resulting from active signaling within a tissue. This finding expands our understanding of 
differences in signaling mechanisms utilized by A- and B-type ephrins and may shed light on the 
significance of reciprocal ephrin/EphB protein expression patterns during development.  
 
Introduction 
Defects in normal boundary formation during embryonic development result in 
malformations and congenital disease, and understanding the underlying mechanisms will 
improve our knowledge of these conditions. Congenital craniofacial diseases are among the 
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most common birth defects, and improved understanding at the cellular and molecular levels will 
be a key step toward developing new treatment strategies. Craniofrontonasal syndrome (CFNS) 
is an X-linked disorder caused by loss of function mutations in EFNB1 that affect multiple 
aspects of craniofacial, neurological, and skeletal development (Twigg et al., 2004; Wieland et 
al., 2004). Unlike typical X-linked conditions, heterozygous females are severely affected, but 
hemizygous males are only mildly affected. Targeted mutagenesis of Efnb1 in mice leads to 
some of the same phenotypes, including increased severity in heterozygous females (Bush and 
Soriano, 2010; Compagni et al., 2003; Davy et al., 2004). This unusual inheritance pattern is 
caused by mosaicism for ephrin-B1 expression after random X inactivation (Wieacker and 
Wieland, 2005), and mosaicism is key to increased severity: rare, severely affected male CFNS 
patients have somatic mosaic mutations in EFNB1 (Twigg et al., 2013).  
Ephrin-B1 is a member of the Eph/ephrin family of signaling molecules, which are the 
largest family of receptor tyrosine kinases in mammals (Kullander and Klein, 2002). Ephs and 
ephrins are separated into two classes: ephrin-As are membrane-bound through a GPI anchor, 
and ephrin-Bs are transmembrane molecules with a cytoplasmic tail. Although there is some 
overlap in binding affinity between the two classes (Himanen et al., 2004), ephrin-B1 solely uses 
EphBs as its signaling partners (Davis et al., 1994; Orioli et al., 1996). Ephrins activate forward 
signaling through Eph receptors in neighboring cells (signaling in trans) by binding to the ligand-
binding domain of the receptor and initiating receptor oligomerization, tyrosine phosphorylation, 
and recruitment of downstream signaling partners. Eph/ephrin signaling plays an important role 
in developmental boundary formation and tissue self-organization, essential processes that 
require signaling between adjacent cells and often involve segregation between different cell 
types (Fagotto, 2014) (see Chapter 2). Complementary expression of Ephs and ephrins in vivo 
can restrict cell intermingling in the zebrafish hindbrain (Xu et al., 1999) and the mouse limb bud 
(Compagni et al., 2003; Davy et al., 2004). Expression of an Eph receptor in animal cap cells 
from one zebrafish embryo and an ephrin in animal cap cells from another restricts intermingling 
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of cells from the two animal caps (Mellitzer et al., 1999), and mixing a population of cells 
expressing an Eph with a population of cells expressing an ephrin results in segregation of the 
two populations in culture (Poliakov et al., 2008). Many of these processes have been attributed 
to bidirectional signaling across the boundary between populations of cells that reciprocally 
express Eph receptors and ephrins. 
In Efnb1+/- mice, ephrin-B1 mosaicism leads to segregation of ephrin-B1 expressing and 
non-expressing cells in neural plate neuroepithelial cells (O’Neill et al., 2016) (see Chapter 3), 
neural crest cells, and neural crest-derived craniofacial mesenchyme (see Chapter 4). Ectopic 
boundaries between ephrin-B1 expression and non-expression domains generated by cell 
segregation correlate with craniofacial dysmorphology, providing an explanation for how 
mosaicism could have phenotypic consequences in CFNS (see Chapter 4). We hypothesize 
that defects in Eph/ephrin-mediated boundary formation underlie CFNS, but the mechanisms by 
which ephrin-B1-mediated cell segregation forms ectopic boundaries remain incompletely 
understood. In addition, a wide variety of mutations in ephrin-B1, including intronic mutations, 
have been discovered in different families (Twigg et al., 2004; Twigg et al., 2006); although 
these mutations are assumed to result in loss of protein function, not all mutations have been 
individually characterized. It is therefore possible that some CFNS-causing mutations could be 
hyper- or hypomorphic alleles that result in changes to ephrin-B1 expression, localization, or 
binding to the EphB receptor. This raises the question of whether differences in ephrin-B1 
expression level, as opposed to presence and absence, may also result in cell segregation and 
phenotypic consequences. Ephrin-B1 expression levels have not been directly analyzed in 
human CFNS patients, but several individuals mosaic for genetic duplications of EFNB1 with 
severe craniofacial phenotypes have been identified (Babbs et al., 2011; Baker et al., 2010; 
Evers et al., 2014), suggesting that mosaicism for differences in expression level of ephrin-B1 
may cause craniofacial dysmorphology. 
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In addition to interacting with the canonical ligand-binding domain of the Eph receptor in 
an adjacent cell (signaling in trans), ephrins expressed in cis (in the same cell) with Eph 
receptors can repress their signaling, a process termed “cis inhibition.” Cis-expression of ephrin-
As with EphA receptors allows fine control of EphA receptor activation in migrating axons, and 
the resulting precise signaling response accurately defines the correct axon termination zone 
(Carvalho et al., 2006; Hornberger et al., 1999). Changing the cis-expression of ephrin-As 
disrupts the magnitude of the EphA signaling response and leads to changes in growth cone 
collapse (Carvalho et al., 2006; Hornberger et al., 1999), demonstrating that cis inhibition has 
functional significance in essential cellular processes. For example, expression of ephrin-A5 in 
cis with EphA3 in the growth cone of a retinal axon reduces the collapse response of the axon 
to exogenous ephrin-A5-Fc applied in trans (Carvalho et al., 2006). In cell culture models, 
coexpression of ephrin-A5 with EphA3 reduces EphA3 tyrosine phosphorylation, which is used 
as a measure of receptor activation (Carvalho et al., 2006). EphA receptors have been 
proposed to interact with ephrin-As in cis using their membrane-proximal fibronectin type III 
domain, a distinct domain from the ligand-binding domain used for trans interactions (Carvalho 
et al., 2006), but cis interactions have also been reported to require the canonical ligand-binding 
domain (Yin et al., 2004). In addition to the topographic mapping of retinal axons to the tectum, 
cis inhibition regulates other forms of axon guidance, such as that of spinal motor axons to the 
limb (Gatto et al., 2014; Kao and Kania, 2011; Kao et al., 2012). Binding of ephrins to Ephs in 
cis has also been demonstrated at the synapse (Antion et al., 2010) and in cancer cell lines 
(Falivelli et al., 2013), suggesting that cis inhibition could be an important general feature of 
Eph/ephrin signaling.  
Although cis inhibition of EphA receptors by ephrin-As has been demonstrated in several 
contexts, it is not known whether ephrin-Bs participate in cis inhibition of EphB receptors. 
Furthermore, this alternative Eph/ephrin signaling mode has not been tested in the context of 
developmental boundary formation; it has been generally accepted that complementary 
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expression of Eph receptors and ephrins in adjacent compartments restricts signaling to the 
boundary between them (Gale et al., 1996; Kania and Klein, 2016; Kullander and Klein, 2002). 
However, EphB receptors and their ephrin-B counterparts are coexpressed during normal 
development of the germ layers, which require Eph/ephrin-mediated boundary formation 
(Rohani et al., 2011; Rohani et al., 2014). EphBs and ephrin-Bs are also coexpressed during the 
development of several tissues in which we see aberrant ephrin-B1-mediated cell segregation in 
the mouse model for CFNS, such as the neural plate neuroepithelium (O’Neill et al., 2016) (see 
Chapter 3) and the palatal shelves (Bush and Soriano, 2010) (see Chapter 4). These data 
suggest that cis-expression of ephrin-Bs may regulate EphB receptor expression and signaling 
to affect normal morphogenesis as well as ectopic boundary formation in congenital disease.  
Here, we examine the consequences of cis-expression of ephrin-B1 and its receptors 
EphB2 and EphB3 on signaling outcomes and Eph/ephrin-mediated boundary formation in 
cellular and mouse model systems. Though we do not find evidence of cis inhibition by 
mechanisms similar to those employed by ephrin-A/EphA signaling, we instead find that 
coexpression of ephrin-B1 and EphB2 modulates signaling by a desensitization mechanism in 
which ephrin-B1 regulates expression levels of EphB receptors, leading to changes in the ability 
of these cells to segregate. Mosaic loss of ephrin-B1 in CFNS may therefore contribute to CFNS 
pathogenesis through loss of cis-regulation in ephrin-B1 negative tissue compartments, leading 
to increased EphB signaling sensitivity specifically in ephrin-B1 non-expressing cells.  
 
Results 
Individual mutations to the G-H loop of ephrin-B1 result in reduced EphB receptor binding but 
still permit activation of signaling 
 To investigate whether ephrin-B1 interacts with EphB receptors in cis, we reasoned that 
it would first be necessary to abrogate binding of ephrin-B1 to EphB receptors in trans. This 
allowed us to separate our consideration of potential cis interactions from trans interactions. In 
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studies of ephrin-A/EphA cis inhibition, single mutations to the ephrin-A5 G-H loop, the protein 
domain responsible for receptor-ephrin binding, were reported to abolish trans interactions while 
still permitting functional cis interactions to occur (Carvalho et al., 2006). We therefore 
generated three different ephrin-B1 expression vectors with single mutations to the G-H loop of 
ephrin-B1, each of which was predicted to disrupt ephrin-B1/EphB binding (Figure 18A). By 
making these mutations, we acknowledged that potential cis interactions requiring a functional 
receptor binding domain would not be under consideration. One of the mutations (c.G373A, 
p.E125K) was paralogous to the “trans-dead” mutation in ephrin-A5 (p.E129K) (Carvalho et al., 
2006) and has been found in a CFNS patient (Apostolopoulou et al., 2012); the other two were 
CFNS patient mutations predicted to cause null loss of function of ephrin-B1 (c.A344C, 
p.Q115P; and c.C355A, p.P119T) (Twigg et al., 2004). To determine whether these single 
mutants had lost the ability to bind to the EphB receptor in trans, we first expressed each single 
G-H loop mutant in HEK293 cells, which do not express significant levels of endogenous ephrin-
B1, EphB2, or EphB3, using the vector backbone pcDNA3.1 and transient transfection. Each 
single G-H loop mutant, as well as wild-type ephrin-B1, can be successfully transiently 
expressed in 293 cells (Figure 18B). To test the ability of these mutants to bind to the EphB2 
receptor, we added unclustered EphB2-Fc, an Fc molecule attached to a soluble EphB2 
receptor ectodomain that will bind wild-type ephrin-B1 at the cell surface, to the culture media of 
each population of ephrin-B1-transfected 293 cells. Pulldown of EphB2-Fc using protein A/G 
resin revealed that compared to ephrin-B1wt, all three single G-H loop mutants (ephrin-B1Q115P, 
ephrin-B1P119T, and ephrin-B1E125K) have dramatically reduced ability to bind to EphB2 in trans 
(Figure 18B, green box). To test the function of these mutants, therefore, we expressed ephrin-
B1wt and each single G-H loop mutant individually in 293 cells, then mixed each ephrin-B1-
expressing cell population with 293 cells stably expressing EphB2 (“EphB2 cells”). EphB2 cells 
do not segregate appreciably from 293 cells alone (Figure 19A) but do segregate from 293 cells 
transiently expressing wild-type ephrin-B1 (Figure 19B). Surprisingly, EphB2 cells also 
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segregated significantly from 293 cells transiently expressing each ephrin-B1 single G-H loop 
mutant (Figure 19C-E). This indicates that although single mutations to the G-H loop reduce 
their binding to EphB2 in trans, they do not ablate the trans function of these G-H loop mutant 
ephrin-B1 proteins.  
 
Combinatorial mutations to the G-H loop of ephrin-B1 abrogate EphB receptor binding and 
activation of signaling 
 It is possible that even in the absence of high levels of receptor ligation, overexpression 
of ephrin-B1 G-H loop mutants can still activate EphB signaling in trans or that low endogenous 
levels of another ephrin-B protein in HEK293 cells may hetero-oligomerize with ephrin-B1 G-H 
loop mutants to form functional complexes (Janes et al., 2011). To distinguish potential cis 
interactions from trans interactions, therefore, it was essential to completely abolish ephrin-B1 
binding to EphB receptors in trans. We therefore generated an ephrin-B1 protein with three 
mutations in the G-H loop (ephrin-B1Q115P/P119T/E125K, or ephrin-B13xTD). When expressed in 293 
cells, ephrin-B13xTD, like its single mutant counterparts, demonstrated dramatically reduced 
binding to EphB2-Fc (Figure 18B, blue box). 293 cells transiently expressing ephrinB13xTD did 
not segregate from EphB2 cells (Figure 19F). Instead, they intermingled with EphB2 cells, 
behaving similarly to negative control 293 cells (compare to Figure 19A). The triple G-H loop 
mutant of ephrin-B1 has therefore lost the ability to bind to EphB2 in trans and activate signaling 
that results in cell segregation and can be used to determine whether cis interactions occur 
between ephrin-B1 and EphB receptors.  
 
Coexpression of ephrin-B1 and EphB2 desensitizes cells to signals from ephrin-B1, a property 
which requires the G-H loop 
 Ephrin-A5 G-H loop mutants retain the ability to bind to EphA3 when coexpressed, and 
their coexpression results in functional differences in growth cone collapse (Carvalho et al., 
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2006); we therefore sought to determine whether ephrin-B1 G-H loop mutants have similar 
properties with respect to EphB2. 293 cells stably expressing EphB2 and transiently 
coexpressing ephrin-B1wt show a high amount of interaction between EphB2 and ephrin-B1 by 
immunoprecipitation of EphB2 and immunoblotting for ephrin-B1 (Figure 20A). This can be 
attributed to trans interactions in addition to any cis effects that may be occurring. Coexpression 
of EphB2 and single G-H loop mutants ephrin-B1Q115P, ephrin-B1P119T, or ephrin-B1E125K, 
however, did not result in a similar level of interaction between EphB2 and any of these ephrin-
B1 proteins (Figure 20A). Although it appeared that a small amount of interaction occurred 
(Figure 20A, green box and green bars), we cannot rule out the contribution of residual trans 
interactions, as these single mutants remain able to interact with EphB2 in a manner sufficient 
to induce cell segregation (Figure 19C-E).  
To determine whether cis expression has a functional effect, therefore, we mixed 293 
cells stably expressing wild-type ephrin-B1 (“ephrin-B1 cells”) with EphB2 cells transiently 
coexpressing either pcDNA3.1, wild-type ephrin-B1, or mutant ephrin-B1. Ephrin-B1 cells were 
mixed with 293 cells alone as a control, which results in cell intermingling (Figure 20B) and 
EphB2 cells segregated dramatically from ephrin-B1 cells (Figure 20C), as did empty vector-
transfected “EphB2 + pcDNA3.1” cells (Figure 20D), consistent with what has been 
demonstrated previously (Poliakov et al., 2008). However, EphB2 cells coexpressing wild-type 
ephrin-B1 or mutants that retain the ability to signal in trans (ephrin-B1Q115P, ephrin-B1P119T, or 
ephrin-B1E125K) were “desensitized” or “blinded” from receiving ephrin-B1 signals in trans from 
the ephrin-B1 cells, resulting in reduced segregation (Figure 20E-H; quantified in Figure 20J). 
This desensitization requires functional signaling via the G-H loop, as coexpression of ephrin-
B13xTD with EphB2 does not reduce the segregation of these cells from ephrin-B1 cells (Figure 
20I). This indicates that ephrin-B1 does not participate in cis inhibition of EphB receptors in the 
same way that ephrin-A5 inhibits EphA3 signaling, as G-H loop mutants do not bind significantly 
to EphB2 when coexpressed. However, coexpression of ephrin-B1 does affect EphB2 signaling 
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response through a desensitization mechanism. This process requires some level of function of 
the G-H loop of ephrin-B1 and may therefore occur either through cis interactions between 
ephrin-B1 and EphB2 within an individual cell, or rather through active signaling in trans 
throughout a population of cells.  
 
Desensitization of EphB2-expressing cells mediated by coexpression of ephrin-B1 occurs 
through modulation of EphB receptor levels 
 Since desensitization of EphB2-expressing cells by ephrin-B1 coexpression requires the 
G-H loop of ephrin-B1, we reasoned that it may take place by active signaling in trans 
throughout the population of cells via endocytosis and degradation of EphB2, a known 
mechanism for termination of Eph/ephrin signaling (Marston et al., 2003; Zimmer et al., 2003). 
Reduced surface expression of the receptor would “blind” these cells to receipt of a further 
signal from ephrin-B1 in trans during a cell mixing experiment. To test this possibility, we 
transfected EphB2 cells with wild-type, single G-H loop mutant, or triple G-H loop mutant ephrin-
B1 and examined EphB2 expression levels by western blot at 48 hours after transfection, the 
time at which mixing experiments were conducted. Coexpression of EphB2 with ephrin-B1wt 
resulted in dramatically decreased EphB2 expression (Figure 21A), as did coexpression of 
EphB2 with ephrin-B1 single G-H loop mutants retaining the ability to signal in trans (ephrin-
B1Q115P, ephrin-B1P119T, or ephrin-B1E125K) (Figure 21A, green box and green bars). This 
indicates that the desensitization we observed likely takes place through reduction in EphB2 
protein levels. This effect requires the G-H loop of ephrin-B1, as coexpression of EphB2 and 
ephrin-B13xTD did not result in decreased EphB2 protein levels (Figure 21A, blue box and blue 
bar). Decreased EphB2 protein level was specific to coexpression of ephrin-B1, as EphB2 
protein was not reduced upon coexpression of another transmembrane protein, CDO (Figure 
21B). Decreases in EphB2 occurred at the protein level, not the transcript level, as Ephb2 
transcript levels were unchanged in EphB2/ephrin-B1 coexpressing cells (Figure 21C). It is 
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therefore likely that the desensitization of EphB2/ephrin-B1 coexpressing cells occurs through 
active signaling that results in internalization and degradation of the EphB2 receptor, preventing 
these cells from responding to further stimulation by ephrin-B1 presented in trans.  
 
Ephrin-B1 regulates EphB receptor expression in vivo 
 293 cells serve as a useful model for Eph/ephrin signaling studies (Jorgensen et al., 
2009; O’Neill et al., 2016; Poliakov et al., 2008), but we wondered whether the desensitization 
effect of ephrin-B1/EphB coexpression was relevant in vivo during embryonic development of 
the craniofacial primordia. We reasoned that mosaic loss of this effect could contribute to 
pathogenic cell segregation in Efnb1+/- mouse embryos, a model for CFNS, if regulation of 
EphB2 and EphB3 receptor levels were disrupted specifically in ephrin-B1 non-expressing cells 
in the head. We therefore investigated EphB2 and EphB3 expression level in embryo heads 
prior to palate fusion by western blotting of whole head lysates of E13.5 embryos mosaic for 
ephrin-B1 loss (Efnb1+/- embryos) or ephrin-B1 null (Efnb1-/Y embryos) (Figure 21D). Indeed, 
complete loss of ephrin-B1 (Figure 21E) resulted in significant increases in EphB2 (Figure 21F) 
and EphB3 (Figure 21G) levels in ephrin-B1 null heads. This effect was not detected in Efnb1+/- 
head lysates by western blot, but it has been shown by immunofluorescence analysis that in 
Efnb1+/- palatal shelves, patches of ephrin-B1 non-expressing cells have increased expression 
of EphB2 and EphB3 (Bush and Soriano, 2010). These observations indicate that loss of ephrin-
B1 results in increased EphB2 and EphB3 accumulation within a population of cells in vivo. In 
hemizygous Efnb1-/Y embryos, increased expression of EphB2 and EphB3 could result in 
widespread increased signaling mediated by other ephrins expressed in the same tissue, but 
this may be a mild effect if few or no other ephrins that signal through EphB2 and EphB3 are 
expressed in this region. Additionally, it seems unlikely that other binding partners of EphB2 and 
EphB3 are present in this region, as their signaling in trans should also result in receptor 
internalization and downregulation. In Efnb1+/- embryos, however, increased EphB2 and EphB3 
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expression only in ephrin-B1 negative cells in a mosaic population could contribute to the 
increased signaling and actin accumulation seen in those cells (O’Neill et al., 2016), 
exacerbating the Eph/ephrin signaling differences already caused by mosaic loss of ephrin-B1.  
 
Designing an Efnb1 misexpression mouse to test the in vivo relevance of differences in ephrin-
B1 expression within a mosaic cell population 
 Based on the observations that several CFNS patient mutations in the G-H loop of 
ephrin-B1 allow retention of some signaling potential, and that EphB receptor levels are 
maintained at lower levels by broad ephrin-B1 expression, we wondered whether broad ectopic 
expression of ephrin-B1 would blunt mosaicism-driven segregation. To test this hypothesis in 
vivo, we designed two mouse lines in which misexpression of either ephrin-B1wt or “trans-dead” 
ephrin-B13xTD is achieved by expression of Cre recombinase. We designed two constructs for 
gene targeting to the ubiquitously expressed ROSA26 locus (Soriano, 1999) in mouse 
embryonic stem cells (mESCs). In the absence of Cre, ephrin-B1 should not be misexpressed 
due to a termination codon flanked by two loxP sites; in the presence of Cre, the termination 
codon will be spliced out, and ephrin-B1wt or ephrin-B13xTD will be expressed under the control of 
the endogenous ROSA26 promoter (Figure 22A). To identify cells in which ephrin-B1 is 
misexpressed, the constructs also contain an mClover2 coding sequence in tandem with the 
Efnb1 coding sequence, with an intervening P2A cleavage sequence.  
When a pcDNA3.1-Efnb1-P2A-mClover2 vector was transiently expressed in HEK293 
cells, bicistronic expression of ephrin-B1 and mClover2 was achieved. P2A cleavage produced 
ephrin-B1 protein at the expected size by western blot, with only a very small amount of 
uncleaved product remaining (Figure 22B, black arrow). mClover2 was also strongly expressed 
and could be detected by fluorescence imaging (Figure 22C). Electroporation of the full 
linearized construct into 129S4 mESCs (Agouti coat color) for targeting to the ROSA26 locus 
and selection using G418, followed by PCR across the 5’ homology arm, revealed an overall 
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targeting efficiency of 9/135 clones (6.7%) for Efnb1wt and 16/105 clones (15.2%) for Efnb13xTD 
(Figure 22D). A second round of targeting resulted in efficiencies of 12/155 clones (7.7%; 
combined efficiency 7.2%) for Efnb1wt and 7/80 clones (8.8%; combined efficiency 12.4%) for 
Efnb13xTD. Quantitative PCR for Neo expression in each targeted clone confirmed that 
homologous recombination resulted in insertion of only one copy of the expression cassette per 
targeted mESC line, with the exception of Efnb13xTD-220, which was therefore not selected for 
injection (Figure S6A). To determine whether recombination occurs as expected when Cre is 
expressed in these mESCs, we transiently transfected targeted Efnb1wt and Efnb13xTD mESC 
lines with a PGK-Cre-bpA expression vector, lysed transfected cells, and extracted DNA to 
perform PCR analysis for the recombined allele. In both lines, we detected the recombined 
allele by PCR only when Cre was present (Figure 22E). Based on this information, we selected 
three mESC lines from each construct for injection into C57BL6/J mouse blastocysts (black coat 
color).  
 Initial injection of mESC clones Efnb1wt-66, Efnb1wt-118, and Efnb1wt-164 from the first 
round of targeting produced either no live pups (Efnb1wt-66, Efnb1wt-164) or no chimeric pups 
(Efnb1wt-118). Injection of mESCs Efnb13xTD-236 and Efnb13xTD-240 from the first round of 
targeting resulted in the production of only one high-percentage chimera (~60%) from mESC 
line Efnb13xTD-240. When mated to C57BL6/J female mice, offspring of the Efnb13xTD-240 
chimera were 31.8% Agouti coat color (Figure S6B), of which 52.9% carried the targeted allele 
(Figure S6C). These mice are currently being backcrossed to the C57BL/6J background. 
Preliminary observations of a breeding scheme between b-Actin-CreTg/o and ROSA26-
Efnb13xTD/+ mice indicate that ubiquitous misexpression of Efnb13xTD in b-Actin-CreTg/o; ROSA26-
Efnb13xTD/+ pups is compatible with life and that these pups do not have any overt craniofacial 
phenotypes. After 10 generations of backcrossing to C57BL/6J, ROSA26-Efnb13xTD/+ mice will 
be crossed to Efnb1lox mice to produce ROSA26-Efnb13xTD/+; Efnb1lox/+ female mice, which will 
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be further crossed to a b-Actin-CreTg/o male mouse to test the efficacy of ubiquitous 
misexpression of ephrin-B13xTD and mClover2 in vivo in b-Actin-CreTg/o; Efnb1D/Y; ROSA26-
Efnb13xTD/+ embryos at E13.5, without the confounding presence of endogenous ephrin-B1 
expression.  
 To obtain ROSA26-Efnb1wt mice, a second set of injections is ongoing for clones 
Efnb1wt-181, Efnb1wt-329, and Efnb1wt-332 from the second round of mESC targeting. High-
percentage chimeras have been obtained from mESC clone Efnb1wt-181; if they produce pups 
carrying the targeted allele, ROSA26Efnb1-wt/+; Efnb1lox/+ female mice will be crossed to a b-Actin-
CreTg/o male stud to determine whether ephrin-B1wt and mClover2 are successfully ubiquitously 
expressed in vivo in b-Actin-CreTg/o; Efnb1D/Y; ROSA26Efnb1-wt/+ embryos at E13.5. If both mouse 
lines perform as expected, we will proceed with further experiments. Because EphB receptor 
accumulation is reduced by expression of ephrin-B1, and both EphB2 and EphB3 forward 
signaling are required for ephrin-B1-mediated cell segregation (O’Neill et al., 2016), we will first 
determine whether ubiquitous expression of ephrin-B1wt reduces segregation in Efnb1+/- 
embryos, using ubiquitous expression of ephrin-B13xTD as a control. We will cross b-Actin-CreTg/o 
studs with Efnb1lox/lox; ROSA26Efnb1-wt/+ and Efnb1lox/lox; ROSA26Efnb1-3xTD/+ females to generate b-
Actin-CreTg/o; Efnb1D/+; ROSA26Efnb1-wt/+ experimental and b-Actin-CreTg/o; Efnb1D/+; ROSA26Efnb1-
3xTD/+ control embryos. We will analyze these embryos for segregation in craniofacial structures 
such as the palatal shelves and frontonasal prominence at E13.5 and quantify segregation to 
determine whether EphB signaling resulting in cell segregation has been blunted by 
misexpression of ephrin-B1 that can actively signal to reduce surface expression of the 
receptors.  
In addition, these mice can also be used to determine whether mosaicism for differing 
levels of ephrin-B1 expression results in segregation and craniofacial phenotypes. ROSA26Efnb1-
wt/+ and ROSA26Efnb1-3xTD/+ female mice will be crossed to tamoxifen-inducible ROSA26CreERT2 
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mice, with tamoxifen injections titrated to produce mosaic recombination in Efnb1+/+; 
ROSA26Efnb1-wt/CreERT2 and Efnb1+/+; ROSA26Efnb1-3xTD/CreERT2 embryos. Efnb1+/+; ROSA26Efnb1-
wt/CreERT2 embryos treated with tamoxifen will be mosaic for differing levels of wild-type ephrin-B1 
expression, while Efnb1+/+; ROSA26Efnb1-3xTD/CreERT2 embryos treated with tamoxifen will have 
mosaic misexpression of “trans-dead” ephrin-B1 and will serve as a control. These embryos will 
be analyzed for mClover2 expression at E13.5 by immunofluorescence analysis of frontal 
sections to determine whether or not segregation occurs between cell populations with differing 
ephrin-B1 expression levels. Embryos will also be examined at E14.5 for changes to craniofacial 
structures by histological analysis of frontal sections, and if pups are born, they will be analyzed 
by skeletal preparation at postnatal day 0 (P0) to determine whether mosaic misexpression of 
wild-type ephrin-B1 results in craniofacial and skeletal phenotypes. These results will shed light 
on the importance of ephrin-B1 expression level for regulating EphB receptor levels and 
signaling in vivo and improve our understanding of how mutations in ephrin-B1 contribute to cell 
segregation and craniofacial dysmorphology in CFNS by determining whether differences in 
expression level of ephrin-B1 can produce these phenotypes. Finally, these mice will serve as 
an important tool for in vivo signaling studies involving manipulation of ephrin-B1 and its 
receptor signaling partners.  
 
Discussion 
 Although a simple bidirectional signaling model for Eph/ephrin signaling, with forward 
and reverse signaling occurring only at tissue boundaries, may be sufficient to describe some 
contexts in which Eph/ephrin signaling mediates boundary formation and maintenance during 
development, it is becoming increasingly evident that complementary expression of Ephs and 
ephrins is not the only situation in which this signaling pathway operates. Multiple Eph receptors 
and their specific ephrin signaling partners are coexpressed in many tissues in which their 
signaling is essential for normal boundary formation, including the germ layers during 
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gastrulation (Rohani et al., 2011; Rohani et al., 2014), the neural plate (O’Neill et al., 2016), the 
developing secondary palate (Bush and Soriano, 2010), and the axons of many pathfinding 
neurons, including spinal motor axons (Kao and Kania, 2011) and retinal axons (Hornberger et 
al., 1999). In addition to signaling at forming boundaries, therefore, intra-tissue Eph/ephrin 
signaling may be important to developmental processes in these structures. Signaling 
directionality is affected by more complex Eph/ephrin expression patterns, and it is now known 
that unidirectional signaling (O’Neill et al., 2016) and antiparallel signaling (Rohani et al., 2014) 
can contribute to boundary formation and tissue separation. (For a discussion of the evidence 
for reverse signaling mechanisms in vivo, please refer to Chapter 2.) Combinatorial expression 
of Eph receptors and ephrins, with some functional redundancy and some signaling specificity, 
can also contribute to increased Eph/ephrin signaling at a boundary relative to the baseline level 
of signaling within each tissue.  
These developments have expanded our understanding of the possible modes of 
Eph/ephrin expression that aid in boundary formation and maintenance, but the purpose of 
intra-tissue Eph/ephrin signaling made possible by these more complex expression patterns 
remains essentially unexplored. It has been proposed that a baseline level of Eph/ephrin 
signaling within a tissue must be comparatively low to prevent dissolution of the tissue by active 
repulsion, and that this baseline signaling within a tissue may even directly oppose its 
dissolution by maintaining adhesion between cells of the same tissue, whereas higher levels of 
signaling at the boundary mediate segregation and boundary maintenance (Rohani et al., 2014). 
However, there is not yet any direct evidence for the regulation of adhesion by intra-tissue 
Eph/ephrin signaling. Instead, we hypothesize that broad Eph/ephrin signaling within a tissue 
acts to decrease adhesion enough to allow for essential cell movements within the tissue and 
does not result in repulsive migration that dissolves the tissue. It is also possible that intra-tissue 
Eph/ephrin signaling plays an as yet undiscovered role. Although EphAs and ephrin-As have 
been shown to interact physically when expressed in the same cell, and this interaction has 
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functional effects on axon guidance, coexpression of EphBs and ephrin-Bs had not been 
characterized at the protein level, and it was unknown how these molecules interact when 
coexpressed to change boundary formation and maintenance. To determine the function of 
Eph/ephrin coexpression in normal and aberrant boundary formation, we turned to cell culture 
and mouse models of CFNS, a disease which we hypothesize is caused by the formation of 
ectopic ephrin-B1 boundaries.  
 Although it has been long assumed that CFNS is caused by heterozygous loss of 
function of ephrin-B1 (Twigg et al., 2004), CFNS patient mutations are found abundantly 
throughout the coding sequence as well as the introns of EFNB1, making comprehensive 
analysis of each mutation difficult. Two missense mutations in ephrin-B1 have been shown to 
decrease its tyrosine phosphorylation after stimulation with preclustered EphB2-Fc (Makarov et 
al., 2010), but the effects of ephrin-B1 mutations on EphB2 signaling have not been examined in 
depth, and we have shown that ephrin-B1 reverse signaling is not required for most CFNS 
phenotypes (Bush and Soriano, 2009) or for cell segregation in the mouse (O’Neill et al., 2016). 
Relatively little is known about how individual ephrin-B1 mutations affect protein expression, 
localization, and function in forward signaling. In investigating possible cis interactions between 
ephrin-B1 and its receptors important for craniofacial development, EphB2 and EphB3, we 
discovered that three single missense mutations to the G-H loop, or receptor-binding domain, of 
ephrin-B1, each of which is found in CFNS patients, do not abolish all binding of ephrin-B1 to 
EphB2. Instead, we found that each single G-H loop mutant had reduced binding to EphB2 but 
maintained the ability to induce receptor signaling to drive cell segregation in an HEK293 cell 
model. This indicates that missense mutations may reduce Eph/ephrin binding rather than 
preventing it altogether; however, we cannot rule out the possibility that the levels of ephrin-B1 
overexpression achieved by transfection allow these single mutants to produce a functional 
segregation effect that would not be seen at endogenous expression levels. As each of the 
single mutations we generated in ephrin-B1 occurs in CFNS patients, our data also raise the 
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possibility that differences in ephrin-B1 expression level or function between cell populations 
may be sufficient to drive segregation resulting in craniofacial phenotypes; this hypothesis will 
require further investigation that will be facilitated by our Efnb1 misexpression mouse.  
Reduction in the physical interaction of ephrin-B1 single G-H loop mutants with Eph-Fc 
fusion proteins does not prevent functional trans signaling, suggesting that even a small amount 
of residual trans binding due to incomplete disruption of receptor-ligand interactions can allow 
signaling between adjacent cells. On a practical experimental note, this finding indicates that 
reduced ephrin-Eph binding by Eph ectodomain-Fc fusion protein pulldown is not a good 
measure of complete disruption of signaling function. Rather, functional tests with a measurable 
outcome parameter for signaling (such as tyrosine phosphorylation, cell segregation, or growth 
cone collapse) are necessary to determine whether ephrin-to-Eph signaling has truly been 
ablated. Notably, the decreased ability of ephrin-A single G-H loop mutants to bind to EphA7-Fc 
was the only criterion used to determine whether or not trans interactions were abolished 
(Carvalho et al., 2006), and thus the reported ephrin-A mutants may also retain some functional 
trans signaling potential. With this knowledge, we can draw several possible conclusions about 
existing cis interaction studies, both ours and others’. (1) It is possible that the reported cis 
interactions between single G-H loop mutants of ephrin-A5 and EphA3 are not cis interactions at 
all, but rather residual trans interactions that are not strongly detected by EphA7-Fc 
immunofluorescence experiments when testing the binding ability of the single mutants, but are 
detected by western blot in coexpression experiments in 293 cells (Carvalho et al., 2006). A 
time course of EphA activation by tyrosine phosphorylation after coexpression, as well as a 
functional growth cone collapse assay to test the responsiveness of EphA3 to signaling from 
ephrin-A5E129K, would aid in ruling out this possibility; although coexpression of ephrin-A5 and 
EphA3 results in decreased EphA3 tyrosine phosphorylation (Carvalho et al., 2006), this could 
also be caused by internalization and degradation of EphA3, depending on the timing of the 
assay. (2) Regardless of whether it is a cis or trans interaction, single mutant ephrin-A5E129K 
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binds much more strongly to EphA3 (Carvalho et al., 2006) than single ephrin-B1 mutants bind 
to EphB2 (Figure 18A), suggesting that the ephrin-B subfamily does behave differently from the 
ephrin-As. Therefore, it is possible that ephrin-Bs do not participate in the same cis inhibitory 
mechanisms used by ephrin-As. This difference between subfamilies may spring from 
differences in expression context – perhaps coexpression in axons permits cis interactions, 
while coexpression in palate mesenchyme does not. It may also result from differences in 
protein structure and steric constraints, as ephrin-As are membrane-linked while ephrin-Bs are 
transmembrane proteins. It is also possible that the subcellular localization of ephrin-As is 
conducive to interaction with EphAs within the same cell; localization of ephrin-As within 
membrane microdomains has been shown to contribute to axon guidance by allowing 
discrimination of cis and trans interactions (Marquardt et al., 2005). Ephrin-B may be trafficked 
to different regions of the cell surface that are not permissive of cis interactions with EphB 
receptors. These possibilities and others merit further consideration in future work.  
 The study of cis interactions between Ephs and ephrins is confounded by the presence 
of trans interactions, a challenge that is difficult to address experimentally. It is important to 
consider that although cis interactions between EphA receptors and ephrin-As have been 
reported to require either the EphA3 membrane-proximal fibronectin type III domain (Carvalho 
et al., 2006) or the Eph receptor canonical ligand-binding domain (Yin et al., 2004), the residues 
of the ephrin important for these interactions have not yet been discovered. It is therefore 
possible that as yet unidentifiied ephrin-Eph cis interactions occur that require the G-H loop of 
the ephrin, a possibility that is not addressed by these studies. By creating three simultaneous 
mutations to the G-H loop of ephrin-B1 to ablate trans interactions in the ephrin-B13xTD mutant, 
we may have changed the architecture of the protein in a way that prevents cis interactions as 
well as trans interactions; we cannot rule out this possibility, but we would argue that it was 
necessary to remove all trans interactions resulting in a functional effect of signaling in order to 
convincingly study cis binding. In the triple mutant protein ephrin-B13xTD, trans signaling is fully 
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disrupted, with no binding by EphB2-Fc pulldown and no ability to induce cell segregation. This 
triple mutant ephrin-B1 protein has no effect on EphB2 signaling response when coexpressed, 
which leads us to the conclusion that coexpression effects of ephrin-B1 require the G-H loop. 
Whether these effects are mediated by trans signaling within the population or an as yet 
unknown cis interaction involving the G-H loop will require further study.  
 If ephrin-Bs do not bind to EphBs in cis to reduce their activation and tyrosine 
phosphorylation when presented with signals from ephrin-Bs in trans, what then is the effect of 
ephrin-B/EphB coexpression in tissue organization? We show that coexpression of wild-type or 
trans-competent single mutant ephrin-B1 results in active signaling within a tissue, leading to 
reduced EphB2 protein expression at the cell surface. This may occur by endocytosis and 
degradation of the EphB receptor, a known termination mechanism for Eph/ephrin signaling that 
allows cell detachment after the interaction necessary for producing the downstream signal 
(Marston et al., 2003; Zimmer et al., 2003). Whatever the mechanism, the functional impact of 
reduced EphB2 expression is striking: EphB2/ephrin-B1 coexpressing cells exhibit a significantly 
reduced ability to segregate from 293 cells stably expressing ephrin-B1. EphB/ephrin-B 
coexpression may therefore serve not as a physical or steric constraint on EphB reception of 
ephrin-B1 signals in trans, but rather as a desensitization mechanism that “blinds” the 
coexpressing cells to these signals through active signaling within a population. This 
desensitization mechanism may contribute to cell segregation by enhancing a differential in 
EphB signaling sensitivity.  
Many of the contexts in which Eph/ephrin coexpression has been demonstrated have 
used in situ hybridization to look at mRNA expression levels; however, early studies of 
reciprocal or complementary expression of Ephs and ephrins used Eph and ephrin ectodomains 
fused to LacZ to determine expression patterns of these molecules (Gale et al., 1996), which 
would show surface protein localization as opposed to transcript expression. In our in vivo 
studies of embryo heads, loss of ephrin-B1 results in upregulation of EphB2 and EphB3 protein 
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expression. In addition, previously published data indicates that in ephrin-B1 mosaic secondary 
palate mesenchyme, ephrin-B1 non-expression domains have increased EphB2 and EphB3 
expression by immunofluorescence (Bush and Soriano, 2010). These data raise the possibility 
that cis-expression of ephrin-B1 with EphB receptors may play a key role in morphogenesis 
during normal craniofacial development by establishing EphB-high and EphB-low compartments 
based on ephrin-B1 expression patterns. Cis-expression of ephrin-Bs with EphB receptors may 
thereby work alongside transcriptional regulation as an additional mechanism for enforcing 
complementary ligand and receptor activity domains during development.  
 These studies identify a new mechanism of regulation of EphB receptor levels and 
signaling and may also shed light on the signaling mechanisms of pathogenic cell segregation in 
CFNS. Although ephrin-B1 does not participate in cis inhibition as described for ephrin-As, 
these studies demonstrate that ephrin-B1 coexpression affects how EphB2-expressing cells 
respond to signals from adjacent cells by regulating surface accumulation of the receptor. In an 
in vivo wild-type situation, therefore, a baseline level of signaling between ephrin-B1/EphB-
coexpressing cells may keep EphB receptor levels low through constant turnover. In an ephrin-
B1 mosaic situation, however, wild-type cells with low EphB expression through this baseline 
signaling mechanism encounter ephrin-B1 non-expressing cells with increased EphB 
expression, resulting in an increased signaling response in these cells. This unidirectional 
signaling differential could provide an explanation for the increased actomyosin seen in these 
cells, which underlies cell segregation in the mouse model for CFNS (O’Neill et al., 2016). The 
downstream signaling partners of EphB receptors mediating changes to actomyosin 
contractility, as well as the mechanisms by which changes to actomyosin contractility result in 
cell segregation, are the subject of important future studies. 
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Materials and Methods 
Mouse lines and maintenance. All animal experiments were performed in accordance with the 
protocols of the University of California, San Francisco Institutional Animal Care and Use 
Committee. Mice were socially housed under a twelve-hour light-dark cycle with food and water 
ad libitum. All alleles used for the experiments herein have been previously described. All mice 
were backcrossed and maintained on a congenic C57BL/6J genetic background. Efnb1lox, MGI: 
3039289 (Davy et al., 2004); b-actin-Cre, MGI: 2176050 (Lewandoski et al., 1997). 
 
Construct design, cloning, and mESC targeting. Ephrin-B1 single and triple G-H loop mutant 
plasmids were designed using VectorNTI software. An existing pcDNA3.1-efnb1wt construct 
(Davy et al., 2004) was first modified by site-directed mutagenesis to correct a signal peptide 
mutation (c.G52T) using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent) 
according to the instructions provided by the manufacturer. Single G-H loop mutations to ephrin-
B1 were made in the “corrected” plasmid using the same kit. The triple G-H loop mutant ephrin-
B1 plasmid was made using the QuikChange Lightning Multi Site-Directed Mutagenesis Kit 
(Agilent) according to the instructions provided by the manufacturer. Ephrin-B1 wild-type and 
3xTD mouse constructs (pROSA26-LSL-efnb1-p2a-mClover2) were built by first adding a P2A 
cleavage sequence to the end of ephrin-B1 in pcDNA3.1-efnb1 (wt or 3xTD) using a synthetic 
nucleotide sequence and PCR cloning. The mClover2 coding sequence, obtained from the 
UCSF Nikon Imaging Center, was then added to the end of the P2A cleavage sequence using 
PCR cloning and the multi-cloning site of pcDNA3.1, producing a 2 amino acid L-E linker 
between the p2a and mClover2 sequences. The efnb1-p2a-mClover2 sequence was then 
cloned into the pBigT plasmid (Srinivas et al., 2001) (Frank Costantini lab plasmids, Addgene 
#21270), which contains a loxP-NeoR-3xPolyA-STOP-loxP cassette, at the NheI restriction site. 
Finally, the LSL-efnb1-p2a-mClover2 sequence was cloned into pROSA26-PA (Srinivas et al., 
2001) (Frank Costantini lab plasmids, Addgene #21271), a modification of pROSA26-1 
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(Soriano, 1999) containing a PacI-AscI linker. Final constructs (wt and 3xTD) were linearized 
using AfeI and electroporated into AK-7 129S4 mESCs (a gift from Akira Imamoto). 
Electroporated mESCs were plated at clonal density and grown on irradiated Soriano ES cell 
feeder line SNL 76/7 STO feeder cells (a gift from Akira Imamoto) under G418 selection for 10-
14 days, after which individual clones were picked for PCR screening and expansion. Primers 
for PCR screening spanned the 5’ ROSA26 homology arm of the construct (Figure 22A, red 
arrows) (Table 7). Positive clones were expanded and frozen back at low passage. Each 
positive mESC clone was tested for construct copy number using quantitative PCR for Neo 
expression compared to Bambi expression as a control (Figure S6A) (Table 7). mESC clones 
transfected with PGK-Cre-bpA to test for recombination were screened using a forward primer 
in the 5’ ROSA26 homology arm and a reverse primer in the first exon of Efnb1 (Figure 22A, 
blue arrows) (Table 7). C57BL/6J blastocyst injections were performed by the Gladstone mESC 
core (targeting 1) or the UC Davis Mouse Biology Program (targeting 2).   
 
293 cell culture and transfection. HEK293 cells, HEK293 cells stably expressing EphB2 and 
membrane-targeted GFP (“EphB2 cells”), and HEK293 cells stably expressing ephrin-B1-HA 
(“ephrin-B1 cells”) were obtained from A. Poliakov and D. Wilkinson (Medical Research Council 
National Institute for Medical Research, London, England, UK) (Jorgensen et al., 2009; Poliakov 
et al., 2008). Cells were cultured at 37°C with 5% CO2 in DMEM high glucose (Gibco 11965-
018) with 10% fetal bovine serum (Hyclone), 2 mM L-glutamine (Gibco), and 1X penicillin-
streptomycin (UCSF Cell Culture Facility). Cells were transfected using Lipofectamine 2000 
(Thermo Fisher Scientific) according to the instructions provided by the manufacturer.    
 
293 cell segregation experiments and quantification of segregation. 24-well glass-bottom plates 
(MatTek) or 4-chamber glass-bottom dishes (Greiner Bio-One) were coated with 10 µg/mL 
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fibronectin (Sigma Aldrich) in D-PBS, calcium- and magnesium-free (Gibco), for 30 minutes at 
37°C before removing excess PBS and adding 0.5 mL HEK293 cell media to each well. Cells to 
be mixed were lifted using 0.25% trypsin-EDTA (Gibco) and counted using a Countess cell 
counting system (Thermo Fisher Scientific). 100,000 cells per condition were added to each well 
and vigorously mixed to achieve a final concentration of 200,000 cells/well (~100,000 cells/cm2). 
Cell mixtures were imaged at 24 hours after mixing using a Zeiss Cell Observer spinning disc 
confocal microscope and a 10X air Plan-Apochromat objective lens. Zen software was used to 
acquire images, adjust brightness and contrast, and export images as .tif files. Quantification of 
segregation was performed using a nearest-neighbor method (Mochizuki et al., 1998) as 
previously described (O’Neill et al., 2016). 
 
Immunoprecipitation. Cells were lysed in NP-40 lysis buffer (20 mM Tris-HCl, 137 mM NaCl, 
10% glycerol, 1% NP-40, 2 mM EDTA) supplemented with the following protease and 
phosphatase inhibitors: aprotinin, 2 μg/mL; leupeptin, 5 μg/mL; pepstatin, 1 μg/mL; PMSF, 1 
mM; NaF, 10 mM; and NaVO4, 1 mM. Lysates were cleared by centrifugation at 16,000 x g for 
10 minutes at 4°C prior to use, and a 50 μL aliquot of lysate was transferred to a separate tube, 
flash frozen, and stored at -80°C. For EphB2-Fc pulldown, 50 μL Protein A/G UltraLink Resin 
slurry (Thermo Fisher Scientific) was added to the remainder of each lysate and rotated for 4 
hours at 4°C, followed by 3 1-hour washes in NP-40 lysis buffer at 4°C with rotation. Complexes 
were eluted from the resin using 25 μL of 2X Laemmli buffer incubated with the resin for 5 
minutes at 95°C. The resulting supernatant was flash frozen and stored at -80°C for 
immunoblotting. For EphB2 coimmunoprecipitation, 2 μg goat anti-EphB2 antibody (R&D 
systems; see Table 6) was added to the remainder of each lysate and rotated overnight at at 
4°C, followed by the same pulldown protocol.  
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Immunoblotting. Cells or tissues were lysed in NP-40 lysis buffer (20 mM Tris-HCl, 137 mM 
NaCl, 10% glycerol, 1% NP-40, 2 mM EDTA) supplemented with 1 mM dithiothreitol (Sigma) 
and the following protease and phosphatase inhibitors: aprotinin, 2 μg/mL; leupeptin, 5 μg/mL; 
pepstatin, 1 μg/mL; PMSF, 1 mM; NaF, 10 mM; and NaVO4, 1 mM. In the case of embryo head 
lysates, a probe sonicator was used for a 10 second pulse after addition of NP-40 to aid in 
breaking up the tissue. Lysates were cleared by centrifugation at 16,000 x g for 10 minutes at 
4°C prior to use. Protein quantification was performed using the Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific). Immunoblotting was performed according to standard procedures 
using Odyssey® TBS blocking buffer (LI-COR) for blocking and dilution of antibodies (Table 6) 
and TBS with 0.1% Tween-20 for washing. Imaging of immunoblots was performed using an 
Odyssey® Infrared Imaging System (LI-COR), and analysis and quantification was carried out 
using Image Studio™ software (LI-COR). 
 
qRT-PCR. Total RNA was extracted from cells using TRIzol (Thermo Fisher Scientific). RNA 
was reverse transcribed using a SuperScript™ II First-Strand Synthesis System for RT-PCR 
(Thermo Fisher Scientific). qRT-PCR was performed using iTaq Universal SYBR Green and a 
CFX96 Real Time System (Bio-Rad), with primer pairs that span exon-intron boundaries (Table 
7). Analysis of relative gene expression was performed using the Pfaffl method (Bio-Rad Real-
Time PCR Applications Guide, http://www.gene-quantification.com/real-time-pcr-guide-bio-
rad.pdf).  
 
Statistics. For analysis of immunoblotting and qRT-PCR data, GraphPad Prism 7.03 was used 
to plot mean expression ± standard deviation of biological and/or technical replicates, as 
indicated in figure legends. To pool data between immunoblots, signal data obtained from the 
Odyssey® Infrared Imaging System (LI-COR) and quantified using Image Studio™ software (LI-
COR) for each blot were normalized to control, and the normalized values were averaged 
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across blots. To determine statistical significance, parametric measures (one-way ANOVA) 
were used if the data met the assumption of equality of group variances as calculated by the 
Brown-Forsythe test and homogeneity of variances across populations as calculated by 
Bartlett’s test. For pairwise comparisons between groups, the Holm-Sidak correction for multiple 
comparisons was made. If these assumptions were not met, nonparametric measures (Kruskal-
Wallace) were used, and for pairwise comparisons between groups, Dunn’s test with correction 
for multiple comparisons was used.  
 
 148 
 
Figure 18. Individual and combinatorial mutations to the G-H loop of ephrin-B1 
dramatically reduce EphB receptor binding. (A) Schematic showing the amino acid 
sequence of part of the G-H loop, or receptor-binding domain, of ephrin-B1, which is highly 
conserved across vertebrates. Red asterisks indicate amino acids mutated individually to create 
single G-H loop mutants Q115P, P119T, and E125K or in combination to create triple G-H loop 
mutant Q115P/P119T/E125K (“3xTD”). (B) 293 cells alone do not express high levels of 
endogenous ephrin-B1 (column 1), but transient transfection of wild-type ephrin-B1 (columns 2 
and 3) or mutant ephrin-B1 (columns 4-7) results in robust expression of the protein. Addition of 
soluble EphB2-Fc to the culture media, followed by Fc pulldown, coprecipitates wild-type ephrin-
B1. However, pulldown of single G-H loop mutant ephrin-B1 is dramatically reduced (green 
box), and triple G-H loop mutant ephrin-B1 is not pulled down (blue box). UT, untransfected. B1, 
ephrin-B1. 
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Figure 19. Single G-H loop mutants of ephrin-B1 retain the ability to activate EphB2, while 
a triple G-H loop mutant does not. (A) 293 cells transfected with empty vector pcDNA3.1 do 
not express high levels of ephrin-Bs or EphB receptors and intermingle with 293 cells stably 
expressing EphB2. (B) 293 cells transiently expressing ephrin-B1wt segregate dramatically from 
EphB2 cells. (C-E) When transiently expressed in 293 cells, ephrin-B1 single G-H loop mutants 
Q115P, P119T, or E125K retain enough receptor binding capacity to initiate segregation from 
EphB2 cells. (F) Triple G-H loop mutant ephrin-B13xTD transiently expressed in 293 cells is not 
able to drive their segregation from EphB2 cells, indicating that this mutant is truly “trans-dead.” 
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Figure 20. Coexpression of EphB2 and trans-competent ephrin-B1 blinds cells to receipt 
of further signals from ephrin-B1 in trans. (A) Coexpression of ephrin-B1wt in EphB2-
expressing 293 cells results in coimmunoprecipitation of ephrin-B1 with EphB2 (red bar), but 
ephrin-B1 single G-H loop mutants do not coimmunoprecipitate significantly with EphB2 when 
coexpressed (green box, green bars). (B) HEK293 cells do not segregate from ephrin-B1 cells, 
but ephrin-B1 cells segregate dramatically from untransfected EphB2 cells (C) or EphB2 cells 
transiently expressing the empty vector pcDNA3.1. (E-H) EphB2 cells coexpressing ephrin-B1wt 
or single G-H loop mutants are desensitized to signals from ephrin-B1 in trans and demonstrate 
reduced segregation from ephrin-B1 cells. (I) EphB2 cells coexpressing ephrin-B13xTD are not 
desensitized and still segregate dramatically from ephrin-B1 cells. (J) Quantification of 
segregation in panels (B-H) using a nearest-neighbor method. **** indicates p<0.001 in 
comparison with segregation of the positive control (C) by ANOVA followed by a Holm-Sidak 
correction for multiple comparisons. The graph displays the results of 2 biological replicates, 
each with 6-9 technical replicates per condition. B1, ephrin-B1; UT, untransfected. Scale bars, 
200 μm. 
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Figure 21. Cis-expression of ephrin-B1 desensitizes EphB2-expressing cells through 
reduction of EphB2 protein levels. (A) Transient transfection of ephrin-B1wt (red bar) or 
ephrin-B1 single G-H loop mutants (green box; green bars) into 293 cells stably expressing 
EphB2 results in decreased EphB2 expression after 48 hours compared with transient 
transfection of empty vector pcDNA3.1 (yellow bar). This process requires the G-H loop, as 
transient transfection of ephrin-B13xTD does not affect EphB2 expression (blue box; blue bar). 
Error bars represent standard deviation of n=3-7 biological replicates per condition; relative 
EphB2 expression (EphB2/HSP70) was normalized to 1 for empty vector-transfected cells. (B) 
Transient transfection of the transmembrane protein CDO does not decrease EphB2 
expression, indicating that this phenomenon is not generally caused by increasing proteins at 
the cell surface. (C) 293 cells do not express significant levels of Ephb2 or Efnb1 compared to 
stably expressing or transfected cells. Decreases in EphB2 occur at the protein level; relative 
Ephb2 expression is not changed in 293 cells expressing Efnb1. (D-G) E13.5 mouse embryo 
heads null for ephrin-B1 expression (Efnb1-/Y) (E) have significant increases in EphB2 (F) and 
EphB3 (G) expression. Error bars represent standard deviation of n=7-8 biological replicates per 
condition. Stars indicate a statistically significant difference between Efnb1+/+ and Efnb1-/Y 
embryos as follows: in (E), **** indicates p<0.0001 by nonparametric Kruskal-Wallace test 
followed by a Dunn’s correction for multiple comparisons; in (F-G), *** indicates p<0.001 by 
ANOVA followed by a Holm-Sidak correction for multiple comparisons. B1, ephrin-B1; UT, 
untransfected. 
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Figure 22. Ephrin-B1 misexpression mouse construct design, testing, and targeting. (A)  
Schematic diagram of targeting construct for conditional ephrin-B1 misexpression under the 
control of the ROSA26 promoter, including depictions of the targeted allele and the recombined 
allele. (B-C) Transient transfection of the Efnb1-P2A-mClover2 portion of the construct into 293 
cells via the pcDNA3.1 plasmid results in P2A cleavage, ephrin-B1 expression at the expected 
size of 49 kDa, and mClover2 expression. Black arrow in (B) indicates a small amount of 
uncleaved protein remaining. (D) Representative gel image showing testing of G418-resistant 
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clones for correct targeting. PCR primers from ROSA26-flanking and splice acceptor DNA, 
indicated by red arrowheads in (A), were used to amplify a fragment of approximately 1.3 kb. 
Black arrows indicate correctly targeted Efnb1wt clones. +, positive control ROSA26 reporter 
mouse DNA; -, negative control mouse DNA; L, ladder. (E) Transient expression of PGK-Cre-
bpA in targeted Efnb1wt and Efnb13xTD mESCs results in the expected recombination event. 
PCR primers from Rosa26-flanking and Efnb1 coding sequence DNA, indicated by blue arrows 
in (A), were used to amplify a 1-kb fragment of the recombined allele. Amplification occurred 
only in Cre-expressing wt and 3xTD mESCs, not in untransfected mESCs. +, Cre-positive 
control mouse DNA; -, Cre-negative control mouse DNA; 0, no DNA control; L, ladder. 
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Figure 23. Differences in cis expression effects of ephrin-As and ephrin-Bs. (A) Cis-
expression of ephrin-As with EphA receptors results in inhibition of EphA activation and 
signaling, with functional effects on axon growth cone collapse. This is thought to act as a 
method for fine-tuning signaling response to accurately define termination zones during axon 
guidance. (B) We have shown that ephrin-Bs do not bind directly to EphB receptors in cis in the 
same way that ephrin-As bind to EphA receptors. Instead, coexpression of ephrin-Bs and EphB 
receptors within a population of cells leads to signaling in trans that results in downregulation of 
EphB receptor expression, desensitizing these cells to receipt of further signals in trans from 
other cell populations.  
 
 
 157 
 
Figure S6. Preliminary characterization of ROSA26Efnb1-3xTD mouse ESCs. (A) qPCR to 
detect copy number of Neo insertion, normalized to the Bambi locus, was employed to test for 
construct integration number in each targeted mESC line compared to tail DNA from control 
ROSA26LacZ reporter mice. All targeted lines had only one integration event except for 
Efnb13xTD-220, which had two copies of Neo. (B) Representative image showing a litter from the 
cross between the highest-percentage Efnb13xTD-240 chimera and a C57BL/6J female. 
Approximately 30% of the pups in each litter had the Agouti coat color. (C) Genotyping of four 
Agouti pups from the first litter from the cross between the highest-percentage Efnb13xTD-240 
chimera and a C57BL/6J female. As expected, 50% of the Agouti pups carried the targeted 
allele. 
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CHAPTER 6. Conclusions and future work 
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This work explores the developmental etiology of the congenital craniofacial disease 
craniofrontonasal syndrome (CFNS), while also aiming to elucidate the general mechanisms of 
ephrin-B1 regulation of cell positioning and boundary formation in the developing craniofacial 
complex. It has been understood for some time that ephrin-B1 is a major player in the area of 
developmental boundary formation and maintenance, as its loss or mutation in humans results 
in defects such as agenesis of the corpus callosum, which results in axons failing to cross the 
midline boundary of the brain; syndactyly and polydactyly, in which boundaries are lost or 
gained in developing digits; coronal craniosynostosis, in which a major boundary between the 
frontal and parietal bones of the skull is lost; and cleft lip and palate, a failure of tissue fusion. 
This evidence and more suggest that ephrin-B1 has key developmental roles in many different 
structures, but the specific mechanisms of ephrin-B1 action during craniofacial development, as 
well as the ways in which ephrin-B1 loss and mosaicism in CFNS contribute to craniofacial 
dysmorphology, have remained incompletely understood. This work addresses three main 
questions that contribute to a greater body of work towards a better understanding of ephrin-B1-
mediated cell segregation in craniofacial development and disease. The research contained 
herein represents a step towards better diagnostics and molecular therapies for CFNS, as well 
as towards a better understanding of the role of one important molecule and its function within a 
signaling pathway that is critical to the developing face. 
Through the first hiPSC model of morphogenesis in a congenital craniofacial disorder, 
we have demonstrated that human CFNS patient iPSC-derived neuroepithelial cells mosaic for 
EPHRIN-B1 expression undergo cell segregation. This knowledge is essential because, 
although cell segregation in the neural plate neuroepithelium (O’Neill et al., 2016), palate 
mesenchyme (Bush and Soriano, 2010) and limb buds (Compagni et al., 2003) was proposed 
as a mechanism by which mosaicism in female heterozygous patients could lead to “cellular 
interference” between ephrin-B1 expressing and non-expressing cells, it was unclear whether or 
not cell segregation occurred in human cells. Our finding that ephrin-B1-mediated cell 
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segregation is conserved in humans suggests not only that its role applies across species, but 
also that this cellular behavior is likely key to human disease pathology. We have also provided 
proof of principle that hiPSC-derived cell types can be used to model morphogenesis in cell 
culture, a premise that will hopefully lead to additional human model systems for structural 
congenital craniofacial anomalies both in our group and elsewhere. In addition, the CFNS 
patient and family hiPSCs we have developed will be a key tool for further mechanistic studies 
of ephrin-B1-mediated cell segregation. These will include determining whether ephrin-B1-
mediated cell segregation occurs in other human cell types relevant to CFNS, such as neural 
crest cells and their derivatives; these experiments will be particularly useful for investigation of 
human phenotypes not recapitulated in the mouse model for CFNS, such as craniosynostosis. 
The CFNS hiPSC model system will also be used to investigate whether differential cortical 
tension regulates segregation in human cells and to determine what downstream signaling 
partners of the EphB receptors mediate this process. 
In addition to its role in mouse and human neural progenitor cells, we have shown that 
ephrin-B1 continues to drive cell segregation behavior in neural crest cells and their derivatives 
in the mouse as late as E12.5-E13.5 (~40 days gestation in humans), indicating that ephrin-B1 
is a potent global regulator of cell segregation in the developing embryo. This finding has clear 
implications for understanding the developmental etiology of CFNS, as well as for the 
development of molecular therapies for this disorder; in order to treat pathogenic cell 
segregation, it is critical to know when and where it occurs. Our work indicates that segregation 
is an ongoing process through development, and it is possible that loss of ephrin-B1 allows 
inappropriate cell migration in even later-formed boundaries in the developing craniofacial 
complex, such as the sutures of the skull. This seems likely given the CFNS patient phenotype 
of craniosynostosis, but although mutations in EFNB1 are responsible for 7% of 
craniosynostosis cases with a genetic diagnosis (Johnson and Wilkie, 2011), whether ectopic 
suture fusion occurs through a cell segregation mechanism or via some other effect of loss of 
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ephrin-B1 remains unknown. In the future, approaches using tissue-specific Cre recombinase 
mouse lines to generate ephrin-B1 mosaicism in the suture mesenchyme or osteoblast 
progenitors may shed light on this important question. More broadly, quantitative comparison of 
facial shapes in embryos with ephrin-B1 mosaicism in different tissues and cell types will allow 
pinpointing of the tissues in which craniofacial dysmorphology arises in CFNS, while similar 
studies in EphB receptor mutant embryos will aid in the determination of which EphB receptor 
signals contribute to craniofacial phenotypes. With the knowledge that segregation continues 
later into development, treatments that block or reverse this aberrant cell behavior have greater 
potential for success, and experiments to determine whether this is possible in vivo will be an 
important step towards the development of targeted molecular therapies for CFNS.   
In an important discovery pertaining to the biochemistry of Eph/ephrin signaling, this 
work also identifies a mechanism by which cis-expression of ephrin-B1 with EphB receptors 
regulates their tissue-wide protein expression and signaling. The function of coexpression of 
Ephs and ephrins is just beginning to be explored, with ephrin-A coexpression repressing EphA 
signaling during axon guidance (Carvalho et al., 2006; Hornberger et al., 1999) and multiple 
Ephs and ephrins contributing to separation of the germ layers in Xenopus (Rohani et al., 2011; 
Rohani et al., 2014). These findings are not contained within the dogma of Eph/ephrin signaling 
in boundary formation, which maintains that reciprocal expression of Ephs and ephrins with 
bidirectional signaling at tissue interfaces forms and preserves tissue boundaries; although this 
can be shown in several different embryonic contexts, such as the rhombomeres (Xu et al., 
1999) and somites (Durbin et al., 2000), we now know that it does not apply to all regions in 
which these molecules are expressed. Instead, we have demonstrated that coexpression of 
ephrin-B1 with EphB2 and EphB3 plays an essential role in the availability of the receptor to 
receive outside signals. Unlike ephrin-A cis inhibition of EphA receptors, ephrin-B1 does not 
bind directly to EphB receptors in cis or attenuate receptor phosphorylation using the same 
mechanisms. Instead, ephrin-B1/EphB coexpression throughout a tissue results in widespread 
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signaling in trans that leads to downregulation of receptor protein expression, thus effectively 
“blinding” or desensitizing these cells to receipt of further signals from other ephrin-expressing 
cells. Although many downstream signaling targets of Eph/ephrin signaling have been identified 
in different contexts, and the behavior of Ephs and ephrins at the cell surface has been 
described, this represents a novel regulatory mechanism that may apply in many situations in 
which Ephs and ephrins are coexpressed. Much remains unknown about the ways in which 
Ephs and ephrins interact, and future work will explore these mechanisms further. In addition, 
because we have shown that expression levels of ephrin-B1 regulate Eph receptor function, this 
work opens the door to studies that take advantage of ephrin-B1 misexpression to overcome the 
effects of mosaicism and aberrant segregation in CFNS by downregulating EphB receptor 
responses, a treatment that could be key to treating this congenital craniofacial disease.  
Although it is a rare disease, craniofrontonasal syndrome is one of a large group of 
congenital disorders affecting the craniofacial complex that we are beginning to better 
understand. Future applications of this research will contribute to this improved understanding 
and aid in the work towards cellular and molecular therapies for this disorder and others, as we 
apply our knowledge of signaling mechanisms and human cell-based model systems to study 
defects in boundary formation in the developing embryo. Further, the ectopic boundary 
formation that occurs in CFNS provides us with an opportunity to delve into studies of cellular 
mechanisms of developmental boundaries, mechanisms which are not yet well understood in 
the development and function of mesenchymal structures. A more in-depth comprehension of 
the cellular behaviors that contribute to the intricate morphogenesis of the face will elucidate key 
cellular and molecular mechanisms that play important roles during normal development and 
disease.   
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Table 6. Antibody information for immunofluorescence (IF) and immunoblotting (IB) 
IF - Conjugated Antibodies Source Catalog # Dilution 
TRA-1-60, Cy3 conjugate Millipore MAB4360C3 1:100 
TRA-1-81, Cy3 conjugate Millipore MAB4381C3 1:100 
NANOG, Alexa Fluor 488 
conjugate 
Millipore MABD24A4 1:100 
SOX2, Cy3 conjugate Millipore MAB4423C3 1:100 
OCT4 (POU5FL), Alexa Fluor 
488 conjugate 
Millipore MAB4419A4 1:100 
IF - Primary Antibodies Source Catalog # Dilution 
βIII-tubulin (TUJ1) Sigma T8660 1:1000 
α-fetoprotein (AFP) Sigma A8452 1:500 
human muscle actin DAKO M0635 1:50 
SOX1 R&D Systems AF3369 1:150 
PAX6 Covance PRB-278P 1:200 
OTX2 Millipore AB9566 1:250 
Ephrin-B1 R&D Systems AF473 0.2 μg/mL 
EphB2 R&D Systems AF467 1:10 
EphB3 R&D Systems AF432 1:20 
GFP Abcam ab13970 1:500 
2H3 (neurofilament) DSHB 2H3 2 μg/mL 
IF - Secondary Antibodies Source Catalog # Dilution 
Donkey anti-rabbit Alexa Fluor 
488 
Jackson IR 711-165-152 1:400 
Donkey anti-mouse Cy2 Jackson IR 715-225-150 1:400 
Donkey anti-chicken Cy2 Jackson IR 703-225-155 1:400 
Donkey anti-goat Cy3 Jackson IR 705-165-003 1:400 
IB - Primary Antibodies Source Catalog # Dilution 
Ephrin-B1 R&D Systems AF473 0.2 μg/mL 
EphB2 R&D Systems AF467 0.4 μg/mL 
EphB3 R&D Systems AF432 0.4 μg/mL 
HSP70 BD Transduction 610607 1:1000 
IB - Secondary Antibodies Source Catalog # Dilution 
Donkey anti-goat IRDye® 
800CW 
LI-COR 
Biosciences 
926-32214 1:5000 
Donkey anti-mouse IRDye® 
680RD 
LI-COR 
Biosciences 
926-68072 1:5000 
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Table 7. Primer sequence information 
qRT-PCR Primers 
Target Forward Primer Sequence (5’ to 3’) Reverse Primer Sequence (5’ to 3’) 
hEFNB1 GTATCCTGGAGCTCCCTCAACC GTAGTACTCATAGGGCCGCC 
hPAX6 TCGGTGGTGTCTTTGTCAACG ACTACCACCGATTGCCCTGG 
hGAPDH TCTTCACCACCATGGAGAAGG CATGGATGACCTTGGCCAGG 
hEFNB2 AATCCAGGTTCTAGCACAGACG GTGCTTCCTGTGTCTCCTCC 
hEPHB2 CCATCAAGCTCTACTGTAACGGG GCTCTGTAGTAGCCATTGCG 
hEPHB3 TGGGTAACATCTGAGTTGGC CTTGAGCTCCACGTAGACCC 
mEfnb1 CGTTGGCCAAGAACCTGGAGC  TCCAGCTTGTCTCCAATCTTCGG  
mEphB2 TGCTGCTGCCGCTGCTAGC TCGTAGCCGCTCACCTCTTCC 
hiPSC screening: Plasmid PCR Primers 
Target Forward Primer Sequence (5’ to 3’) Reverse Primer Sequence (5’ to 3’) 
EBNA-1 ATCAGGGCCAAGACATAGAGATG GCCAATGCAACTTGGACGTT 
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 
mESC screening: PCR and qPCR Primers 
Target Forward Primer Sequence (5’ to 3’) Reverse Primer Sequence (5’ to 3’) 
ROSA26-adSA 
(screening) 
GAGAGCCTCGGCTAGGTAGG GATACCGTCGATCCCCACTG 
ROSA26-Efnb1 
(recombination) 
GCACTTGCTCTCCCAAAGTC CTTCATAGTGCGGGTGCG 
ROSA26R 
(genotype) 
AAAGTCGCTCTGAGTTGTTAT GGAGCGGGAGAAATGGATATG 
and 
GCGAAGAGTTTGTCCTCAACC 
Neo (qPCR) AAGGCACTGGCTGCTATTGG ATCCTGATCGACAAGACCG 
mBambi 
(qPCR) 
GGGTTCACGCGATGTTTATGT TTGCAAGTGAGTCCAGGCAGC 
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Table 8. Genetic crosses and sample sizes for mouse embryo experiments  
          Morphometrics b-actin-CreTg/o x Efnb1lox/lox or C57BL/6J 
E11.5 E12.5 E13.5 E14.5 
control 
(Efnb1lox/Y; Efnb1lox/+; wt) 28 23 29 45 
b-actin-CreTg/o; Efnb1Δ/Y 
(Efnb1Δ/Y) 21 19 17 25 
b-actin-CreTg/o; Efnb1+/Δ 
(Efnb1+/Δ) 26 17 13 29 
Immunofluorescence 
b-actin-CreTg/o; XGFP/Y x Efnb1lox/lox 
E10.5 E11.5 E12.5 E13.5 
control 
Efnb1+XGFP/lox 2 -- -- 1 
b-actin-CreTg/o; Efnb1+XGFP/Δ 
(Efnb1+XGFP/Δ) 3 -- -- 2 
 Sox10-CreTg/o; XGFP/Y x Efnb1lox/lox 
 E10.5 E11.5 E12.5 E13.5 
control 
Efnb1+XGFP/lox 4 4 -- 4 
Sox10-CreTg/o; Efnb1+XGFP/Δ 6 2 -- 5 
 ROSA26mTmG/mTmG x Sox10-CreTg/o 
 E10.5 E11.5 E12.5 E13.5 
Sox10-CreTg/o; 
ROSA26mTmG/+ 1 -- -- -- 
 Sox1Cre/+; XGFP/Y x Efnb1lox/lox 
 E10.5 E11.5 E12.5 E13.5 
control 
Efnb1+XGFP/lox -- -- -- -- 
Sox1Cre/+; Efnb1+XGFP/Δ -- -- -- 2 
 ROSA26mTmG/mTmG x Sox1Cre/+ 
 E10.5 E11.5 E12.5 E13.5 
Sox1Cre/+; ROSA26mTmG/+ -- -- -- 3 
 Shox2IresCre/+; XGFP/Y x Efnb1lox/lox 
 E10.5 E11.5 E12.5 E13.5 
control 
Efnb1+XGFP/lox -- 3 3 3 
Shox2IresCre/+; Efnb1+XGFP/Δ -- 3 4 4 
  
ROSA26mTmG/mTmG x Shox2IresCre/+ 
 E10.5 E11.5 E12.5 E13.5 
Shox2IresCre/+; 
ROSA26mTmG/+ -- 2 2 2 
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